WO2020103815A1 - Glp-1r agonists and uses thereof - Google Patents
Glp-1r agonists and uses thereofInfo
- Publication number
- WO2020103815A1 WO2020103815A1 PCT/CN2019/119373 CN2019119373W WO2020103815A1 WO 2020103815 A1 WO2020103815 A1 WO 2020103815A1 CN 2019119373 W CN2019119373 W CN 2019119373W WO 2020103815 A1 WO2020103815 A1 WO 2020103815A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- halogen
- optionally substituted
- saturated
- alkoxy
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title description 37
- 150000001875 compounds Chemical class 0.000 claims abstract description 390
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 45
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 27
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 208000008589 Obesity Diseases 0.000 claims abstract description 16
- 235000020824 obesity Nutrition 0.000 claims abstract description 16
- 201000009104 prediabetes syndrome Diseases 0.000 claims abstract description 15
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims abstract description 9
- 208000001280 Prediabetic State Diseases 0.000 claims abstract description 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 137
- 150000002367 halogens Chemical class 0.000 claims description 137
- 229920006395 saturated elastomer Polymers 0.000 claims description 121
- 150000003839 salts Chemical class 0.000 claims description 103
- 239000012453 solvate Substances 0.000 claims description 78
- -1 preferably Inorganic materials 0.000 claims description 59
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 52
- 125000000623 heterocyclic group Chemical group 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 49
- 229910052799 carbon Inorganic materials 0.000 claims description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
- 125000001072 heteroaryl group Chemical group 0.000 claims description 40
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 27
- 239000008103 glucose Substances 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 230000001771 impaired effect Effects 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims description 18
- 206010016654 Fibrosis Diseases 0.000 claims description 17
- 150000002431 hydrogen Chemical class 0.000 claims description 17
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 15
- 229910052805 deuterium Inorganic materials 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 206010022489 Insulin Resistance Diseases 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 11
- 230000002440 hepatic effect Effects 0.000 claims description 11
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 10
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 10
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 10
- 201000001320 Atherosclerosis Diseases 0.000 claims description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 208000037803 restenosis Diseases 0.000 claims description 10
- 230000002792 vascular Effects 0.000 claims description 10
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 9
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 9
- 208000029078 coronary artery disease Diseases 0.000 claims description 9
- 230000004761 fibrosis Effects 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 230000004584 weight gain Effects 0.000 claims description 9
- 235000019786 weight gain Nutrition 0.000 claims description 9
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 8
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 8
- 206010056465 Food craving Diseases 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 8
- 208000035180 MODY Diseases 0.000 claims description 8
- 230000007882 cirrhosis Effects 0.000 claims description 8
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 8
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 8
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 8
- 201000001421 hyperglycemia Diseases 0.000 claims description 8
- 208000001921 latent autoimmune diabetes in adults Diseases 0.000 claims description 8
- 201000006950 maturity-onset diabetes of the young Diseases 0.000 claims description 8
- 230000000291 postprandial effect Effects 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 7
- 125000002619 bicyclic group Chemical group 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 7
- 201000008980 hyperinsulinism Diseases 0.000 claims description 7
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims description 6
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims description 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 6
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 208000030814 Eating disease Diseases 0.000 claims description 6
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 6
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 6
- 208000007976 Ketosis Diseases 0.000 claims description 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 6
- 235000014632 disordered eating Nutrition 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 208000010444 Acidosis Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 102000018616 Apolipoproteins B Human genes 0.000 claims description 5
- 108010027006 Apolipoproteins B Proteins 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 5
- 208000002177 Cataract Diseases 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 206010012335 Dependence Diseases 0.000 claims description 5
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 5
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 5
- 201000005569 Gout Diseases 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 5
- 201000001431 Hyperuricemia Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 206010022562 Intermittent claudication Diseases 0.000 claims description 5
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 5
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 5
- 208000002720 Malnutrition Diseases 0.000 claims description 5
- 206010027417 Metabolic acidosis Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 5
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 5
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 5
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 206010049416 Short-bowel syndrome Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 208000007536 Thrombosis Diseases 0.000 claims description 5
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 230000010014 adipocyte dysfunction Effects 0.000 claims description 5
- 238000002399 angioplasty Methods 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 5
- 208000020832 chronic kidney disease Diseases 0.000 claims description 5
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 5
- 230000019771 cognition Effects 0.000 claims description 5
- 206010009887 colitis Diseases 0.000 claims description 5
- 208000018631 connective tissue disease Diseases 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 5
- 230000008694 endothelial dysfunction Effects 0.000 claims description 5
- 208000004104 gestational diabetes Diseases 0.000 claims description 5
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 5
- 230000004153 glucose metabolism Effects 0.000 claims description 5
- 201000001881 impotence Diseases 0.000 claims description 5
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 5
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
- 230000004140 ketosis Effects 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 230000001071 malnutrition Effects 0.000 claims description 5
- 235000000824 malnutrition Nutrition 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 5
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 5
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 208000017520 skin disease Diseases 0.000 claims description 5
- 201000002859 sleep apnea Diseases 0.000 claims description 5
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 5
- 230000009529 traumatic brain injury Effects 0.000 claims description 5
- 230000036269 ulceration Effects 0.000 claims description 5
- 230000009278 visceral effect Effects 0.000 claims description 5
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims description 4
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 208000021017 Weight Gain Diseases 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 2
- 101150065749 Churc1 gene Proteins 0.000 claims description 2
- 102100038239 Protein Churchill Human genes 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 211
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 194
- 230000014759 maintenance of location Effects 0.000 description 170
- 239000000243 solution Substances 0.000 description 162
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 142
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 119
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 114
- 239000007787 solid Substances 0.000 description 91
- 238000006243 chemical reaction Methods 0.000 description 87
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 80
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 78
- 239000012043 crude product Substances 0.000 description 78
- 210000004027 cell Anatomy 0.000 description 76
- 239000011541 reaction mixture Substances 0.000 description 72
- 238000003556 assay Methods 0.000 description 70
- 239000011734 sodium Substances 0.000 description 67
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 66
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 62
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 62
- 238000005160 1H NMR spectroscopy Methods 0.000 description 57
- 239000004698 Polyethylene Substances 0.000 description 56
- 235000019439 ethyl acetate Nutrition 0.000 description 54
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 54
- 239000012267 brine Substances 0.000 description 53
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
- 239000000047 product Substances 0.000 description 45
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 43
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 42
- 125000004043 oxo group Chemical group O=* 0.000 description 41
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 39
- 239000003921 oil Substances 0.000 description 38
- 235000019198 oils Nutrition 0.000 description 38
- 102000000072 beta-Arrestins Human genes 0.000 description 37
- 108010080367 beta-Arrestins Proteins 0.000 description 37
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- 239000002904 solvent Substances 0.000 description 36
- 238000002953 preparative HPLC Methods 0.000 description 35
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 28
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 27
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 27
- 230000000694 effects Effects 0.000 description 26
- 239000000741 silica gel Substances 0.000 description 26
- 229910002027 silica gel Inorganic materials 0.000 description 26
- 229960001866 silicon dioxide Drugs 0.000 description 26
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 25
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 24
- 239000003153 chemical reaction reagent Substances 0.000 description 23
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 231100000673 dose–response relationship Toxicity 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 20
- 239000000460 chlorine Substances 0.000 description 20
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 19
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 19
- 239000012044 organic layer Substances 0.000 description 19
- 230000007115 recruitment Effects 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 238000004587 chromatography analysis Methods 0.000 description 18
- BGHNWJOTRMAJGU-LBPRGKRZSA-N tert-butyl 2-(chloromethyl)-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClCC1=NC2=C(N1C[C@H]1OCC1)C=C(C=C2)C(=O)OC(C)(C)C BGHNWJOTRMAJGU-LBPRGKRZSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 238000004809 thin layer chromatography Methods 0.000 description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 17
- 238000004440 column chromatography Methods 0.000 description 15
- 239000012224 working solution Substances 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 230000004913 activation Effects 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- 229940002612 prodrug Drugs 0.000 description 14
- 239000000651 prodrug Substances 0.000 description 14
- 238000001704 evaporation Methods 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 230000008020 evaporation Effects 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 12
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 239000005457 ice water Substances 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 10
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 10
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 10
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 10
- XNOUMOGYWRFGNN-NRFANRHFSA-N 2-[[4-[2-[(4-chloro-2-fluorophenyl)methoxy]pyrimidin-4-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=NC=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F XNOUMOGYWRFGNN-NRFANRHFSA-N 0.000 description 10
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 10
- 238000010791 quenching Methods 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 9
- 239000002502 liposome Substances 0.000 description 9
- FANVZBORIFTZCO-QFIPXVFZSA-N 2-[[4-[1-[2-(4-chloro-2-fluorophenyl)ethyl]-6-oxopyridazin-3-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CCN2N=C(C=CC2=O)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F FANVZBORIFTZCO-QFIPXVFZSA-N 0.000 description 8
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 8
- 239000006285 cell suspension Substances 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 8
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 239000012131 assay buffer Substances 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- XUZRWKWJKDCQNA-UHFFFAOYSA-N (4-chloro-2-fluorophenyl)methanol Chemical compound OCC1=CC=C(Cl)C=C1F XUZRWKWJKDCQNA-UHFFFAOYSA-N 0.000 description 6
- UFCSSWZQROEFBZ-UHFFFAOYSA-N 1-(bromomethyl)-4-chloro-2-fluorobenzene Chemical compound FC1=CC(Cl)=CC=C1CBr UFCSSWZQROEFBZ-UHFFFAOYSA-N 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 6
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 6
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000003158 alcohol group Chemical group 0.000 description 6
- 108010005774 beta-Galactosidase Proteins 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 241000282567 Macaca fascicularis Species 0.000 description 5
- 239000012124 Opti-MEM Substances 0.000 description 5
- 230000009102 absorption Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000013262 cAMP assay Methods 0.000 description 5
- 239000013058 crude material Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 230000003914 insulin secretion Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 5
- 239000004570 mortar (masonry) Substances 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 230000007863 steatosis Effects 0.000 description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 4
- WSEVKKHALHSUMB-RYVRVIGHSA-N (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O WSEVKKHALHSUMB-RYVRVIGHSA-N 0.000 description 4
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- ZWGFXBUAAHAZQT-UHFFFAOYSA-N 2-(4-chloro-2-fluorophenyl)ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCC1=C(C=C(C=C1)Cl)F ZWGFXBUAAHAZQT-UHFFFAOYSA-N 0.000 description 4
- AVKFYJSWNXESHL-QHCPKHFHSA-N 2-[[4-[4-[(4-chloro-2-fluorophenyl)methyl]-2,3-dihydropyrido[3,2-b][1,4]oxazin-6-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CN2C3=C(OCC2)C=CC(=N3)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F AVKFYJSWNXESHL-QHCPKHFHSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000012097 Lipofectamine 2000 Substances 0.000 description 4
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 4
- 108010019598 Liraglutide Proteins 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 230000011496 cAMP-mediated signaling Effects 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 4
- 229960001259 diclofenac Drugs 0.000 description 4
- 239000013024 dilution buffer Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 108010024703 exendin (9-39) Proteins 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229950000991 ipragliflozin Drugs 0.000 description 4
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- 229960002701 liraglutide Drugs 0.000 description 4
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000004808 supercritical fluid chromatography Methods 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 3
- FILKGCRCWDMBKA-UHFFFAOYSA-N 2,6-dichloropyridine Chemical compound ClC1=CC=CC(Cl)=N1 FILKGCRCWDMBKA-UHFFFAOYSA-N 0.000 description 3
- YQDFGTHQEZIQHI-UHFFFAOYSA-N 2-(4-chloro-2-fluorophenyl)ethanol Chemical compound OCCC1=CC=C(Cl)C=C1F YQDFGTHQEZIQHI-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- SZHOTNFYNMDJIN-QHCPKHFHSA-N 2-[[4-[1-[2-(4-chloro-2-fluorophenyl)ethyl]-2-oxopyridin-3-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CCN2C(C(=CC=C2)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)=O)C=C1)F SZHOTNFYNMDJIN-QHCPKHFHSA-N 0.000 description 3
- SBAZFGZBPFPRQU-VWLOTQADSA-N 2-[[4-[3-[2-(4-chloro-2-fluorophenyl)ethyl]-2-oxobenzimidazol-1-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CCN2C(N(C3=C2C=CC=C3)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)=O)C=C1)F SBAZFGZBPFPRQU-VWLOTQADSA-N 0.000 description 3
- JVSPDXNOXPAUJA-UHFFFAOYSA-N 2-bromo-6-(1,2,3,6-tetrahydropyridin-4-yl)pyridine Chemical compound BrC1=CC=CC(C=2CCNCC=2)=N1 JVSPDXNOXPAUJA-UHFFFAOYSA-N 0.000 description 3
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 3
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- 201000001321 Bardet-Biedl syndrome Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102100029648 Beta-arrestin-2 Human genes 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 3
- 206010004716 Binge eating Diseases 0.000 description 3
- 208000032841 Bulimia Diseases 0.000 description 3
- 206010006550 Bulimia nervosa Diseases 0.000 description 3
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 3
- 241000579895 Chlorostilbon Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 206010013654 Drug abuse Diseases 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- MCIACXAZCBVDEE-CUUWFGFTSA-N Ertugliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@@]23O[C@@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl MCIACXAZCBVDEE-CUUWFGFTSA-N 0.000 description 3
- 108010011459 Exenatide Proteins 0.000 description 3
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- 206010056715 Laurence-Moon-Bardet-Biedl syndrome Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000033489 Syndromic obesity Diseases 0.000 description 3
- 206010046543 Urinary incontinence Diseases 0.000 description 3
- 206010001584 alcohol abuse Diseases 0.000 description 3
- 208000025746 alcohol use disease Diseases 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 229940005529 antipsychotics Drugs 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 108010032967 beta-Arrestin 2 Proteins 0.000 description 3
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 3
- 208000014679 binge eating disease Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000003491 cAMP production Effects 0.000 description 3
- 229960001713 canagliflozin Drugs 0.000 description 3
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229960003834 dapagliflozin Drugs 0.000 description 3
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 229910052876 emerald Inorganic materials 0.000 description 3
- 239000010976 emerald Substances 0.000 description 3
- 229960003345 empagliflozin Drugs 0.000 description 3
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 3
- 210000001163 endosome Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229950006535 ertugliflozin Drugs 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 229960001519 exenatide Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000002825 functional assay Methods 0.000 description 3
- 230000030136 gastric emptying Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 102000056448 human GLP1R Human genes 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 description 3
- 230000002267 hypothalamic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000037493 inherited obesity Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229950004994 meglitinide Drugs 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- SLQIJFSQRNXACV-JTQLQIEISA-N methyl 2-(chloromethyl)-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClCC1=NC2=C(N1C[C@H]1OCC1)C=C(C=C2)C(=O)OC SLQIJFSQRNXACV-JTQLQIEISA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229960005095 pioglitazone Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229960004586 rosiglitazone Drugs 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000003419 tautomerization reaction Methods 0.000 description 3
- XPCOMGQZULAPHO-UHFFFAOYSA-N tert-butyl 4-(6-bromopyridin-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(C=2N=C(Br)C=CC=2)=C1 XPCOMGQZULAPHO-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- YKXCWZVUWWQSAV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O YKXCWZVUWWQSAV-BTVCFUMJSA-N 0.000 description 2
- NGJOFQZEYQGZMB-KTKZVXAJSA-N (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NGJOFQZEYQGZMB-KTKZVXAJSA-N 0.000 description 2
- VQDLBVPUNIIBJZ-UHFFFAOYSA-N 1-[(4-chloro-2-fluorophenyl)methyl]-6-piperidin-4-ylindole Chemical compound ClC1=CC(=C(CN2C=CC3=CC=C(C=C23)C2CCNCC2)C=C1)F VQDLBVPUNIIBJZ-UHFFFAOYSA-N 0.000 description 2
- FFPUJPMNHBNSSZ-UHFFFAOYSA-N 1-[2-(4-chloro-2-fluorophenyl)ethyl]-3-piperazin-1-ylpyridin-2-one Chemical compound ClC1=CC(=C(CCN2C(C(=CC=C2)N2CCNCC2)=O)C=C1)F FFPUJPMNHBNSSZ-UHFFFAOYSA-N 0.000 description 2
- XULHAJLFVXHAHA-UHFFFAOYSA-N 1-[2-(4-chloro-2-fluorophenyl)ethyl]-3-piperidin-4-ylbenzimidazol-2-one Chemical compound ClC1=CC(=C(CCN2C(N(C3=C2C=CC=C3)C2CCNCC2)=O)C=C1)F XULHAJLFVXHAHA-UHFFFAOYSA-N 0.000 description 2
- BVSIORWCMWIFGV-UHFFFAOYSA-N 1-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperazin-2-one Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2C(CNCC2)=O)C=C1)F BVSIORWCMWIFGV-UHFFFAOYSA-N 0.000 description 2
- FEYDZHNIIMENOB-UHFFFAOYSA-N 2,6-dibromopyridine Chemical compound BrC1=CC=CC(Br)=N1 FEYDZHNIIMENOB-UHFFFAOYSA-N 0.000 description 2
- WKAZXGAJEGPUAY-UHFFFAOYSA-N 2-(4-chloro-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C=C1F WKAZXGAJEGPUAY-UHFFFAOYSA-N 0.000 description 2
- UUMBOOZPQMLWQG-UHFFFAOYSA-N 2-[(4-chloro-2-fluorophenyl)methoxy]-4-piperazin-1-ylpyrimidine hydrochloride Chemical compound Cl.ClC1=CC(=C(COC2=NC=CC(=N2)N2CCNCC2)C=C1)F UUMBOOZPQMLWQG-UHFFFAOYSA-N 0.000 description 2
- FYLBLWBDLQEZED-UHFFFAOYSA-N 2-[(4-chloro-2-fluorophenyl)methoxy]-4-piperidin-4-ylpyrimidine 4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(C=C1)S(=O)(=O)O.ClC1=CC(=C(COC2=NC=CC(=N2)C2CCNCC2)C=C1)F FYLBLWBDLQEZED-UHFFFAOYSA-N 0.000 description 2
- WJAQNXZTBISDSK-UHFFFAOYSA-N 2-[2-(4-chloro-2-fluorophenyl)ethyl]-6-piperazin-1-ylpyridazin-3-one Chemical compound ClC1=CC(=C(CCN2N=C(C=CC2=O)N2CCNCC2)C=C1)F WJAQNXZTBISDSK-UHFFFAOYSA-N 0.000 description 2
- HLAFLGRQXBWFLA-NRFANRHFSA-N 2-[[4-[1-[(4-chloro-2-fluorophenyl)methyl]-6-oxopyridazin-3-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CN2N=C(C=CC2=O)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F HLAFLGRQXBWFLA-NRFANRHFSA-N 0.000 description 2
- CBBXAUBZEZFWPQ-MHZLTWQESA-N 2-[[4-[1-[(4-chloro-2-fluorophenyl)methyl]indol-6-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CN2C=CC3=CC=C(C=C23)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F CBBXAUBZEZFWPQ-MHZLTWQESA-N 0.000 description 2
- XMMVNFSGCSWZIT-QFIPXVFZSA-N 2-[[4-[2-[(4-chloro-2-fluorophenyl)methoxy]pyrimidin-4-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=NC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F XMMVNFSGCSWZIT-QFIPXVFZSA-N 0.000 description 2
- FAAGQBIHHPSWAS-QHCPKHFHSA-N 2-[[4-[3-[(4-chloro-2-fluorophenyl)methoxy]-2-oxopyridin-1-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC=2C(N(C=CC=2)C2=CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)=O)C=C1)F FAAGQBIHHPSWAS-QHCPKHFHSA-N 0.000 description 2
- FYTIMAWSMMBRFC-QFIPXVFZSA-N 2-[[4-[4-[(4-chloro-2-fluorophenyl)methoxy]-1H-imidazo[4,5-c]pyridin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=NC(=CC3=C2NC=N3)C=2CCN(CC=2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F FYTIMAWSMMBRFC-QFIPXVFZSA-N 0.000 description 2
- YREPORRLYFQYPP-QFIPXVFZSA-N 2-[[4-[4-[(4-chloro-2-fluorophenyl)methoxy]pyrimidin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=NC(=NC=C2)C2=CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F YREPORRLYFQYPP-QFIPXVFZSA-N 0.000 description 2
- AICKOVRRTUZUPC-SANMLTNESA-N 2-[[4-[6-(6-chloro-3,4-dihydro-1H-isoquinolin-2-yl)pyridin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC=1C=C2CCN(CC2=CC=1)C1=CC=CC(=N1)C=1CCN(CC=1)CC1=NC2=C(N1C[C@H]1OCC1)C=C(C=C2)C(=O)O AICKOVRRTUZUPC-SANMLTNESA-N 0.000 description 2
- MZISRUYJTDFMTD-DEOSSOPVSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-N-methylsulfonyl-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxamide Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2=CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)NS(=O)(=O)C)C=C1)F MZISRUYJTDFMTD-DEOSSOPVSA-N 0.000 description 2
- MWONLUVWVAHTHZ-NRFANRHFSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-3-oxopiperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2C(CN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)=O)C=C1)F MWONLUVWVAHTHZ-NRFANRHFSA-N 0.000 description 2
- KCZMCUBHPZPERS-VWLOTQADSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperazin-1-yl]methyl]-1-[[(2S)-oxetan-2-yl]methyl]indole-6-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)CC=2N(C3=CC(=CC=C3C=2)C(=O)O)C[C@H]2OCC2)C=C1)F KCZMCUBHPZPERS-VWLOTQADSA-N 0.000 description 2
- OWFLEAZNTIOBPX-QFIPXVFZSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methylamino]pyridin-2-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CNC2=CC=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F OWFLEAZNTIOBPX-QFIPXVFZSA-N 0.000 description 2
- HLOTYODPTNOHMJ-DEOSSOPVSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2=CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F HLOTYODPTNOHMJ-DEOSSOPVSA-N 0.000 description 2
- LVBYWKUWUYPCKI-SUHMBNCMSA-N 2-[[4-[6-[(6-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)oxy]pyridin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC=1C=C2CCCC(C2=CC=1)OC1=CC=CC(=N1)C=1CCN(CC=1)CC1=NC2=C(N1C[C@H]1OCC1)C=C(C=C2)C(=O)O LVBYWKUWUYPCKI-SUHMBNCMSA-N 0.000 description 2
- JBYKJQHCAWQDRQ-UHFFFAOYSA-N 2-chloro-4-[(4-chloro-2-fluorophenyl)methoxy]pyrimidine Chemical compound ClC1=NC=CC(=N1)OCC1=C(C=C(C=C1)Cl)F JBYKJQHCAWQDRQ-UHFFFAOYSA-N 0.000 description 2
- YIPAQVRDEANTRW-UHFFFAOYSA-N 2-chloro-6-[(4-chloro-2-fluorophenyl)methoxy]pyridine Chemical compound ClC1=NC(=CC=C1)OCC1=C(C=C(C=C1)Cl)F YIPAQVRDEANTRW-UHFFFAOYSA-N 0.000 description 2
- MSICGKUDCSUMJZ-UHFFFAOYSA-N 3-chloro-2-methoxypyridine Chemical compound COC1=NC=CC=C1Cl MSICGKUDCSUMJZ-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- CWSDMQVAPOFQTL-UHFFFAOYSA-N 3-fluoro-4-[[6-(1,2,3,6-tetrahydropyridin-4-yl)pyridin-2-yl]oxymethyl]benzonitrile Chemical compound FC=1C=C(C#N)C=CC=1COC1=NC(=CC=C1)C=1CCNCC=1 CWSDMQVAPOFQTL-UHFFFAOYSA-N 0.000 description 2
- WOVRBUAVPPFTOT-UHFFFAOYSA-N 4-[(4-chloro-2-fluorophenyl)methoxy]-2-(1,2,3,6-tetrahydropyridin-4-yl)pyrimidine Chemical compound ClC1=CC(=C(COC2=NC(=NC=C2)C=2CCNCC=2)C=C1)F WOVRBUAVPPFTOT-UHFFFAOYSA-N 0.000 description 2
- VSXVJRKBBNJVOG-UHFFFAOYSA-N 4-[(4-chloro-2-fluorophenyl)methyl]-6-piperazin-1-yl-2,3-dihydropyrido[3,2-b][1,4]oxazine Chemical compound ClC1=CC(=C(CN2C3=C(OCC2)C=CC(=N3)N2CCNCC2)C=C1)F VSXVJRKBBNJVOG-UHFFFAOYSA-N 0.000 description 2
- BSCXJGYBFUSMSF-UHFFFAOYSA-N 4-[(6-chloropyridin-2-yl)oxymethyl]-3-fluorobenzonitrile Chemical compound ClC1=CC=CC(=N1)OCC1=C(C=C(C#N)C=C1)F BSCXJGYBFUSMSF-UHFFFAOYSA-N 0.000 description 2
- XLUJMQZRMFIOCU-UHFFFAOYSA-N 4-[3-[(4-chloro-2-fluorophenyl)methoxy]phenyl]-1,2,3,6-tetrahydropyridine Chemical compound ClC1=CC(=C(COC=2C=C(C=CC=2)C=2CCNCC=2)C=C1)F XLUJMQZRMFIOCU-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- PTQQSRXKXUUPFN-UHFFFAOYSA-N 6-bromo-3-(3-bromopropoxy)-2-nitropyridine Chemical compound [O-][N+](=O)C1=NC(Br)=CC=C1OCCCBr PTQQSRXKXUUPFN-UHFFFAOYSA-N 0.000 description 2
- OIDKBUZBTRUYPP-UHFFFAOYSA-N 6-bromo-3-(3-bromopropoxy)pyridin-2-amine Chemical compound NC1=NC(Br)=CC=C1OCCCBr OIDKBUZBTRUYPP-UHFFFAOYSA-N 0.000 description 2
- KXJJFSADMPLSMS-UHFFFAOYSA-N 6-bromo-4-[(4-chloro-2-fluorophenyl)methyl]-2,3-dihydropyrido[3,2-b][1,4]oxazine Chemical compound BrC=1C=CC=2OCCN(C=2N=1)CC1=C(C=C(C=C1)Cl)F KXJJFSADMPLSMS-UHFFFAOYSA-N 0.000 description 2
- CCEGQKNJJZETCD-UHFFFAOYSA-N 6-chloro-1,2,3,4-tetrahydronaphthalen-1-ol Chemical compound ClC1=CC=C2C(O)CCCC2=C1 CCEGQKNJJZETCD-UHFFFAOYSA-N 0.000 description 2
- ZXWBSZJVGPCUAG-UHFFFAOYSA-N 6-chloro-2-(6-chloropyridin-2-yl)-3,4-dihydro-1H-isoquinoline Chemical compound ClC=1C=C2CCN(CC2=CC=1)C1=NC(=CC=C1)Cl ZXWBSZJVGPCUAG-UHFFFAOYSA-N 0.000 description 2
- QZTLQKIBFFFCIS-UHFFFAOYSA-N 6-chloro-2-[6-(1,2,3,6-tetrahydropyridin-4-yl)pyridin-2-yl]-3,4-dihydro-1H-isoquinoline Chemical compound ClC=1C=C2CCN(CC2=CC=1)C1=CC=CC(=N1)C=1CCNCC=1 QZTLQKIBFFFCIS-UHFFFAOYSA-N 0.000 description 2
- NJIAKNWTIVDSDA-FQEVSTJZSA-N 7-[4-(1-methylsulfonylpiperidin-4-yl)phenyl]-n-[[(2s)-morpholin-2-yl]methyl]pyrido[3,4-b]pyrazin-5-amine Chemical compound C1CN(S(=O)(=O)C)CCC1C1=CC=C(C=2N=C(NC[C@H]3OCCNC3)C3=NC=CN=C3C=2)C=C1 NJIAKNWTIVDSDA-FQEVSTJZSA-N 0.000 description 2
- VEHVLYRRUAQJIN-UHFFFAOYSA-N 7-bromo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazepine Chemical compound O1CCCNC2=NC(Br)=CC=C21 VEHVLYRRUAQJIN-UHFFFAOYSA-N 0.000 description 2
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 2
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 2
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010018763 Biotin carboxylase Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 102000012234 Cannabinoid receptor type 1 Human genes 0.000 description 2
- 108050002726 Cannabinoid receptor type 1 Proteins 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- AFPCTAFCWUODLH-SANMLTNESA-N ClC1=CC(=C(COC=2C=C(C=CC=2)C=2CCN(CC=2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F Chemical compound ClC1=CC(=C(COC=2C=C(C=CC=2)C=2CCN(CC=2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F AFPCTAFCWUODLH-SANMLTNESA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 description 2
- DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 2
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 description 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000581815 Homo sapiens Regenerating islet-derived protein 3-alpha Proteins 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 2
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 108010075639 MAP Kinase Kinase Kinase 5 Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 2
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 2
- WNTPECVRXOEDIC-UHFFFAOYSA-N N-(7-chloro-3,4-dihydro-2H-chromen-4-yl)-2-methylpropane-2-sulfinamide Chemical compound ClC1=CC=C2C(CCOC2=C1)NS(=O)C(C)(C)C WNTPECVRXOEDIC-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- PMRRRRNVSWSYAV-UHFFFAOYSA-N N-[(4-chloro-2-fluorophenyl)methyl]-6-piperazin-1-ylpyridin-2-amine Chemical compound ClC1=CC(=C(CNC2=NC(=CC=C2)N2CCNCC2)C=C1)F PMRRRRNVSWSYAV-UHFFFAOYSA-N 0.000 description 2
- 102100038991 Neuropeptide Y receptor type 2 Human genes 0.000 description 2
- 101710197945 Neuropeptide Y receptor type 2 Proteins 0.000 description 2
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 2
- QLXKHBNJTPICNF-QMCAAQAGSA-N Sergliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=CC=CC=C1CC1=CC=C(OC)C=C1 QLXKHBNJTPICNF-QMCAAQAGSA-N 0.000 description 2
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229960004733 albiglutide Drugs 0.000 description 2
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 229960001667 alogliptin Drugs 0.000 description 2
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- NGPTUGDXURRBBD-UHFFFAOYSA-N benzyl 4-(6-chloropyridazin-3-yl)piperazine-1-carboxylate Chemical compound N1=NC(Cl)=CC=C1N1CCN(C(=O)OCC=2C=CC=CC=2)CC1 NGPTUGDXURRBBD-UHFFFAOYSA-N 0.000 description 2
- ZUSDVNFSUVPFDX-UHFFFAOYSA-N benzyl 4-(6-oxo-1h-pyridazin-3-yl)piperazine-1-carboxylate Chemical compound C1CN(C2=NNC(=O)C=C2)CCN1C(=O)OCC1=CC=CC=C1 ZUSDVNFSUVPFDX-UHFFFAOYSA-N 0.000 description 2
- YYIQGSYCCNQAGV-UHFFFAOYSA-N benzyl 4-aminopiperidine-1-carboxylate Chemical compound C1CC(N)CCN1C(=O)OCC1=CC=CC=C1 YYIQGSYCCNQAGV-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 108010005794 dulaglutide Proteins 0.000 description 2
- 229960005175 dulaglutide Drugs 0.000 description 2
- 229950003693 dutogliptin Drugs 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 229960004346 glimepiride Drugs 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 102000004241 human proIslet peptide Human genes 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229940028435 intralipid Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 229960002397 linagliptin Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 229960001093 lixisenatide Drugs 0.000 description 2
- 108010004367 lixisenatide Proteins 0.000 description 2
- CHHXEZSCHQVSRE-UHFFFAOYSA-N lobeglitazone Chemical compound C1=CC(OC)=CC=C1OC1=CC(N(C)CCOC=2C=CC(CC3C(NC(=O)S3)=O)=CC=2)=NC=N1 CHHXEZSCHQVSRE-UHFFFAOYSA-N 0.000 description 2
- 229950007685 lobeglitazone Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- GVOVRQLENBTMTR-UHFFFAOYSA-N methyl 1-(4-methylphenyl)sulfonyl-2-[[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]methyl]indole-6-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCN(CC1)CC=1N(C2=CC(=CC=C2C=1)C(=O)OC)S(=O)(=O)C1=CC=C(C)C=C1 GVOVRQLENBTMTR-UHFFFAOYSA-N 0.000 description 2
- SVOUIWXYZGNTFX-UHFFFAOYSA-N methyl 2-(piperazin-1-ylmethyl)-1H-indole-6-carboxylate Chemical compound N1(CCNCC1)CC=1NC2=CC(=CC=C2C=1)C(=O)OC SVOUIWXYZGNTFX-UHFFFAOYSA-N 0.000 description 2
- WJOZGPUJUMZTCC-UHFFFAOYSA-N methyl 2-[[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]methyl]-1H-indole-6-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCN(CC1)CC=1NC2=CC(=CC=C2C=1)C(=O)OC WJOZGPUJUMZTCC-UHFFFAOYSA-N 0.000 description 2
- JBQCVBLFISTROD-QHCPKHFHSA-N methyl 2-[[4-[2-[(4-chloro-2-fluorophenyl)methoxy]pyrimidin-4-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(COC2=NC=CC(=N2)C2CCN(CC2)CC=2N(C3=C(N=2)C=CC(=C3)C(=O)OC)C[C@H]2OCC2)C=C1)F JBQCVBLFISTROD-QHCPKHFHSA-N 0.000 description 2
- ZSHKWBFBAWKNHV-UHFFFAOYSA-N methyl 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperazin-1-yl]methyl]-1H-indole-6-carboxylate Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)CC=2NC3=CC(=CC=C3C=2)C(=O)OC)C=C1)F ZSHKWBFBAWKNHV-UHFFFAOYSA-N 0.000 description 2
- BQZVHVYEWMVZAO-PAMMARIWSA-N methyl 2-[[4-[6-[(6-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)oxy]pyridin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC=1C=C2CCCC(C2=CC=1)OC1=CC=CC(=N1)C1=CCN(CC1)CC1=NC2=C(N1C[C@H]1OCC1)C=C(C=C2)C(=O)OC BQZVHVYEWMVZAO-PAMMARIWSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 2
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 description 2
- 229960001601 obeticholic acid Drugs 0.000 description 2
- 239000003401 opiate antagonist Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 108700027806 rGLP-1 Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229950011516 remogliflozin etabonate Drugs 0.000 description 2
- UAOCLDQAQNNEAX-ABMICEGHSA-N remogliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 description 2
- 229960002354 repaglinide Drugs 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 108010060325 semaglutide Proteins 0.000 description 2
- 229950011186 semaglutide Drugs 0.000 description 2
- 229950000378 sergliflozin etabonate Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229960004034 sitagliptin Drugs 0.000 description 2
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 229960000351 terfenadine Drugs 0.000 description 2
- SNQFMTPNNVXRLY-FQEVSTJZSA-N tert-butyl 2-[[4-(6-bromopyridin-2-yl)-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound BrC1=CC=CC(=N1)C1=CCN(CC1)CC1=NC2=C(N1C[C@H]1OCC1)C=C(C=C2)C(=O)OC(C)(C)C SNQFMTPNNVXRLY-FQEVSTJZSA-N 0.000 description 2
- SCOCVBIYLFNNEK-PMERELPUSA-N tert-butyl 2-[[4-[1-[(4-chloro-2-fluorophenyl)methyl]indol-6-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(CN2C=CC3=CC=C(C=C23)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)OC(C)(C)C)C=C1)F SCOCVBIYLFNNEK-PMERELPUSA-N 0.000 description 2
- QZEUOGVISHXHNL-SANMLTNESA-N tert-butyl 2-[[4-[1-[2-(4-chloro-2-fluorophenyl)ethyl]-2-oxopyridin-3-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(CCN2C(C(=CC=C2)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)OC(C)(C)C)=O)C=C1)F QZEUOGVISHXHNL-SANMLTNESA-N 0.000 description 2
- MYUPDQZGOHWLQE-VWLOTQADSA-N tert-butyl 2-[[4-[1-[2-(4-chloro-2-fluorophenyl)ethyl]-6-oxopyridazin-3-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(CCN2N=C(C=CC2=O)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)OC(C)(C)C)C=C1)F MYUPDQZGOHWLQE-VWLOTQADSA-N 0.000 description 2
- ZHHSCPHKZNOZJH-DEOSSOPVSA-N tert-butyl 2-[[4-[2-[(4-chloro-2-fluorophenyl)methoxy]pyrimidin-4-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(COC2=NC=CC(=N2)N2CCN(CC2)CC=2N(C3=C(N=2)C=CC(=C3)C(=O)OC(C)(C)C)C[C@H]2OCC2)C=C1)F ZHHSCPHKZNOZJH-DEOSSOPVSA-N 0.000 description 2
- LMGVGZPKRZPULD-SANMLTNESA-N tert-butyl 2-[[4-[3-[(4-chloro-2-fluorophenyl)methoxy]-2-oxopyridin-1-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(COC=2C(N(C=CC=2)C2=CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)OC(C)(C)C)=O)C=C1)F LMGVGZPKRZPULD-SANMLTNESA-N 0.000 description 2
- WOXOOGSXKVHXJN-LJAQVGFWSA-N tert-butyl 2-[[4-[3-[(4-chloro-2-fluorophenyl)methoxy]phenyl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(COC=2C=C(C=CC=2)C=2CCN(CC=2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)OC(C)(C)C)C=C1)F WOXOOGSXKVHXJN-LJAQVGFWSA-N 0.000 description 2
- PAWXYQKGZFYEPE-NDEPHWFRSA-N tert-butyl 2-[[4-[3-[2-(4-chloro-2-fluorophenyl)ethyl]-2-oxobenzimidazol-1-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(CCN2C(N(C3=C2C=CC=C3)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)OC(C)(C)C)=O)C=C1)F PAWXYQKGZFYEPE-NDEPHWFRSA-N 0.000 description 2
- FWSLSXFIHGFFFY-VWLOTQADSA-N tert-butyl 2-[[4-[4-[(4-chloro-2-fluorophenyl)methoxy]pyrimidin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(COC2=NC(=NC=C2)C2=CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)OC(C)(C)C)C=C1)F FWSLSXFIHGFFFY-VWLOTQADSA-N 0.000 description 2
- JHDPHGCETOTQSU-DEOSSOPVSA-N tert-butyl 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-3-oxopiperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2C(CN(CC2)CC=2N(C3=C(N=2)C=CC(=C3)C(=O)OC(C)(C)C)C[C@H]2OCC2)=O)C=C1)F JHDPHGCETOTQSU-DEOSSOPVSA-N 0.000 description 2
- OMOJBUIGBZXHKK-VWLOTQADSA-N tert-butyl 2-[[4-[6-[(4-chloro-2-fluorophenyl)methylamino]pyridin-2-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound C(C)(C)(C)OC(=O)C=1C=CC2=C(N(C(=N2)CN2CCN(CC2)C2=NC(=CC=C2)NCC2=C(C=C(C=C2)Cl)F)C[C@H]2OCC2)C=1 OMOJBUIGBZXHKK-VWLOTQADSA-N 0.000 description 2
- VVSQFBNCSCURDT-UHFFFAOYSA-N tert-butyl 4-(1H-indol-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=CC1)c1ccc2cc[nH]c2c1 VVSQFBNCSCURDT-UHFFFAOYSA-N 0.000 description 2
- UZWNSZQOPAPHMO-UHFFFAOYSA-N tert-butyl 4-(2-chloropyrimidin-4-yl)-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound ClC1=NC=CC(=N1)C1=CCN(CC1)C(=O)OC(C)(C)C UZWNSZQOPAPHMO-UHFFFAOYSA-N 0.000 description 2
- GZYDEJABHMSOIM-UHFFFAOYSA-N tert-butyl 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=NC(Cl)=N1 GZYDEJABHMSOIM-UHFFFAOYSA-N 0.000 description 2
- OFIRPWPZQULQCR-UHFFFAOYSA-N tert-butyl 4-(2-methoxypyridin-3-yl)piperazine-1-carboxylate Chemical compound COC1=NC=CC=C1N1CCN(C(=O)OC(C)(C)C)CC1 OFIRPWPZQULQCR-UHFFFAOYSA-N 0.000 description 2
- UVSRGXXCMBISLX-UHFFFAOYSA-N tert-butyl 4-(3-hydroxyphenyl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(C=2C=C(O)C=CC=2)=C1 UVSRGXXCMBISLX-UHFFFAOYSA-N 0.000 description 2
- RXJYXRDBYZANLO-UHFFFAOYSA-N tert-butyl 4-(6-chloropyridin-2-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC(Cl)=N1 RXJYXRDBYZANLO-UHFFFAOYSA-N 0.000 description 2
- HJMORMWPHUBBQD-UHFFFAOYSA-N tert-butyl 4-[1-[(4-chloro-2-fluorophenyl)methyl]indol-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound ClC1=CC(=C(CN2C=CC3=CC=C(C=C23)C2=CCN(CC2)C(=O)OC(C)(C)C)C=C1)F HJMORMWPHUBBQD-UHFFFAOYSA-N 0.000 description 2
- YDAHXGJBVOMOED-UHFFFAOYSA-N tert-butyl 4-[2-[(4-chloro-2-fluorophenyl)methoxy]pyrimidin-4-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound ClC1=CC(=C(COC2=NC=CC(=N2)C2=CCN(CC2)C(=O)OC(C)(C)C)C=C1)F YDAHXGJBVOMOED-UHFFFAOYSA-N 0.000 description 2
- STIXTXRXKGWESM-UHFFFAOYSA-N tert-butyl 4-[3-[(4-chloro-2-fluorophenyl)methoxy]-2-oxopyridin-1-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound ClC1=CC(=C(COC=2C(N(C=CC=2)C2=CCN(CC2)C(=O)OC(C)(C)C)=O)C=C1)F STIXTXRXKGWESM-UHFFFAOYSA-N 0.000 description 2
- PBMVZEOTPJUJRL-UHFFFAOYSA-N tert-butyl 4-[3-[(4-chloro-2-fluorophenyl)methoxy]phenyl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound ClC1=CC(=C(C=C1)COC=1C=C(C=CC=1)C=1CCN(CC=1)C(=O)OC(C)(C)C)F PBMVZEOTPJUJRL-UHFFFAOYSA-N 0.000 description 2
- UAHIIUIPAOVJTO-UHFFFAOYSA-N tert-butyl 4-[4-[(4-chloro-2-fluorophenyl)methoxy]pyrimidin-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound ClC1=CC(=C(COC2=NC(=NC=C2)C2=CCN(CC2)C(=O)OC(C)(C)C)C=C1)F UAHIIUIPAOVJTO-UHFFFAOYSA-N 0.000 description 2
- PSOONBYKWZNCNL-UHFFFAOYSA-N tert-butyl 4-[6-(6-chloro-3,4-dihydro-1H-isoquinolin-2-yl)pyridin-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound ClC=1C=C2CCN(CC2=CC=1)C1=CC=CC(=N1)C=1CCN(CC=1)C(=O)OC(C)(C)C PSOONBYKWZNCNL-UHFFFAOYSA-N 0.000 description 2
- GJIMHRDYYHSEED-UHFFFAOYSA-N tert-butyl 4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-3-oxopiperazine-1-carboxylate Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2C(CN(CC2)C(=O)OC(C)(C)C)=O)C=C1)F GJIMHRDYYHSEED-UHFFFAOYSA-N 0.000 description 2
- HVFJPCIEZKMLOH-UHFFFAOYSA-N tert-butyl 4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound C(#N)C1=CC(=C(C=C1)COC1=CC=CC(=N1)C=1CCN(CC=1)C(=O)OC(C)(C)C)F HVFJPCIEZKMLOH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229950006667 tofogliflozin Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 229960001254 vildagliptin Drugs 0.000 description 2
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- SCVHJVCATBPIHN-SJCJKPOMSA-N (3s)-3-[[(2s)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound N([C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C(=C(F)C=C(F)C=1F)F)C(=O)C(=O)NC1=CC=CC=C1C(C)(C)C SCVHJVCATBPIHN-SJCJKPOMSA-N 0.000 description 1
- YBNDRTRLXPEWKQ-UHFFFAOYSA-N (4-chloro-2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1F YBNDRTRLXPEWKQ-UHFFFAOYSA-N 0.000 description 1
- ODMMHGMIZYLHNN-UHFFFAOYSA-N (4-chloro-2-fluorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1F ODMMHGMIZYLHNN-UHFFFAOYSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- SHKXZIQNFMOPBS-OOMQYRRCSA-N (4r)-4-[(3s,5s,7r,8r,9s,10s,12s,13r,14s,17r)-7,12-dihydroxy-3-(icosanoylamino)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound O[C@H]1C[C@@H]2[C@@]3(C)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC)C[C@H]3C[C@@H](O)[C@H]2[C@@H]2CC[C@H]([C@H](C)CCC(O)=O)[C@]21C SHKXZIQNFMOPBS-OOMQYRRCSA-N 0.000 description 1
- HDHDTKMUACZDAA-PHNIDTBTSA-N (4r,7s,10s,13r,16s,19r,22r)-22-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1h-imidazol-5-ylmethyl)-7-(1h-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20 Chemical compound C([C@@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](C(N[C@@H](CC=2N=CNC=2)C(=O)N1)=O)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(N)=O)C1=CC=CC=C1 HDHDTKMUACZDAA-PHNIDTBTSA-N 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- HXBMIQJOSHZCFX-UHFFFAOYSA-N 1-(bromomethyl)-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1CBr HXBMIQJOSHZCFX-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- AMAQSWJMMLVTNI-UHFFFAOYSA-N 1-[(4-chloro-2-fluorophenyl)methyl]-6-piperazin-1-ylpyrrolo[2,3-b]pyridine Chemical compound ClC1=CC(=C(CN2C=CC=3C2=NC(=CC=3)N2CCNCC2)C=C1)F AMAQSWJMMLVTNI-UHFFFAOYSA-N 0.000 description 1
- ILFQESBNIFRZNC-UHFFFAOYSA-N 1-[2-(4-chloro-2-fluorophenyl)ethyl]-3-piperidin-4-yl-4H-quinazolin-2-one Chemical compound ClC1=CC(=C(CCN2C(N(CC3=CC=CC=C23)C2CCNCC2)=O)C=C1)F ILFQESBNIFRZNC-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- MAKFMOSBBNKPMS-UHFFFAOYSA-N 2,3-dichloropyridine Chemical compound ClC1=CC=CN=C1Cl MAKFMOSBBNKPMS-UHFFFAOYSA-N 0.000 description 1
- FFRFTURYWWFKIC-UHFFFAOYSA-N 2,6-dibromo-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Br)N=C1Br FFRFTURYWWFKIC-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- UQMJDENQJRBEQI-UHFFFAOYSA-N 2-(4-chloro-2-fluorophenyl)acetaldehyde Chemical compound FC1=CC(Cl)=CC=C1CC=O UQMJDENQJRBEQI-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- ZZWWXIBKLBMSCS-FQEVSTJZSA-N 2-[1-[(2r)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl]-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno[2,3-d]pyrimidin-3-yl]-2-methylpropanoic acid Chemical compound COC1=CC=CC=C1[C@@H](OC1CCOCC1)CN1C(=O)N(C(C)(C)C(O)=O)C(=O)C2=C1SC(C=1OC=CN=1)=C2C ZZWWXIBKLBMSCS-FQEVSTJZSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- RJKBDCZSQXFDFZ-VWLOTQADSA-N 2-[[4-[1-[(4-chloro-2-fluorophenyl)methoxy]isoquinolin-3-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=NC(=CC3=CC=CC=C23)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F RJKBDCZSQXFDFZ-VWLOTQADSA-N 0.000 description 1
- PZVMFYOLRBLQAZ-MHZLTWQESA-N 2-[[4-[1-[(4-chloro-2-fluorophenyl)methyl]indol-6-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CN2C=CC3=CC=C(C=C23)C2=CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F PZVMFYOLRBLQAZ-MHZLTWQESA-N 0.000 description 1
- ZEDXZUWIJWCGPL-SANMLTNESA-N 2-[[4-[1-[(4-chloro-2-fluorophenyl)methyl]indol-6-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CN2C=CC3=CC=C(C=C23)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F ZEDXZUWIJWCGPL-SANMLTNESA-N 0.000 description 1
- UHJYFDBSAFMVDQ-VWLOTQADSA-N 2-[[4-[1-[(4-chloro-2-fluorophenyl)methyl]pyrrolo[2,3-b]pyridin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CN2C=CC=3C2=NC(=CC=3)C2=CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F UHJYFDBSAFMVDQ-VWLOTQADSA-N 0.000 description 1
- IZRRPNYSZZRUPH-DEOSSOPVSA-N 2-[[4-[1-[(4-chloro-2-fluorophenyl)methyl]pyrrolo[2,3-b]pyridin-6-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CN2C=CC=3C2=NC(=CC=3)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F IZRRPNYSZZRUPH-DEOSSOPVSA-N 0.000 description 1
- GWRMIJTXNPICMZ-VWLOTQADSA-N 2-[[4-[1-[(4-chloro-2-fluorophenyl)methyl]pyrrolo[2,3-b]pyridin-6-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CN2C=CC=3C2=NC(=CC=3)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F GWRMIJTXNPICMZ-VWLOTQADSA-N 0.000 description 1
- BOYYFQSYQVCQHP-MHZLTWQESA-N 2-[[4-[1-[2-(4-chloro-2-fluorophenyl)ethyl]-2-oxo-4H-quinazolin-3-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CCN2C(N(CC3=CC=CC=C23)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)=O)C=C1)F BOYYFQSYQVCQHP-MHZLTWQESA-N 0.000 description 1
- DBZCKCORMUQUII-QHCPKHFHSA-N 2-[[4-[1-[2-(4-chloro-2-fluorophenyl)ethyl]-6-oxopyridazin-3-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CCN2N=C(C=CC2=O)C2=CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F DBZCKCORMUQUII-QHCPKHFHSA-N 0.000 description 1
- VTHALWHPJGLMRD-DEOSSOPVSA-N 2-[[4-[2-[(4-chloro-2-fluorophenyl)methoxy]pyridin-4-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=NC=CC(=C2)C=2CCN(CC=2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F VTHALWHPJGLMRD-DEOSSOPVSA-N 0.000 description 1
- VRFIPRVJUYROBV-QFIPXVFZSA-N 2-[[4-[2-[(4-chloro-2-fluorophenyl)methoxy]pyrimidin-4-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=NC=CC(=N2)C=2CCN(CC=2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F VRFIPRVJUYROBV-QFIPXVFZSA-N 0.000 description 1
- YMJAVARPOCYRPX-QFIPXVFZSA-N 2-[[4-[2-[(4-cyano-2-fluorophenyl)methoxy]pyrimidin-4-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=NC=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F YMJAVARPOCYRPX-QFIPXVFZSA-N 0.000 description 1
- XUMCHFYSXBEMHP-QHCPKHFHSA-N 2-[[4-[3-[(4-chloro-2-fluorophenyl)methoxy]-2-fluorophenyl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC=2C(=C(C=CC=2)C2=CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)F)C=C1)F XUMCHFYSXBEMHP-QHCPKHFHSA-N 0.000 description 1
- ZXXMTLZAMALRFP-QHCPKHFHSA-N 2-[[4-[3-[(4-chloro-2-fluorophenyl)methoxy]-4,5-difluorophenyl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC=2C=C(C=C(C=2F)F)C2=CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F ZXXMTLZAMALRFP-QHCPKHFHSA-N 0.000 description 1
- ODPFZFQILOFMOY-DEOSSOPVSA-N 2-[[4-[3-[(4-chloro-2-fluorophenyl)methoxy]-4-fluorophenyl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC=2C=C(C=CC=2F)C=2CCN(CC=2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F ODPFZFQILOFMOY-DEOSSOPVSA-N 0.000 description 1
- AFKRWEBWKXZZBO-VWLOTQADSA-N 2-[[4-[3-[(4-chloro-2-fluorophenyl)methoxy]-5-fluorophenyl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC=2C=C(C=C(C=2)F)C=2CCN(CC=2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F AFKRWEBWKXZZBO-VWLOTQADSA-N 0.000 description 1
- YDZXZTHSZIUORL-DEOSSOPVSA-N 2-[[4-[4-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC(=NC=C2)C=2CCN(CC=2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F YDZXZTHSZIUORL-DEOSSOPVSA-N 0.000 description 1
- JVXUVMZIPFZNHT-UHFFFAOYSA-N 2-[[4-[4-[(4-chloro-2-fluorophenyl)methyl]-2,3-dihydropyrido[3,2-b][1,4]oxazin-6-yl]piperazin-1-yl]methyl]-3-[(1-methylimidazol-2-yl)methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CN2C3=C(OCC2)C=CC(=N3)N2CCN(CC2)CC2=NC3=C(N2CC=2N(C=CN=2)C)C=C(C=C3)C(=O)O)C=C1)F JVXUVMZIPFZNHT-UHFFFAOYSA-N 0.000 description 1
- BBRVJYFDFKKZFR-SANMLTNESA-N 2-[[4-[4-[2-(3-chlorophenyl)ethyl]-2,3-dihydropyrido[3,2-b][1,4]oxazin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC=1C=C(CCN2C3=C(OCC2)C=CC(=N3)C2=CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=CC=1 BBRVJYFDFKKZFR-SANMLTNESA-N 0.000 description 1
- WZLVLUKCHADEFS-DEOSSOPVSA-N 2-[[4-[5-[(4-chloro-2-fluorophenyl)methoxy]-2-fluorophenyl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC=2C=CC(=C(C=2)C=2CCN(CC=2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)F)C=C1)F WZLVLUKCHADEFS-DEOSSOPVSA-N 0.000 description 1
- JTVGXWLBPOCNBG-DEOSSOPVSA-N 2-[[4-[5-[(4-chloro-2-fluorophenyl)methoxy]pyridin-3-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC=2C=C(C=NC=2)C=2CCN(CC=2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F JTVGXWLBPOCNBG-DEOSSOPVSA-N 0.000 description 1
- IDXTUASCDZUNKW-QFIPXVFZSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyrazin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CN=CC(=N2)C2=CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F IDXTUASCDZUNKW-QFIPXVFZSA-N 0.000 description 1
- MYMZDHKKBXEXOO-NRFANRHFSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyrazin-2-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CN=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F MYMZDHKKBXEXOO-NRFANRHFSA-N 0.000 description 1
- FEBNJTUQUXISQN-QFIPXVFZSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyrazin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CN=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F FEBNJTUQUXISQN-QFIPXVFZSA-N 0.000 description 1
- RARUUNZXAQMNPM-QHCPKHFHSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2=CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F RARUUNZXAQMNPM-QHCPKHFHSA-N 0.000 description 1
- XWXBDYLDKURBRP-QFIPXVFZSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-3-oxo-1,4-diazepan-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2C(CN(CCC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)=O)C=C1)F XWXBDYLDKURBRP-QFIPXVFZSA-N 0.000 description 1
- MHSLCEIQJLBJPG-QFIPXVFZSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-5-oxo-1,4-diazepan-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2CCN(CCC2=O)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F MHSLCEIQJLBJPG-QFIPXVFZSA-N 0.000 description 1
- AZGHRMSBZBTCCO-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperazin-1-yl]methyl]-1-methylindole-6-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)CC=2N(C3=CC(=CC=C3C=2)C(=O)O)C)C=C1)F AZGHRMSBZBTCCO-UHFFFAOYSA-N 0.000 description 1
- CMYNDMRCLVCWIC-QHCPKHFHSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methyl-methylamino]pyridin-2-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CN(C2=CC=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C)C=C1)F CMYNDMRCLVCWIC-QHCPKHFHSA-N 0.000 description 1
- CTYDSQLBIOCDLD-DEOSSOPVSA-N 2-[[4-[6-[(4-chlorophenyl)methoxy]pyridin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC=C(COC2=CC=CC(=N2)C=2CCN(CC=2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1 CTYDSQLBIOCDLD-DEOSSOPVSA-N 0.000 description 1
- NDJMYVFSIBJOHG-QHCPKHFHSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyrazin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CN=CC(=N2)C2=CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F NDJMYVFSIBJOHG-QHCPKHFHSA-N 0.000 description 1
- HESKXCZERNKUOO-QFIPXVFZSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyrazin-2-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CN=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F HESKXCZERNKUOO-QFIPXVFZSA-N 0.000 description 1
- BPOJFLXKPVTGNP-QHCPKHFHSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyrazin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CN=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F BPOJFLXKPVTGNP-QHCPKHFHSA-N 0.000 description 1
- KJWXOOXFYBCXCK-ZZHFZYNASA-N 2-[[4-[6-[(7-chloro-3,4-dihydro-2H-chromen-4-yl)amino]pyridin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC=C2C(CCOC2=C1)NC1=CC=CC(=N1)C1=CCN(CC1)CC1=NC2=C(N1C[C@H]1OCC1)C=C(C=C2)C(=O)O KJWXOOXFYBCXCK-ZZHFZYNASA-N 0.000 description 1
- HBMIWBJUBOJRRF-VWLOTQADSA-N 2-[[4-[7-(4-chloro-2-fluorophenyl)-1-oxo-3,4-dihydroisoquinolin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(C=C1)C1=CC=C2CCN(C(C2=C1)=O)C1CCN(CC1)CC1=NC2=C(N1C[C@H]1OCC1)C=C(C=C2)C(=O)O)F HBMIWBJUBOJRRF-VWLOTQADSA-N 0.000 description 1
- XFVKKYJIVRXQDR-DEOSSOPVSA-N 2-[[4-[7-[(4-chloro-2-fluorophenyl)methoxy]-1H-pyrrolo[2,3-c]pyridin-5-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC=2N=C(C=C3C=2NC=C3)C=2CCN(CC=2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F XFVKKYJIVRXQDR-DEOSSOPVSA-N 0.000 description 1
- PGHNGLVZADBTLT-VWLOTQADSA-N 2-[[4-[8-[(4-chloro-2-fluorophenyl)methyl]-6,7-dihydro-5H-1,8-naphthyridin-2-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(CN2CCCC=3C=CC(=NC2=3)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F PGHNGLVZADBTLT-VWLOTQADSA-N 0.000 description 1
- WPQPMBHBAJENFB-VNXZQDSDSA-N 2-[[5-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2C3CN(C(C2)C3)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F WPQPMBHBAJENFB-VNXZQDSDSA-N 0.000 description 1
- UDHDQUIQHUQKFG-VHYCJAOWSA-N 2-[[5-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-2,5-diazabicyclo[2.2.2]octan-2-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2C3CN(C(C2)CC3)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F UDHDQUIQHUQKFG-VHYCJAOWSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 1
- GUSWJGOYDXFJSI-UHFFFAOYSA-N 3,6-dichloropyridazine Chemical compound ClC1=CC=C(Cl)N=N1 GUSWJGOYDXFJSI-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- YYLORWGZTAPRTJ-UHFFFAOYSA-N 3-[(4-chloro-2-fluorophenyl)methoxy]-1H-pyridin-2-one Chemical compound ClC1=CC(=C(COC=2C(NC=CC=2)=O)C=C1)F YYLORWGZTAPRTJ-UHFFFAOYSA-N 0.000 description 1
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 description 1
- SNUFTZWLPMCGGW-DEOSSOPVSA-N 3-[[(2S)-oxetan-2-yl]methyl]-2-[[4-[6-[[4-(trifluoromethyl)phenyl]methoxy]pyridin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound O1[C@@H](CC1)CN1C(=NC2=C1C=C(C=C2)C(=O)O)CN1CCC(=CC1)C1=NC(=CC=C1)OCC1=CC=C(C=C1)C(F)(F)F SNUFTZWLPMCGGW-DEOSSOPVSA-N 0.000 description 1
- SNBIAKJEFSCBDU-QFIPXVFZSA-N 3-[[(2S)-oxetan-2-yl]methyl]-2-[[4-[6-[[6-(trifluoromethyl)pyridin-3-yl]methoxy]pyridin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound O1[C@@H](CC1)CN1C(=NC2=C1C=C(C=C2)C(=O)O)CN1CC=C(CC1)C1=NC(=CC=C1)OCC=1C=NC(=CC=1)C(F)(F)F SNBIAKJEFSCBDU-QFIPXVFZSA-N 0.000 description 1
- MNOJRWOWILAHAV-UHFFFAOYSA-N 3-bromophenol Chemical compound OC1=CC=CC(Br)=C1 MNOJRWOWILAHAV-UHFFFAOYSA-N 0.000 description 1
- YGAURRAHPYQHDC-UHFFFAOYSA-N 3-fluoro-4-(hydroxymethyl)benzonitrile Chemical compound OCC1=CC=C(C#N)C=C1F YGAURRAHPYQHDC-UHFFFAOYSA-N 0.000 description 1
- FDXNZTUWNBRZDX-UHFFFAOYSA-N 4,6-dichloro-1h-imidazo[4,5-c]pyridine Chemical compound ClC1=NC(Cl)=CC2=C1N=CN2 FDXNZTUWNBRZDX-UHFFFAOYSA-N 0.000 description 1
- DTKXKBVOPZRELF-UHFFFAOYSA-N 4-[(4-chloro-2-fluorophenyl)methoxy]-6-(1,2,3,6-tetrahydropyridin-4-yl)-1H-imidazo[4,5-c]pyridine Chemical compound ClC1=CC(=C(COC2=NC(=CC3=C2NC=N3)C=2CCNCC=2)C=C1)F DTKXKBVOPZRELF-UHFFFAOYSA-N 0.000 description 1
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 1
- IETKPTYAGKZLKY-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IETKPTYAGKZLKY-UHFFFAOYSA-N 0.000 description 1
- WKDPVUNVIQTGBA-UHFFFAOYSA-N 5-bromo-7-[(4-chloro-2-fluorophenyl)methoxy]-1H-pyrrolo[2,3-c]pyridine Chemical compound BrC=1C=C2C(=C(N=1)OCC1=C(C=C(C=C1)Cl)F)NC=C2 WKDPVUNVIQTGBA-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- AIZTZRXTVNJWCI-UHFFFAOYSA-N 6-bromo-1-[(4-chloro-2-fluorophenyl)methyl]pyrrolo[2,3-b]pyridine Chemical compound BrC1=CC=C2C(=N1)N(C=C2)CC1=C(C=C(C=C1)Cl)F AIZTZRXTVNJWCI-UHFFFAOYSA-N 0.000 description 1
- MAWGHOPSCKCTPA-UHFFFAOYSA-N 6-bromo-1h-indole Chemical compound BrC1=CC=C2C=CNC2=C1 MAWGHOPSCKCTPA-UHFFFAOYSA-N 0.000 description 1
- LKXJGVGBEDEAAW-UHFFFAOYSA-N 6-bromo-1h-pyrrolo[2,3-b]pyridine Chemical compound BrC1=CC=C2C=CNC2=N1 LKXJGVGBEDEAAW-UHFFFAOYSA-N 0.000 description 1
- LJUDFYPEMLMAEA-UHFFFAOYSA-N 6-bromo-2-[(4-chloro-2-fluorophenyl)methoxy]-3-nitropyridine Chemical compound BrC1=CC=C(C(=N1)OCC1=C(C=C(C=C1)Cl)F)[N+](=O)[O-] LJUDFYPEMLMAEA-UHFFFAOYSA-N 0.000 description 1
- GSGNTVQLHGOEMB-UHFFFAOYSA-N 6-bromo-2-nitropyridin-3-ol Chemical compound OC1=CC=C(Br)N=C1[N+]([O-])=O GSGNTVQLHGOEMB-UHFFFAOYSA-N 0.000 description 1
- OTGDCHNSXQUISE-UHFFFAOYSA-N 6-bromo-3,4-dihydro-2h-pyrido[3,2-b][1,4]oxazine Chemical compound O1CCNC2=NC(Br)=CC=C21 OTGDCHNSXQUISE-UHFFFAOYSA-N 0.000 description 1
- NSURINBXOVVUNR-UHFFFAOYSA-N 6-chloro-1,2,3,4-tetrahydroisoquinoline Chemical compound C1NCCC2=CC(Cl)=CC=C21 NSURINBXOVVUNR-UHFFFAOYSA-N 0.000 description 1
- WQKHERPPDYPMNX-UHFFFAOYSA-N 6-chloro-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(Cl)=CC=C21 WQKHERPPDYPMNX-UHFFFAOYSA-N 0.000 description 1
- NZHQOQHMVYLJFM-UHFFFAOYSA-N 6-chloro-4-[(4-chloro-2-fluorophenyl)methoxy]-1H-imidazo[4,5-c]pyridine Chemical compound ClC1=CC2=C(C(=N1)OCC1=C(C=C(C=C1)Cl)F)NC=N2 NZHQOQHMVYLJFM-UHFFFAOYSA-N 0.000 description 1
- OKEGJCZJBGKEIA-UHFFFAOYSA-N 7-(4-chloro-2-fluorophenyl)-2-piperidin-4-yl-3,4-dihydroisoquinolin-1-one Chemical compound ClC1=CC(=C(C=C1)C1=CC=C2CCN(C(C2=C1)=O)C1CCNCC1)F OKEGJCZJBGKEIA-UHFFFAOYSA-N 0.000 description 1
- CIMHKLQNIUEENC-UHFFFAOYSA-N 7-(4-chloro-2-fluorophenyl)-3,4-dihydro-2H-isoquinolin-1-one Chemical compound ClC1=CC(=C(C=C1)C1=CC=C2CCNC(C2=C1)=O)F CIMHKLQNIUEENC-UHFFFAOYSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- MKWZTQIJYJMOSM-UHFFFAOYSA-N 7-[(4-chloro-2-fluorophenyl)methoxy]-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[2,3-c]pyridine Chemical compound ClC1=CC(=C(COC=2N=C(C=C3C=2NC=C3)C=2CCNCC=2)C=C1)F MKWZTQIJYJMOSM-UHFFFAOYSA-N 0.000 description 1
- DRDDOAWCDDBYHZ-UHFFFAOYSA-N 7-bromo-3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1CNC(=O)C2=CC(Br)=CC=C21 DRDDOAWCDDBYHZ-UHFFFAOYSA-N 0.000 description 1
- YBCBUDKINFJWHE-UHFFFAOYSA-N 7-chloro-2,3-dihydrochromen-4-one Chemical compound O=C1CCOC2=CC(Cl)=CC=C21 YBCBUDKINFJWHE-UHFFFAOYSA-N 0.000 description 1
- ZKRTWXXJEXSHCT-UHFFFAOYSA-N 7-chloro-3,4-dihydro-2h-chromen-4-amine Chemical compound ClC1=CC=C2C(N)CCOC2=C1 ZKRTWXXJEXSHCT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100029649 Beta-arrestin-1 Human genes 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229940123169 Caspase inhibitor Drugs 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- STSMZKCOEVVELA-QHCPKHFHSA-N ClC1=CC(=C(COC2=CC=CC(=N2)N2CCN(CCC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2CCN(CCC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F STSMZKCOEVVELA-QHCPKHFHSA-N 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 108020003264 Cotransporters Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101000785259 Crocosmia x crocosmiiflora Myricetin 3-O-glucosyl 1,2-rhamnoside 6'-O-caffeoyltransferase AT2 Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- BZCALJIHZVNMGJ-HSZRJFAPSA-N Fasiglifam Chemical compound CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C1=CC=CC(COC=2C=C3OC[C@@H](CC(O)=O)C3=CC=2)=C1 BZCALJIHZVNMGJ-HSZRJFAPSA-N 0.000 description 1
- 101150108864 Ffar1 gene Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229940125827 GPR40 agonist Drugs 0.000 description 1
- 229940126043 Galectin-3 inhibitor Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 description 1
- 229940123232 Glucagon receptor agonist Drugs 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- HNSCCNJWTJUGNQ-UHFFFAOYSA-N Glyclopyramide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NC(=O)NN1CCCC1 HNSCCNJWTJUGNQ-UHFFFAOYSA-N 0.000 description 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 description 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 1
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 description 1
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 description 1
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 description 1
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 1
- 101000581402 Homo sapiens Melanin-concentrating hormone receptor 1 Proteins 0.000 description 1
- 101000633401 Homo sapiens Neuropeptide Y receptor type 5 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 229940119490 Ketohexokinase inhibitor Drugs 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 1
- 101150113964 MPK5 gene Proteins 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 description 1
- 102100023724 Melanocortin receptor 4 Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229940125818 PF-05221304 Drugs 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 108700027412 Pegbelfermin Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102100029909 Peptide YY Human genes 0.000 description 1
- 108010088847 Peptide YY Proteins 0.000 description 1
- 229940122985 Peptide agonist Drugs 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 102000015925 Proto-oncogene Mas Human genes 0.000 description 1
- 108050004181 Proto-oncogene Mas Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091006614 SLC10A2 Proteins 0.000 description 1
- 108091006277 SLC5A1 Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- KPWYNAGOBXLMSE-UHFFFAOYSA-N Tipelukast Chemical compound CCCC1=C(O)C(C(C)=O)=CC=C1SCCCOC1=CC=C(C(C)=O)C(OCCCC(O)=O)=C1CCC KPWYNAGOBXLMSE-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 1
- 102000005456 Vesicular Transport Adaptor Proteins Human genes 0.000 description 1
- 108010031770 Vesicular Transport Adaptor Proteins Proteins 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 101100264077 Xenopus laevis wrn gene Proteins 0.000 description 1
- NALKUTSPQGNISH-YFKPBYRVSA-N [(2S)-oxetan-2-yl]methyl methanesulfonate Chemical compound CS(=O)(=O)OC[C@H]1OCC1 NALKUTSPQGNISH-YFKPBYRVSA-N 0.000 description 1
- ULVBLFBUTQMAGZ-RTNCXNSASA-N [(2r,3r,4s,5r,6r)-6-[[3-[(3s,4r,5r)-3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-5-yl]phenyl]carbamoylamino]-3,5-dihydroxy-4-phenylmethoxyoxan-2-yl]methyl hydrogen sulfate Chemical compound O([C@H]1[C@H](O)[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]1O)NC(=O)NC=1C=CC=C(C=1)[C@@H]1C2=CC(=CC=C2S(=O)(=O)C[C@@]([C@@H]1O)(CC)CCCC)N(C)C)CC1=CC=CC=C1 ULVBLFBUTQMAGZ-RTNCXNSASA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- QJWJPMLDQYEPPW-AUKZVGPFSA-N aclimostat Chemical compound O1CCN(CC1)CCC1CN(C1)C(=O)O[C@H]1[C@H]([C@@H]([C@@]2(CO2)CC1)[C@]1(O[C@@H]1CC=C(C)C)C)OC QJWJPMLDQYEPPW-AUKZVGPFSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- DAYKLWSKQJBGCS-NRFANRHFSA-N aleglitazar Chemical compound C1=2C=CSC=2C(C[C@H](OC)C(O)=O)=CC=C1OCCC(=C(O1)C)N=C1C1=CC=CC=C1 DAYKLWSKQJBGCS-NRFANRHFSA-N 0.000 description 1
- 229950010157 aleglitazar Drugs 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- LDXYBEHACFJIEL-HNNXBMFYSA-N anagliptin Chemical compound C=1N2N=C(C)C=C2N=CC=1C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N LDXYBEHACFJIEL-HNNXBMFYSA-N 0.000 description 1
- 229950009977 anagliptin Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229950010663 balaglitazone Drugs 0.000 description 1
- 238000007681 bariatric surgery Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- ZEZFKUBILQRZCK-MJSCXXSSSA-N beloranib Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=2C=CC(OCCN(C)C)=CC=2)C[C@@]21CO2 ZEZFKUBILQRZCK-MJSCXXSSSA-N 0.000 description 1
- 229950009345 beloranib Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002837 benzphetamine Drugs 0.000 description 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- CTOUWUYDDUSBQE-UHFFFAOYSA-N benzyl piperazine-1-carboxylate Chemical compound C1CNCCN1C(=O)OCC1=CC=CC=C1 CTOUWUYDDUSBQE-UHFFFAOYSA-N 0.000 description 1
- 108010032969 beta-Arrestin 1 Proteins 0.000 description 1
- 239000003858 bile acid conjugate Substances 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229940047123 bupropion and naltrexone Drugs 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- PNDKCRDVVKJPKG-WHERJAGFSA-N cenicriviroc Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 description 1
- 229950011033 cenicriviroc Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000000633 chiral stationary phase gas chromatography Methods 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 239000003753 cholecystokinin receptor stimulating agent Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000000841 delta opiate receptor agonist Substances 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940110377 dl- arginine Drugs 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229950001279 elafibranor Drugs 0.000 description 1
- 229950000234 emricasan Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229950007405 fasiglifam Drugs 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002458 gemigliptin Drugs 0.000 description 1
- AFLFKFHDSCQHOL-IZZDOVSWSA-N gft505 Chemical compound C1=CC(SC)=CC=C1C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 AFLFKFHDSCQHOL-IZZDOVSWSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229950002888 glyclopyramide Drugs 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000013029 homogenous suspension Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000011246 intracellular protein detection Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 1
- 229960005060 lorcaserin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- WJEBNIVVLJEIKE-UHFFFAOYSA-N methyl 3-amino-4-iodobenzoate Chemical compound COC(=O)C1=CC=C(I)C(N)=C1 WJEBNIVVLJEIKE-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229950001135 muraglitazar Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 150000006636 nicotinic acid Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- MKMPWKUAHLTIBJ-ISTRZQFTSA-N omarigliptin Chemical compound C1([C@H]2OC[C@@H](C[C@@H]2N)N2CC3=CN(N=C3C2)S(=O)(=O)C)=CC(F)=CC=C1F MKMPWKUAHLTIBJ-ISTRZQFTSA-N 0.000 description 1
- 229950000074 omarigliptin Drugs 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960000436 phendimetrazine Drugs 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- GGOZGYRTNQBSSA-UHFFFAOYSA-N pyridine-2,3-diol Chemical compound OC1=CC=CN=C1O GGOZGYRTNQBSSA-UHFFFAOYSA-N 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000033300 receptor internalization Effects 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
- 229950010764 rivoglitazone Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- MRWFZSLZNUJVQW-DEOSSOPVSA-N saroglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C(C=2C=CC(SC)=CC=2)=CC=C1C MRWFZSLZNUJVQW-DEOSSOPVSA-N 0.000 description 1
- 229950006544 saroglitazar Drugs 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229950001912 setmelanotide Drugs 0.000 description 1
- 108700030852 setmelanotide Proteins 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229950009513 simtuzumab Drugs 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001797 sucrose acetate isobutyrate Substances 0.000 description 1
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 description 1
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 1
- 229950000034 teneligliptin Drugs 0.000 description 1
- RAXYDXBLJDYTOQ-UHFFFAOYSA-N tert-butyl 2-(chloromethyl)-3-[(1-methylimidazol-2-yl)methyl]benzimidazole-5-carboxylate Chemical compound ClCC1=NC2=C(N1CC=1N(C=CN=1)C)C=C(C=C2)C(=O)OC(C)(C)C RAXYDXBLJDYTOQ-UHFFFAOYSA-N 0.000 description 1
- RDUFNPUNLRNQBP-MHZLTWQESA-N tert-butyl 2-[[4-[1-[(4-chloro-2-fluorophenyl)methyl]pyrrolo[2,3-b]pyridin-6-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(CN2C=CC=3C2=NC(=CC=3)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)OC(C)(C)C)C=C1)F RDUFNPUNLRNQBP-MHZLTWQESA-N 0.000 description 1
- SRQSSPVHFXBDGI-PMERELPUSA-N tert-butyl 2-[[4-[1-[2-(4-chloro-2-fluorophenyl)ethyl]-2-oxo-4H-quinazolin-3-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(CCN2C(N(CC3=CC=CC=C23)C2CCN(CC2)CC=2N(C3=C(N=2)C=CC(=C3)C(=O)OC(C)(C)C)C[C@H]2OCC2)=O)C=C1)F SRQSSPVHFXBDGI-PMERELPUSA-N 0.000 description 1
- CFJDFEZCMRENEB-VWLOTQADSA-N tert-butyl 2-[[4-[4-[(4-chloro-2-fluorophenyl)methoxy]-1H-imidazo[4,5-c]pyridin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(COC2=NC(=CC3=C2NC=N3)C=2CCN(CC=2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)OC(C)(C)C)C=C1)F CFJDFEZCMRENEB-VWLOTQADSA-N 0.000 description 1
- FKQKCSLJAOCWEF-GDLZYMKVSA-N tert-butyl 2-[[4-[6-(6-chloro-3,4-dihydro-1H-isoquinolin-2-yl)pyridin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2R)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC=1C=C2CCN(CC2=CC=1)C1=CC=CC(=N1)C=1CCN(CC=1)CC1=NC2=C(N1C[C@@H]1OCC1)C=C(C=C2)C(=O)OC(C)(C)C FKQKCSLJAOCWEF-GDLZYMKVSA-N 0.000 description 1
- FKQKCSLJAOCWEF-LJAQVGFWSA-N tert-butyl 2-[[4-[6-(6-chloro-3,4-dihydro-1H-isoquinolin-2-yl)pyridin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC=1C=C2CCN(CC2=CC=1)C1=CC=CC(=N1)C=1CCN(CC=1)CC1=NC2=C(N1C[C@H]1OCC1)C=C(C=C2)C(=O)OC(C)(C)C FKQKCSLJAOCWEF-LJAQVGFWSA-N 0.000 description 1
- GNTCUAVHBMAUIS-NDEPHWFRSA-N tert-butyl 2-[[4-[7-(4-chloro-2-fluorophenyl)-1-oxo-3,4-dihydroisoquinolin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(C=C1)C1=CC=C2CCN(C(C2=C1)=O)C1CCN(CC1)CC1=NC2=C(N1C[C@H]1OCC1)C=C(C=C2)C(=O)OC(C)(C)C)F GNTCUAVHBMAUIS-NDEPHWFRSA-N 0.000 description 1
- FCMLWBBLOASUSO-UHFFFAOYSA-N tert-butyl 3-oxopiperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNC(=O)C1 FCMLWBBLOASUSO-UHFFFAOYSA-N 0.000 description 1
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 1
- UPUMJWQNKCLODN-UHFFFAOYSA-N tert-butyl 4-[4-[(4-chloro-2-fluorophenyl)methoxy]-1H-imidazo[4,5-c]pyridin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound ClC1=CC(=C(COC2=NC(=CC3=C2NC=N3)C=2CCN(CC=2)C(=O)OC(C)(C)C)C=C1)F UPUMJWQNKCLODN-UHFFFAOYSA-N 0.000 description 1
- FFJMVDQNSIFUEC-UHFFFAOYSA-N tert-butyl 4-[7-(4-chloro-2-fluorophenyl)-1-oxo-3,4-dihydroisoquinolin-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound ClC1=CC(=C(C=C1)C1=CC=C2CCN(C(C2=C1)=O)C=1CCN(CC=1)C(=O)OC(C)(C)C)F FFJMVDQNSIFUEC-UHFFFAOYSA-N 0.000 description 1
- ZADJQLLNFYQJHU-UHFFFAOYSA-N tert-butyl 4-[7-[(4-chloro-2-fluorophenyl)methoxy]-1H-pyrrolo[2,3-c]pyridin-5-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound ClC1=CC(=C(COC=2N=C(C=C3C=2NC=C3)C=2CCN(CC=2)C(=O)OC(C)(C)C)C=C1)F ZADJQLLNFYQJHU-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 1
- 229950004704 tesaglitazar Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 229950004996 tipelukast Drugs 0.000 description 1
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- IWYJYHUNXVAVAA-OAHLLOKOSA-N trelagliptin Chemical compound C=1C(F)=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 IWYJYHUNXVAVAA-OAHLLOKOSA-N 0.000 description 1
- 229950010728 trelagliptin Drugs 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 229950003931 volixibat Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Definitions
- Type 1 diabetes develops when the body’s immune system destroys pancreatic beta cells, the only cells in the body that make the hormone insulin that regulates blood glucose. To survive, people with Type 1 diabetes must have insulin administered by injection or a pump.
- Type 2 diabetes mellitus (referred to generally as T2DM) usually begins with either insulin resistance or when there is insufficient production of insulin to maintain an acceptable glucose level.
- Insulin secretogogues including sulphonyl-ureas (e.g., glipizide, glimepiride, glyburide) , meglitinides (e.g., nateglidine, repaglinide) , dipeptidyl peptidase IV (DPP-IV) inhibitors (e.g., sitagliptin, vildagliptin, alogliptin, dutogliptin, linagliptin, saxogliptin) , and glucagon-like peptide-1 receptor (GLP-1R) agonists (e.g., liraglutide, albiglutide, exenatide, lixisenatide, dulaglutide, semaglutide) , which enhance secretion of insulin by acting on the pancreatic beta-cells.
- sulphonyl-ureas e.g., glipizide, glimepiride,
- Sulphonyl-ureas and meglitinides have limited efficacy and tolerability, cause weight gain and often induce hypoglycemia.
- DPP-IV inhibitors have limited efficacy.
- Marketed GLP-1R agonists are peptides administered by subcutaneous injection. Liraglutide is additionally approved for the treatment of obesity.
- Biguanides e.g., metformin
- Biguanides are thought to act primarily by decreasing hepatic glucose production. Biguanides often cause gastrointestinal disturbances and lactic acidosis, further limiting their use.
- Inhibitors of alpha-glucosidase decrease intestinal glucose absorption. These agents often cause gastrointestinal disturbances.
- Thiazolidinediones e.g., pioglitazone, rosiglitazone
- a specific receptor peroxisome proliferator-activated receptor-gamma
- Insulin is used in more severe cases, either alone or in combination with the above agents, and frequent use may also lead to weight gain and carries a risk of hypoglycemia.
- Sodium-glucose linked transporter cotransporter 2 (SGLT2) inhibitors e.g., dapagliflozin, empagliflozin, canagliflozin, ertugliflozin
- SGLT2 inhibitors inhibit reabsorption of glucose in the kidneys and thereby lower glucose levels in the blood.
- This emerging class of drugs may be associated with ketoacidosis and urinary tract infections.
- the drugs have limited efficacy and do not address the most important problems, the declining ⁇ -cell function and the associated obesity.
- Obesity is a chronic disease that is highly prevalent in modern society and is associated with numerous medical problems including hypertension, hypercholesterolemia, and coronary heart disease. It is further highly correlated with T2DM and insulin resistance, the latter of which is generally accompanied by hyperinsulinemia or hyperglycemia, or both. In addition, T2DM is associated with a two to fourfold increased risk of coronary artery disease. Presently, the only treatment that eliminates obesity with high efficacy is bariatric surgery, but this treatment is costly and risky. Pharmacological intervention is generally less efficacious and associated with side effects.
- T2DM is most commonly associated with hyperglycemia and insulin resistance
- other diseases associated with T2DM include hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, obesity, dyslipidemia, hypertension, hyperinsulinemia and nonalcoholic fatty liver disease (NAFLD) .
- NAFLD nonalcoholic fatty liver disease
- NAFLD is the hepatic manifestation of metabolic syndrome, and is a spectrum of hepatic conditions encompassing steatosis, non-alcoholic steatohepatitis (NASH) , fibrosis, cirrhosis and ultimately hepatocellular carcinoma.
- NAFLD and NASH are considered the primary fatty liver diseases as they account for the greatest proportion of individuals with elevated hepatic lipids.
- the severity of NAFLD/NASH is based on the presence of lipid, inflammatory cell infiltrate, hepatocyte ballooning, and the degree of fibrosis. Although not all individuals with steatosis progress to NASH, a substantial portion does.
- GLP-1 is a 30 amino acid long incretin hormone secreted by the L-cells in the intestine in response to ingestion of food. GLP-1 has been shown to stimulate insulin secretion in a physiological and glucose-dependent manner, decrease glucagon secretion, inhibit gastric emptying, decrease appetite, and stimulate proliferation of beta-cells. In non-clinical experiments GLP-1 promotes continued beta-cell competence by stimulating transcription of genes important for glucose-dependent insulin secretion and by promoting beta-cell neogenesis (Meier et al., Biodrugs. 17 (2) : 93-102, 2013) .
- GLP-1 plays an important role regulating post-prandial blood glucose levels by stimulating glucose-dependent insulin secretion by the pancreas resulting in increased glucose absorption in the periphery. GLP-1 also suppresses glucagon secretion, leading to reduced hepatic glucose output. In addition, GLP-1 delays gastric emptying and slows small bowel motility delaying food absorption. In people with T2DM, the normal post-prandial rise in GLP-1 is absent or reduced (Vilsboll et al., Diabetes. 50: 609-613, 2001) .
- GLP-1 receptor agonists such as GLP-1, liraglutide and exendin-4
- FPG and PPG fasting and postprandial glucose
- the invention provides a compound represented by structural formula (I) :
- X 1 , X 2 , X 3 , X 4 , and X 5 are each independently selected from N and CH; wherein no more than three of X 1 , X 2 , X 3 , X 4 , and X 5 are N and wherein ring A does not contain 3 nitrogen ring atoms at 3 contiguous positions;
- W is selected from O, S, CR 5 R 6 , and NR 5’ ;
- Y 1 , Y 3 , Y 4 , and Y 5 are each independently selected from N, NH, CH, and CH 2 ;
- Y 2 and Y 6 are each independently selected from N, C, or CH;
- Z 1 and Z 2 are each independently selected from N, C, and CH; wherein at least one of Z 1 and Z 2 is N;
- T 2 , T 3 , and T 4 are each independently selected from N, NR 4 , O, S, C, and CR 4 ;
- T 6 , T 7 , and T 8 are each independently selected from N and CR 4 ;
- T 2 , T 3 , T 4 , T 6 , T 7 , and T 8 are selected from N, O, and S;
- EE is –COOH or a carboxylic group surrogate, optionally, the carboxylic group surrogate is:
- R a is selected from hydrogen, deuterium, halogen, -CN, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, NR 5’ R 6’ , 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C 1 -C 6 alkyl or C 1 -C 6 alkoxy represented by R a is optionally substituted with one or more groups selected from halogen, oxo, CN, OH, and C 3 -C 6 saturated or partially saturated cycloalkyl; and wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclyl represented by R a or in the group represented by R a is optionally substituted with one or more groups selected from halogen, oxo, CN, OH, C 1 -C 3 alkyl (optionally
- R b is selected from hydrogen, deuterium, halogen, -CN, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, NR 5’ R 6’ , 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C 1 -C 6 alkyl or C 1 -C 6 alkoxy represented by R b is optionally substituted with one or more groups selected from halogen, oxo, CN, OH, and C 3 -C 6 saturated or partially saturated cycloalkyl; and wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclyl represented by R b or in the group represented by R b is optionally substituted with one or more groups selected from halogen, oxo, CN, OH, C 1 -C 3 alkyl (optionally
- R c is selected from hydrogen, deuterium, halogen, -CN, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, NR 5’ R 6’ , 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C 1 -C 6 alkyl or C 1 -C 6 alkoxy represented by R c is optionally substituted with one or more groups selected from halogen, oxo, CN, OH, and C 3 -C 6 saturated or partially saturated cycloalkyl; and wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclyl represented by R c or in the group represented by R c is optionally substituted with one or more groups selected from halogen, oxo, CN, and NR 5’ R 6’ ;
- R d is selected from hydrogen, deuterium, halogen, -CN, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, NR 5’ R 6’ , 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C 1 -C 6 alkyl or C 1 -C 6 alkoxy represented by R d is optionally substituted with one or more groups selected from halogen, oxo, CN, and saturated or partially saturated C 3 -C 6 cycloalkyl; and wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclyl represented by R d or in the group represented by R d is optionally substituted with one or more groups selected from halogen, oxo, CN, and NR 5’ R 6’ ;
- each R 1 is independently selected from halogen, -CN, OH, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, NR 5’ R 6’ , 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkenyl, or C 1 -C 6 alkynyl represented by R 1 is optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3 , OH, OCH 3 , OCH 2 CH 3 , and saturated or partially saturated C 3 -C 6 cycloalkyl (optionally substituted with one or more groups selected from halogen, oxo, CN,
- each R 2 is independently selected from halogen, -CN, OH, oxo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, NR 5’ R 6’ , 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C 1 -C 6 alkyl or C 1 -C 6 alkoxy represented by R 2 is optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3 , OH, OCH 3 , OCH 2 CH 3 , and saturated or partially saturated C 3 -C 6 cycloalkyl (optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3 , OH, OCH 3 , OCH 2 CH 3 ) ; and wherein the aryl, heteroaryl, saturated or partially saturated cycloalky
- each R 3 is independently selected from halogen, -CN, OH, oxo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, NR 5’ R 6’ , 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C 1 -C 6 alkyl or C 1 -C 6 alkoxy represented by R 3 is optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3 , OH, OCH 3 , OCH 2 CH 3 , and saturated or partially saturated C 3 -C 6 cycloalkyl (optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3 , OH, OCH 3 , OCH 2 CH 3 ) ; and wherein the aryl, heteroaryl, saturated or partially saturated cycloalky
- each R 4 is H, deuterium, halogen, OH, -CN, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or NR 5’ R 6’ , wherein the C 1 -C 6 alkyl and C 1 -C 6 alkoxy represented by R 4 is optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3 , and saturated or partially saturated C 3 -C 6 cycloalkyl (optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3 , OH, OCH 3 , OCH 2 CH 3 ) ;
- R 5 and R 6 are each independently selected from hydrogen, deuterium, halogen, CN, OH, oxo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, NR 5’ R 6’ , 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkenyl, or C 1 -C 6 alkynyl represented by R 5 or R 6 is optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3 , OH, OCH 3 , OCH 2 CH 3 , and saturated or partially saturated C 3 -C 6 cycloalkyl (optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3 , OH,
- R 5’ and R 6’ are each independently selected from hydrogen, deuterium, and C 1 -C 6 alkyl;
- n is an integer selected from 0, 1, 2, 3, and 4,
- n is an integer selected from 0, 1, 2, 3, 4, and 5
- o is an integer selected from 0, 1, 2, 3, 4, and 5.
- the invention provides a compound according to the first embodiment, wherein the compound is represented by the structural formula (II-A) :
- R d is H, F, CH 3 , or CF 3 , wherein the remainder of the variables are as defined in the first embodiment.
- the invention provides a compound according to the first or second embodiment, wherein the compound is represented by structural formula (III-A) :
- T 2 is N
- T 4 is N or CR 4
- R 4 is H, halogen, OH, CN, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, or C 1 -C 3 alkoxy; or T 2 is C, and T 4 is NR 4 , wherein R 4 is H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, wherein the remainder of the variables are as defined in the first or second embodiment.
- the invention provides a compound according to the first, second, or third embodiments, wherein the compound is represented by structural formula (IV-A) :
- T 4 is N or CH; and R a is H, CH 3 , or CF 3 ; or R a , R 1 and X 5 , taken together with their respective intervening carbons, form 5-7 membered cycloalkenyl or 5-7 membered partially saturated monoheterocyclyl, wherein the remainder of the variables are as defined in the first, second, or third embodiment.
- the invention provides a compound according to the first, second, third or fourth embodiments, wherein R b is
- R b is optionally substituted with 1 or 2 groups selected from oxo, CN, F, Cl, C 1 -C 3 alkyl, and C 1 -C 3 alkoxy, wherein the C 1 -C 3 alkyl or C 1 -C 3 alkoxy in the group represented by R b is optionally substituted with 1 or 2 groups selected from F, OH, and OCH 3 , wherein the remainder of the variables are as defined in the first, second, third or fourth embodiment.
- the invention provides a compound according to first, second, third or fourth embodiments, wherein R b is
- R b is optionally substituted with 1 or 2 groups selected from halogen, OH, NR 5’ R 6’ , C 1 -C 3 alkyl, and C 1 -C 3 alkoxy, wherein the C 1 -C 3 alkyl or C 1 -C 3 alkoxy in the group represented by R b is optionally substituted with 1 or 2 groups selected from F, OH, and OCH 3 , wherein the remainder of the variables are as defined in the first, second, third or fourth embodiment.
- the invention provides a compound according to the fourth embodiment, wherein is wherein the remainder of the variables are as defined in the first, second, third or fourth embodiment.
- the invention provides a compound according to first, second, third, fourth, fifth, sixth, or seventh embodiments, wherein is
- R 3 is halogen, CN, OH, oxo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, or NR 5’ R 6’ ; and o is an integer selected from 0, 1, 2, and 3, wherein the remainder of the variables are as defined in the first, second, third, fourth, fifth, sixth, or seventh embodiment.
- the invention provides a compound according to first, second, third, fourth, fifth, sixth, seventh, or eighth embodiment, wherein is wherein the remainder of the variables are as defined in the first, second, third, fourth, fifth, sixth, seventh, or eighth embodiment.
- the invention provides a compound according to first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment, wherein is each of which is optionally substituted with 1 or 2 groups selected from halogen, CN, and oxo; or two R 3 groups taken together with ring C, form bridged (C 5 -C 8 ) heterocyclene or bridged (C 5 -C 8 ) cycloalkylene, wherein the remainder of the variables are as defined in the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
- the invention provides a compound according to first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment, wherein is wherein R 3 is halogen, CN, oxo, CH 3 , CF 3 , CH 2 CH 3 , or CH 2 CF 3 ; and o is 0 or 1, wherein the remainder of the variables are as defined in the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment.
- the invention provides a compound according to first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or eleventh embodiment, wherein is: wherein each R 2 is independently selected from halogen, -CN, OH, oxo, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, and C 1 -C 2 alkoxy; and n is an integer selected from 0, 1, 2, and 3, wherein the remainder of the variables are as defined in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or eleventh embodiment.
- the invention provides a compound according to first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, or twelfth embodiment, wherein is
- R 2 is halogen, -CN, OH, oxo, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, or C 1 -C 2 alkoxy
- n is 0 or 1
- the remainder of the variables are as defined in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, or twelfth embodiment.
- the invention provides a compound according to the twelfth embodiment, wherein two R 2 groups together with ring B form a bicyclic structure:
- each of which is optionally substituted with 1 or 2 groups selected from halogen, oxo, CN, CF 3 , C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, C 1 -C 2 alkoxy, -NH 2 , -NHC 1 -C 2 alkyl, and –N (C 1 -C 2 alkyl) 2 , wherein the remainder of the variables are as defined in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, or twelfth embodiment.
- the invention provides a compound according to the fourteenth embodiment, wherein two R 2 groups together with ring B form a bicyclic structure:
- the invention provides a compound according to the twelfth embodiment, wherein W and ring B form a bicyclic structure:
- the invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, or sixteenth embodiment, wherein ring A is each R 1 is independently selected from halogen, OH, CN, CF 3 , C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, C 1 -C 2 alkoxy, -NH 2 , -NHC 1 -C 2 alkyl, –N (C 1 -C 2 alkyl) 2 , and C 2 -C 4 alkynyl optionally substituted with cyclopropane; and m is an integer selected from 0, 1, 2, and 3, wherein the remainder of the variables are as defined in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, or sixteenth embodiment.
- the invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, or seventeenth embodiment, wherein ring A is and m is 0 or 1, and R 1 is halogen, CN, CH 3 , CF 3 , OH, or C 2 -C 4 alkynyl optionally substituted with cyclopropane; preferably ring A is wherein the remainder of the variables are as defined in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, or seventeenth embodiment.
- the invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, or sixteenth embodiment, wherein ring A is
- each R 1 is independently selected from halogen, OH, CN, CF 3 , C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, C 1 -C 2 alkoxy, -NH 2 , -NHC 1 -C 2 alkyl, –N (C 1 -C 2 alkyl) 2 , and C 2 -C 4 alkynyl optionally substituted with cyclopropane; and m is an integer selected from 0, 1, and 2, wherein the remainder of the variables are as defined in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, or sixteenth embodiment.
- the invention provides a compound according to the nineteenth embodiment, wherein ring A is
- m is 0 or 1 wherein the remainder of the variables are as defined in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, or nineteenth embodiment.
- the invention provides a compound according to any one of the first through fifteenth and the seventeenth through twentieth embodiments, wherein W is O, NH or CH 2 , wherein the remainder of the variables are as defined in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, seventeenth, eighteenth, nineteenth or twentieth embodiment.
- the invention provides a compound according to any one of the first through twentieth embodiments, wherein R 1 is selected from halogen, CN, CH 3 , CF 3 , and C ⁇ CH, wherein the remainder of the variables are as defined in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, or twenty-first embodiment.
- the invention provides a compound according to the first embodiment, wherein the compound is represented by the structural formula (I’) :
- X 1 , X 2 , X 3 , X 4 , and X 5 are each independently selected from N and CH; wherein no more than three of X 1 , X 2 , X 3 , X 4 , and X 5 are N and ring A does not contain 3 nitrogen ring atoms at 3 contiguous positions;
- W is selected from O, CR 5’ R 6’ , and NR 5’ ;
- Y 1 , Y 3 , Y 4 , and Y 5 are each independently selected from N, NH, CH, and CH 2 ;
- Y 2 and Y 6 are each independently selected from N, C, or CH;
- T 6 , T 7 , and T 8 are each independently selected from N and CR 4 ; and no more than 2 of T 6 , T 7 , and T 8 are selected from N;
- R a is selected from hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, NR 5’ R 6’ , wherein the C 1 -C 6 alkyl or C 1 -C 6 alkoxy represented by R a is optionally substituted with one or more groups selected from halogen, oxo, CN, and OH;
- R b is 5-6 membered heteroaryl or 4-7 membered saturated or partially saturated heterocyclyl, wherein the heteroaryl or saturated or partially saturated heterocyclyl represented by R b is optionally substituted with one or more groups selected from halogen, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 hydroxyalkyl, C 1 -C 3 alkoxy, and C 1 -C 3 haloalkoxy;
- R c is hydrogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl
- each R 1 is independently halogen, -CN, OH, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, NR 5’ R 6’ , phenyl, 5-6 membered heteroaryl, 4-6 membered saturated or partially saturated cycloalkyl and 3-7 membered saturated or partially saturated heterocyclyl, wherein the C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl represented by R 1 is optionally substituted with one or more groups selected from halogen, CN, OH, and C 3 -C 6 cycloalkyl; and wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclyl represented by R 1 or in the group represented by R 1 is optionally substituted with one or more groups selected from
- each R 2 is independently selected from halogen, oxo, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, and NR 5’ R 6’ ;
- each R 3 is independently halogen, -CN, oxo, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, or C 1 -C 6 haloalkoxy; and/or
- each R 4 is independently H, halogen, or C 1 -C 6 alkyl optionally substituted with one or more groups selected from halogen;
- R 5’ and R 6’ are each independently hydrogen or C 1 -C 6 alkyl
- n 0, 1, 2, 3, or 4;
- n 0, 1, 2, 3, or 4;
- o 0, 1, 2, 3, or 4, wherein the remainder of the variables are as defined in the first embodiment.
- the invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, or twenty-third (e.g., twenty-third) embodiment, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein is wherein R 3 is independently halogen, C 1 -C 4 alkyl, or C 1 -C 4 haloalkyl; and o is 0, 1, or 2.
- the invention provides a compound according to first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, or twenty-fourth (e.g., twenty-third or twenty-fourth) embodiment, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein is wherein R 4 is H or halogen, preferably, H or F.
- the invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, or twenty-fifth (e.g., twenty-third, twenty-fourth or twenty-fifth) embodiment, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein EE is –COOH, -C (O) NHOH, -C (O) NHSO 2 CH 3 , -C (O) NHSO 2 CF 3 ,
- the invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, or twenty-sixth (e.g., twenty-third, twenty-fourth, twenty-fifth, or twenty-sixth) embodiment, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein R b is each of which is optionally substituted with one or more groups selected from C 1 -C 3 alkyl; and R c is H or C 1 -C 3 alkyl.
- the invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, or twenty-seventh (e.g., twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, or twenty-seventh) embodiment, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein is
- the invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, or twenty-eighth (e.g., twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, or twenty-eighth) embodiment, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein is
- the invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, or twenty-ninth (e.g., twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, or twenty-ninth) embodiment, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein W is O, NH or CH 2 , and R a is H.
- the invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, or thirtieth (e.g., twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, or thirtieth) embodiment, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein is wherein R 2 is halogen; n is 0, 1, or 2.
- the invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, or thirty-first (e.g., twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, or thirty-first) embodiment, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein is R 2 is F; and n is 0, 1, or 2.
- the invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, or thirty-second (e.g., twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, or thirty-second) embodiment, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein ring A is
- each R 1 is independently selected from halogen, CN, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 4 alkynyl optionally substituted with cyclopropyl, 5-6 membered heteroaryl (wherein the hetero ring atom is nitrogen) optionally substituted with C 1 -C 4 alkyl; and/or
- n 0, 1, 2, or 3.
- the invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, thirty-second, or thirty-third (e.g., twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, thirty-second or thirty-third) embodiment, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein W is O.
- the invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, thirty-second, thirty-third, or thirty-fourth (e.g., twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, thirty-second, thirty-third, or thirty-fourth) embodiment, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein ring A is each R 1 is independently selected from halogen, CN, C 1
- the invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, thirty-second, thirty-third, thirty-fourth, or thirty-fifth (e.g., twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, thirty-second, thirty-third, thirty-fourth, or thirty-fifth) embodiment, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein R 1 is selected from halogen and
- the compound, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof is selected from the compounds disclosed in examples and Table 1.
- the invention provides a pharmaceutical composition comprising the compound according to any one of the first through thirty-seventh embodiments, and a pharmaceutically acceptable excipient.
- the invention provides a method of treating cardiometabolic and associated diseases comprising administering to a subject in need of such treatment a therapeutically effective amount of any one of the compound according to any one of the first through twenty-second embodiments, wherein the disease is T1D, T2DM, pre-diabetes, idiopathic T1D (Type 1b) , LADA (latent autoimmune diabetes in adults) , EOD (early-onset T2DM) , YOAD (youth-onset atypical diabetes) , MODY (maturity onset diabetes of the young) , malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea, obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., T
- the invention includes use of a therapeutically effective amount of the compound according to any one of the first through twenty-second embodiments in the manufacture of a medicament for treating a subject in need of with cardiometabolic and associated diseases, wherein the disease is T1D, T2DM, pre-diabetes, idiopathic T1D (Type 1b) , LADA (latent autoimmune diabetes in adults) , EOD (early-onset T2DM) , YOAD (youth-onset atypical diabetes) , MODY (maturity onset diabetes of the young) , malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea, obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g.
- FIGs. 1A and 1B show dose-response curves for the GLP-1R/ ⁇ -Arrestin recruitment assay using certain compounds of the invention and GLP-1 (7-37) as control.
- the vertical axis represents relative effects of the test compounds normalized to percentage of effect by the natural ligand GLP-1 (7-37) .
- FIG. 1A compares Compounds 1, 10, 11, 19, and 35 to GLP-1 (7-37) .
- the two panels of FIG. 1B compare Compounds 225, 237, &239 (left panel) and 236 &238 (right panel) to GLP-1 (7-37) .
- FIGs. 2A and 2B show dose-response curves for the GLP-1R/ ⁇ -Arrestin internalization assay using certain compounds of the invention and GLP-1 (7-37) as control.
- the vertical axis represents relative effects of the test compounds normalized to percentage of effect by the natural ligand GLP-1 (7-37) .
- the two panels in FIG. 2A compare Compounds 19 &28 (left panel) , and Compounds 9, 33, &35 (right panel) , respectively, to GLP-1 (7-37) .
- the three panels in FIG. 2B compare Compounds 221, 222, &225 (left panel) , 224 &239 (middle panel) , and 236 (right panel) , respectively, to GLP-1 (7-37) .
- FIGs. 3 and 4 show time-course responses of GLP-1R and ⁇ -arrestin2 interaction as measured by the NanoBit Assay, in the presence of indicated different concentrations (serial 4-fold dilutions) of GLP-1 (7-37) peptide (natural agonist of GLP-1R) , as well as two representative compounds of the instant application (i.e., Compounds 19 and 35) .
- the black curves are for Compound 35. It is apparent that the compounds of the invention behaved differently from the natural peptide agonist GLP-1.
- FIGs. 5A-5C show NanoBit assay time-course responses for both GLP-1 (7-37) and Compound 19, 10, or 35, respectively, at different compound concentrations.
- FIG. 6 shows dose-response curves of GLP-1R and ⁇ -arrestin2 interaction as measured by the NanoBit Assay, in the presence of indicated different time points (i.e., 0, 15, 30, 60, 120, 210, and 300 sec) of GLP-1 peptide (natural agonist of GLP-1R) , as well as three representative compounds of the instant application (i.e., Compounds 10, 19 and 35) .
- t 6 min (300s) was chosen for dose response EC 50 determination.
- data analysis /report can be done to obtain EC 50 values when compounds reach maximal signals at about 450-500 sec ( ⁇ 8 min) .
- FIGs. 7A-7B show dose-response curves for the GLP-1R/ ⁇ -Arrestin NanoBit assay using certain compounds of the invention and GLP-1 (7-37) as control.
- the vertical axis represents relative effects of the test compounds normalized to percentage of effect by the natural ligand GLP-1 (7-37) .
- the two panels in FIG. 7A compare Compounds 19 &35 to GLP-1 (7-37) at 3 min. and 5 min. readouts, respectively.
- the two panels in FIG. 7B compare Compound 10 to GLP-1 (7-37) at 3 min. and 5 min. readouts, respectively.
- FIGs. 8A-8F show favorable pharmacokinetic (PK) property of the subject compounds, as compared to a control compound ( “Compound 418” ) , in the form of substantially constant mean plasma concentration -time profiles for Compounds 19 (Dose 1) (FIG. 8A) , 28 (Dose 1) (FIG. 8B) , 29 (Dose 2) (FIG. 8C) , 225 (Dose 2) (FIG. 8D) , Compounds 19 (Dose 2) (FIG. 8E) , and Compounds 418 (Dose 2) (FIG. 8F) , respectively.
- PK pharmacokinetic
- the invention provides a compound of any one of the formulae described above (e.g., Formulae I, II-A, III-A, and IV-A) .
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of any one of the formulae described above (e.g., Formulae I, II-A, III-A, and IV-A) , or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, as defined in any one of the embodiments described herein, in a mixture with at least one pharmaceutically acceptable excipient.
- the invention provides a compound of any one of the formulae described above (e.g., Formulae I, II-A, III-A, and IV-A) , or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, as defined in any one of the embodiments described herein, for use as a medicament.
- a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof as defined in any one of the embodiments described herein, for use as a medicament.
- the invention provides a compound of any one of the formulae described above (e.g., Formulae I, II-A, III-A, and IV-A) , or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, as defined in any one of the embodiments described herein, for use in the prevention and/or treatment of cardiometabolic and associated diseases discussed herein, including T2DM, pre-diabetes, NASH, and cardiovascular disease.
- a compound of any one of the formulae described above e.g., Formulae I, II-A, III-A, and IV-A
- a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof as defined in any one of the embodiments described herein, for use in the prevention and/or treatment of cardiometabolic and associated diseases discussed herein, including T2DM, pre-diabetes, NASH, and cardiovascular disease.
- the invention provides a method of treating a disease for which an agonist of GLP-1R is indicated, in a subject in need of such prevention and/or treatment, comprising administering to the subject a therapeutically effective amount of a compound of any one of the formulae described above (e.g., Formulae I, II-A, III-A, and IV-A) , or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, as defined in any one of the embodiments described herein.
- a compound of any one of the formulae described above e.g., Formulae I, II-A, III-A, and IV-A
- a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof as defined in any one of the embodiments described herein.
- the invention provides a use of a compound of any one of the formulae described above (e.g., Formulae I, II-A, III-A, and IV-A) , or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, as defined in any one of the embodiments described herein, for the manufacture of a medicament for treating a disease or condition for which an agonist of the GLP-1R is indicated.
- a compound of any one of the formulae described above e.g., Formulae I, II-A, III-A, and IV-A
- a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof as defined in any one of the embodiments described herein
- the invention provides a compound of any one of the formulae described above (e.g., Formulae I, II-A, III-A, and IV-A) , or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, as defined in any one of the embodiments described herein, for use in the treatment of a disease or condition for which an agonist of GLP-1R is indicated.
- a compound of any one of the formulae described above e.g., Formulae I, II-A, III-A, and IV-A
- a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof as defined in any one of the embodiments described herein, for use in the treatment of a disease or condition for which an agonist of GLP-1R is indicated.
- the invention provides a pharmaceutical composition for the treatment of a disease or condition for which an agonist of the GLP-1R is indicated, comprising a compound of any one of the formulae described above (e.g., Formulae I, II-A, III-A, and IV-A) , or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, as defined in any one of the embodiments described herein.
- a pharmaceutical composition for the treatment of a disease or condition for which an agonist of the GLP-1R is indicated comprising a compound of any one of the formulae described above (e.g., Formulae I, II-A, III-A, and IV-A) , or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, as defined in any one of the embodiments described herein.
- the invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of any one of the formulae described above (e.g., Formulae I, II-A, III-A, and IV-A) , or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, as defined in any one of the embodiments described herein, for use in the treatment and/or prevention of cardiometabolic and associated diseases discussed herein, including T2DM, pre-diabetes, NASH, and cardiovascular disease.
- a pharmaceutical composition comprising a compound of any one of the formulae described above (e.g., Formulae I, II-A, III-A, and IV-A) , or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, as defined in any one of the embodiments described herein, for use in the treatment and/or prevention of cardiometabolic and associated diseases discussed herein, including T2DM, pre-diabetes, NASH, and cardiovascular disease.
- the invention provides a compound of any one of the formulae described above (e.g., Formulae I, II-A, III-A, and IV-A) , or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, as defined in any one of the embodiments described herein, for use in the treatment and/or treatment for cardiometabolic and associated diseases including diabetes (T1D and/or T2DM, including pre-diabetes) , idiopathic T1D (Type 1b) , latent autoimmune diabetes in adults (LADA) , early-onset T2DM (EOD) , youth-onset atypical diabetes (YOAD) , maturity onset diabetes of the young (MODY) , malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proxi
- necrosis and apoptosis stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson’s Disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, prevention
- the disease or disorder is obesity, eating disorders, weight gain from use of other agents, excessive sugar craving, and dyslipidemia.
- the disease or disorder is obesity.
- the disease or disorder is pre-diabetes.
- the disease or disorder is T2DM.
- the disease or disorder is NASH.
- the disease or disorder is NAFLD.
- the disease or disorder is a cardiovescular disease, such as hypertension.
- the invention provides a method of enhancing or stimulating GLP-1R-mediated cAMP signaling with reduced ⁇ -arrestin /arrestin-2 recruitment, comprising administering a compound of any one of the formulae described above (e.g., Formulae I, II-A, III-A, and IV-A) , or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, as defined in any one of the embodiments described herein.
- a compound of any one of the formulae described above e.g., Formulae I, II-A, III-A, and IV-A
- a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof as defined in any one of the embodiments described herein.
- the compounds of the invention while being full agonists ofGLP-1R-mediated cAMP signaling, are partial agonists of ⁇ - arrestin recruitment to activated GLP-1R, compared to the natural GLP-1R ligand GLP-1, in that maximal ⁇ -arrestin recruitment to activated GLP-1R by the compounds of the invention is lower than maximal ⁇ -arrestin recruitment by GLP-1.
- Such partial and/or biased agonists of GLP-1R for cAMP signaling may provide a more sustained cAMP signaling activity for better efficacy and lowered side effects.
- the method of the invention may be advantageously used for the treatment of any of the diseases or conditions described herein, such as type II diabetes (T2D) and related diseases.
- T2D type II diabetes
- the treatment elicits a glycemic benefit without concomitant increase, or at least reduced increase, in a GI side effect such as nausea, vomiting, or diarrhea.
- the treatment has greater tolerability compared to a control treatment that has normal or enhanced ⁇ -arrestin recruitment (such as ⁇ -arrestin recruitment by GLP-1) .
- alkyl as used herein, means a straight or branched chain monovalent hydrocarbon group of formula -C n H (2n+1) .
- Non-limiting examples include methyl, ethyl, propyl, butyl, 2-methyl-propyl, 1, 1-dimethylethyl, pentyl and hexyl.
- alkylene as used herein, means a straight or branched chain divalent hydrocarbon group of formula -C n H 2n -. Non-limiting examples include ethylene, and propylene.
- cycloalkyl as used herein, means a cyclic, hydrocarbon group containing at least three carbon atoms (e.g., C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , or C 3-8 or C 3-6 ) .
- the cycloalkyl may be (fully) saturated or partially saturated (i.e., not aromatic, for example, cycloalkenyl or cycloalknyl) , and may contain one or more carbon-carbon double bond (s) .
- a fully saturated cycloalkyl has the formula C n H (2n-1) .
- Non-limiting examples include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- halogen refers to fluoride, chloride, bromide, or iodide.
- heterocycloalkyl refers to a (fully saturated or partially saturated, for example, heterocycloalkenyl) 3-12 membered cycloalkyl group, such as those defined above, in which one or more (e.g., one to four) of the ring carbon atom (s) has been replaced with a group selected from -O-, -S-, or -N-, wherein the nitrogen may provide a point of attachment or may be substituted as provided within each embodiment. Where nitrogen provides a point of attachment, a structural drawing of a heterocycloalkyl would have a hydrogen on said nitrogen.
- the cycloalkyl or the heterocycloalkyl/heterocyclyl may be unsubstituted, or be substituted with one or more substituents as valency allows, wherein the substituents can be independently selected from a number of groups such as oxo, -CN, halogen, alkyl and alkoxyl, opotionally, the alkyl substitution may be further substituted.
- heteroaryl refers to a monocyclic or multicyclic aromatic hydrocarbon in which at least one of the ring carbon atoms (typically 1 to 4, more typically 1 or 2) has been replaced with a heteroatom independently selected from oxygen, nitrogen and sulfur.
- “5-14 membered heteroaryl” includes monocyclic, bicyclic or tricyclic ring systems.
- the heteroaryl is based on a C 5-8 aryl with one or more of its ring carbon atoms replaced by the heteroatom.
- An heteroaryl group may be attached through a ring carbon atom or, where valency permits, through a ring nitrogen atom.
- the heteroaryl may be unsubstituted, or be substituted with one or more substituents as valency allows with the substituents being independently selected from halogen, OH, alkyl, alkoxyl, and amino (e.g., NH 2 , NHalkyl, N (alkyl) 2 ) , optionally, the alkyl may be further substituted.
- a wavy line denotes a point of attachment of a substituent to another group.
- compositions of any one of the formulae described above include acid addition and base salts.
- Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulfate/sulfate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulfate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate
- Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, bis (2-hydroxyethyl) amine (diolamine) , glycine, lysine, magnesium, meglumine, 2-aminoethanol (olamine) , potassium, sodium, 2-Amino-2- (hydroxymethyl) propane-1, 3-diol (tris or tromethamine) and zinc salts.
- bases include the aluminium, arginine, benzathine, calcium, choline, diethylamine, bis (2-hydroxyethyl) amine (diolamine) , glycine, lysine, magnesium, meglumine, 2-aminoethanol (olamine) , potassium, sodium, 2-Amino-2- (hydroxymethyl) propane-1, 3-diol (tris or tromethamine) and zinc salts.
- Hemisalts of acids and bases may also be formed, for example, hemisulfate and hemicalcium salts.
- suitable salts see Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth (Wiley-VCH, 2002) . Incorporated herein by reference.
- the resulting salt may precipitate out and be collected by filtration or may be recovered by evaporation of the solvent.
- the degree of ionisation in the resulting salt may vary from completely ionised to almost non-ionised.
- solvate is used herein to describe a molecular complex comprising the compound of any one of the formulae described above, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
- hydrate is employed when said solvent is water.
- Isolated site hydrates are ones in which the water molecules are isolated from direct contact with each other by intervening organic molecules.
- channel hydrates the water molecules lie in lattice channels where they are next to other water molecules.
- metal-ion coordinated hydrates the water molecules are bonded to the metal ion.
- the complex When the solvent or water is tightly bound, the complex may have a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water/solvent content may be dependent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm.
- the compounds of any one of the formulae described above may exhibit one or more kinds of isomerism (e.g. optical, geometric or tautomeric isomerism) .
- the compounds of any one of the formulae described above may also be isotopically labelled. Such variation is implicit to the compounds of any one of the formulae described above defined as they are by reference to their structural features and therefore within the scope of the invention.
- Stereoisomers are compounds that differ only in their spatial arrangement. Stereoisomers include all diastereomeric, enantiomeric, and epimeric forms as well as racemates and mixtures thereof.
- the term “geometric isomer” refers to compounds having at least one double bond, wherein the double bond (s) may exist in cis (also referred to as syn or Delta (E) ) or trans (also referred to as anti or sixteen (Z) ) forms as well as mixtures thereof.
- geometric isomer When a geometric isomer is depicted by name or structure, it is to be understood that the named or depicted isomer exists to a greater degree than another isomer, that is that the geometric isomeric purity of the named or depicted geometric isomer is greater than 50%, such as at least 60%, 70%, 80%, 90%, 99%, or 99.9%pure by weight. Geometric isomeric purity is determined by dividing the weight of the named or depicted geometric isomer in the mixture by the total weight of all of the geomeric isomers in the mixture.
- Racemic mixture means 50%of one enantiomer and 50%of is corresponding enantiomer.
- a compound with one chiral center is named or depicted without indicating the stereochemistry of the chiral center, it is understood that the name or structure encompasses both possible enantiomeric forms (e.g., both enantiomerically-pure, enantiomerically-enriched or racemic ) of the compound.
- Enantiomeric and diastereomeric mixtures can be resolved into their component enantiomers or stereoisomers by well-known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent.
- Enantiomers and diastereomers also can be obtained from diastereomerically-or enantiomerically-pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods.
- a compound When a compound is designated by a name or structure that indicates a single enantiomer, unless indicated otherwise, the compound is at least 60%, 70%, 80%, 90%, 99%or 99.9%optically pure (also referred to as “enantiomerically pure” ) .
- Optical purity is the weight in the mixture of the named or depicted enantiomer divided by the total weight in the mixture of both enantiomers.
- stereochemistry of a disclosed compound is named or depicted by structure, and the named or depicted structure encompasses more than one stereoisomer (e.g., as in a diastereomeric pair)
- the stereoisomeric purity of the named or depicted stereoisomers at least 60%, 70%, 80%, 90%, 99%or 99.9%by weight.
- the stereoisomeric purity in this case is determined by dividing the total weight in the mixture of the stereoisomers encompassed by the name or structure by the total weight in the mixture of all of the stereoisomers.
- the pharmaceutically acceptable salts of compounds of any one of the formulae described above may also contain a counterion which is optically active (e.g. d-lactate or l-lysine) or racemic (e.g. dl-tartrate or dl-arginine) .
- a counterion which is optically active (e.g. d-lactate or l-lysine) or racemic (e.g. dl-tartrate or dl-arginine) .
- Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.
- racemate or the racemate of a salt or derivative
- HPLC high pressure liquid chromatography
- the racemate or a racemic precursor
- a suitable optically active compound for example, an alcohol, or, in the case where the compound of any one of the formulae described above contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid.
- the resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer (s) by means well known to a skilled person.
- Chiral compounds of any one of the formulae described above (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50%by volume of isopropanol, typically from 2%to 20%, and from 0 to 5%by volume of an alkylamine, typically 0.1%diethylamine.
- the present invention also includes all pharmaceutically acceptable isotopically-labeled compounds of any one of the formulae described above wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.
- isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 Cl, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, phosphorus, such as 32 P, and sulfur, such as 35 S.
- isotopically-labelled compounds of any one of the formulae described above for example those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
- Substitution with heavier isotopes such as deuterium, i.e., 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements.
- Isotopically-labeled compounds of any one of the formulae described above can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
- solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g., D 2 O, d 6 -acetone, d 6 -DMSO.
- One way of carrying out the invention is to administer a compound of any one of the formulae described above in the form of a prodrug.
- certain derivatives of a compound of any one of the formulae described above which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into a compound of any one of the formulae described above having the desired activity, for example by hydrolytic cleavage, particularly hydrolytic cleavage promoted by an esterase or peptidase enzyme.
- Such derivatives are referred to as “prodrugs. ” Further information on the use of prodrugs may be found in Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and W.
- Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of any one of the formulae described above with certain moieties known to those skilled in the art as “pro-moieties” as described, for example, in Design of Prodrugs by H. Bundgaard (Elsevier, 1985) and Y.M. Choi-Sledeski and C.G. Wermuth, Designing Prodrugs and Bioprecursors in Practice of Medicinal Chemistry, (Fourth Edition) , Chapter 28, 657-696 (Elsevier, 2015) .
- a prodrug in accordance with the invention is (a) an ester or amide derivative of a carboxylic acid in a compound of any one of the formulae described above; (b) an ester, carbonate, carbamate, phosphate or ether derivative of a hydroxyl group in a compound of any one of the formulae described above; (c) an amide, imine, carbamate or amine derivative of an amino group in a compound form any one of the formulae described above; (d) an oxime or imine derivative of a carbonyl group in a compound of any one of the formulae described above; or (e) a methyl, primary alcohol or aldehyde group that can be metabolically oxidized to a carboxylic acid in a compound of any one of the formulae described above.
- prodrugs in accordance with the invention include:
- Certain compounds of any one of the formulae described above may themselves act as prodrugs of other compounds of any one of the formulae described above. It is also possible for two compounds of any one of the formulae described above to be joined together in the form of a prodrug. In certain circumstances, a prodrug of a compound of any one of the formulae described above may be created by internally linking two functional groups in a compound of any one of the formulae described above, for instance by forming a lactone.
- references to compounds of any one of the formulae described above are taken to include the compounds themselves and prodrugs thereof.
- the invention includes such compounds of any one of the formulae described above as well as pharmaceutically acceptable salts of such compounds and pharmaceutically acceptable solvates of said compounds and salts.
- a compound of the invention is administered in an amount effective to treat a condition as described herein.
- the compounds of the invention can be administered as compound per se, or alternatively, as a pharmaceutically acceptable salt.
- the compound per se or pharmaceutically acceptable salt thereof will simply be referred to as the compounds of the invention.
- the compounds of the invention are administered by any suitable route in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
- the compounds of the invention may be administered orally, rectally, vaginally, parenterally, or topically.
- the compounds of the invention may be administered orally.
- Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the bloodstream directly from the mouth.
- the compounds of the invention may also be administered directly into the bloodstream, into muscle, or into an internal organ.
- Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous.
- Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
- the compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally.
- the compounds of the invention can also be administered intranasally or by inhalation.
- the compounds of the invention may be administered rectally or vaginally.
- the compounds of the invention may also be administered directly to the eye or ear.
- the dosage regimen for the compounds of the invention and/or compositions containing said compounds is based on a variety of factors, including the type, age, weight, sex and medical condition of the patient; the severity of the condition; the route of administration; and the activity of the particular compound employed. Thus the dosage regimen may vary widely.
- the total daily dose of a compound of the invention is typically from about 0.001 to about 100 mg/kg (i.e., mg compound of the invention per kg body weight) for the treatment of the indicated conditions discussed herein.
- total daily dose of the compound of the invention is from about 0.01 to about 30 mg/kg, and in another embodiment, from about 0.03 to about 10 mg/kg, and in yet another embodiment, from about 0.1 to about 3 mg/kg.
- the administration of the compounds of the invention will be repeated a plurality of times in a day (typically no greater than 4 times) . Multiple doses per day typically may be used to increase the total daily dose, if desired.
- the patient is a human, such as a human with one of the treatable disease indications or disorders described elsewhere herein.
- compositions may be provided in the form of tablets containing 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 30.0 50.0, 75.0, 100, 125, 150, 175, 200, 250 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient.
- a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, or in another embodiment, from about 1 mg to about 100 mg of active ingredient.
- doses may range from about 0.01 to about 10 mg/kg/minute during a constant rate infusion.
- Suitable subjects or patients according to the invention include mammalian subjects, including human, or non-human mammals such as primates, rodents (mice, rats, hamsters, rabbits etc) .
- humans are suitable subjects. Human subjects may be of either gender and at any stage of development. In certain embodiments, the human is a child less than 18 years old, 15 years old or around 14 years old, 12 years old, 10 years old, or less than 5 years old.
- the invention comprises pharmaceutical compositions.
- Such pharmaceutical compositions comprise a compound of the invention presented with a pharmaceutically acceptable carrier.
- Other pharmacologically active substances can also be present.
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
- pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof, and may include isotonic agents, for example, sugars, sodium chloride, or polyalcohols such as mannitol, or sorbitol in the composition.
- Pharmaceutically acceptable substances such as wetting agents or minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the antibody or antibody portion.
- compositions of this invention may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions) , dispersions or suspensions, tablets, pills, powders, liposomes and suppositories.
- liquid solutions e.g., injectable and infusible solutions
- dispersions or suspensions tablets, pills, powders, liposomes and suppositories.
- the form depends on the intended mode of administration and therapeutic application.
- compositions are in the form of injectable or infusible solutions, such as compositions similar to those used for passive immunization of humans with antibodies in general.
- One mode of administration is parenteral (e.g. intravenous, subcutaneous, intraperitoneal, intramuscular) .
- the antibody is administered by intravenous infusion or injection.
- the antibody is administered by intramuscular or subcutaneous injection.
- Oral administration of a solid dose form may be, for example, presented in discrete units, such as hard or soft capsules, pills, cachets, lozenges, or tablets, each containing a predetermined amount of at least one compound of the invention.
- the oral administration may be in a powder or granule form.
- the oral dose form is sub-lingual, such as, for example, a lozenge.
- the compounds of any one of the formulae described above are ordinarily combined with one or more adjuvants.
- Such capsules or tablets may contain a controlled release formulation.
- the dosage forms also may comprise buffering agents or may be prepared with enteric coatings.
- oral administration may be in a liquid dose form.
- Liquid dosage forms for oral administration include, for example, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art (e.g., water) .
- Such compositions also may comprise adjuvants, such as wetting, emulsifying, suspending, flavoring (e.g., sweetening) , and/or perfuming agents.
- the invention comprises a parenteral dose form.
- Parenter administration includes, for example, subcutaneous injections, intravenous injections, intraperitoneally, intramuscular injections, intrasternal injections, and infusion.
- injectable preparations i.e., sterile injectable aqueous or oleaginous suspensions
- suitable dispersing, wetting agents, and/or suspending agents may be formulated according to the known art using suitable dispersing, wetting agents, and/or suspending agents.
- the invention comprises a topical dose form.
- Topical administration includes, for example, transdermal administration, such as via transdermal patches or iontophoresis devices, intraocular administration, or intranasal or inhalation administration.
- Compositions for topical administration also include, for example, topical gels, sprays, ointments, and creams.
- a topical formulation may include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas.
- Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used.
- Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol.
- Penetration enhancers may be incorporated -see, for example, Finnin and Morgan, J. Pharm. Sci., 88: 955-958, 1999.
- Formulations suitable for topical administration to the eye include, for example, eye drops wherein the compound of this invention is dissolved or suspended in a suitable carrier.
- a typical formulation suitable for ocular or aural administration may be in the form of drops of a micronized suspension or solution in isotonic, pH-adjusted, sterile saline.
- Other formulations suitable for ocular and aural administration include ointments, biodegradable (i.e., absorbable gel sponges, collagen) and non-biodegradable (i.e., silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes.
- a polymer such as crossed linked polyacrylic acid, polyvinyl alcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methylcellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride.
- a preservative such as benzalkonium chloride.
- Such formulations may also be delivered by iontophoresis.
- the compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant.
- Formulations suitable for intranasal administration are typically administered in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurized container, pump, spray, atomizer (preferably an atomizer using electrohydrodynamics to produce a fine mist) , or nebulizer, with or without the use of a suitable propellant, such as 1, 1, 1, 2-tetrafluoroethane or 1, 1, 1, 2, 3, 3, 3-heptafluoropropane.
- the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
- the invention comprises a rectal dose form.
- rectal dose form may be in the form of, for example, a suppository. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
- compositions of the invention may be prepared by any of the well-known techniques of pharmacy, such as effective formulation and administration procedures.
- the compounds of the invention can be used alone, or in combination with other therapeutic agents.
- the invention provides any of the uses, methods or compositions as defined herein wherein the compound of any embodiment of any one of the formulae described above herein, or pharmaceutically acceptable salt thereof, or pharmaceutically acceptable solvate of said compound or salt, is used in combination with one or more other therapeutic agent discussed herein.
- the administration of two or more compounds “in combination” means that all of the compounds are administered closely enough in time that each may generate a biological effect in the same time frame. The presence of one agent may alter the biological effects of the other compound (s) .
- the two or more compounds may be administered simultaneously, concurrently or sequentially. Additionally, simultaneous administration may be carried out by mixing the compounds prior to administration or by administering the compounds at the same point in time but as separate dosage forms at the same or different site of administration.
- the invention provides methods of treatment that include administering compounds of the present invention in combination with one or more other pharmaceutical agents, wherein the one or more other pharmaceutical agents may be selected from the agents discussed herein.
- the compounds of this invention are administered with an anti-diabetic agent including but not limited to a biguanide (e.g., metformin) , a sulfonylurea (e.g., tolbutamide, glibenclamide, gliclazide, chlorpropamide, tolazamide, acetohexamide, glyclopyramide, glimepiride, or glipizide) , a thiazolidinedione (e.g., pioglitazone, rosiglitazone, or lobeglitazone) , a glitazar (e.g., saroglitazar, aleglitazar, muraglitazar or tesaglitazar) , a meglitinide (e.g., nateglinide, repaglinide) , a dipeptidyl peptidase 4 (DPP-4) inhibitor (e.g., si), a
- glucose-dependent insulinotropic peptide GIP
- an alpha glucosidase inhibitor e.g. voglibose, acarbose, or miglitol
- an insulin or an insulin analogue including the pharmaceutically acceptable salts of the specifically named agents and the pharmaceutically acceptable solvates of said agents and salts.
- the compounds of this invention are administered with an anti-obesity agent including but not limited to peptide YY or an analogue thereof, a neuropeptide Y receptor type 2 (NPYR2) agonist, a NPYR1 or NPYR5 antagonist, a cannabinoid receptor type 1 (CB1R) antagonist, a lipase inhibitor (e.g., orlistat) , a human proislet peptide (HIP) , a melanocortin receptor 4 agonist (e.g., setmelanotide) , a melanin concentrating hormone receptor 1 antagonist, a farnesoid X receptor (FXR) agonist (e.g.
- an anti-obesity agent including but not limited to peptide YY or an analogue thereof, a neuropeptide Y receptor type 2 (NPYR2) agonist, a NPYR1 or NPYR5 antagonist, a cannabinoid receptor type 1 (CB1
- obeticholic acid obeticholic acid
- zonisamide phentermine (alone or in combination with topiramate)
- phentermine alone or in combination with topiramate
- a norepinephrine/dopamine reuptake inhibitor e.g., buproprion
- opioid receptor antagonist e.g., naltrexone
- a combination of norepinephrine/dopamine reuptake inhibitor and opioid receptor antagonist e.g., a combination of bupropion and naltrexone
- a GDF-15 analog sibutramine, a cholecystokinin agonist, amylin and analogues therof (e.g., pramlintide) , leptin and analogues thereof (e.g., metroleptin)
- a serotonergic agent e.g., lorcaserin
- the compounds of this invention are administered with an agent to treat NASH including but not limited to PF-05221304, an FXR agonist (e.g., obeticholic acid) , a PPAR ⁇ / ⁇ agonist (e.g., elafibranor) , a synthetic fatty acid-bile acid conjugate (e.g., aramchol) , a caspase inhibitor (e.g., emricasan) , an anti-lysyl oxidase homologue 2 (LOXL2) monoclonal antibody (e.g., pumpuzumab) , a galectin 3 inhibitor (e.g., GR-MD-02) , a MAPK5 inhibitor (e.g., GS-4997) , a dual antagonist of chemokine receptor 2 (CCR2) and CCR5 (e.g., cenicriviroc) , a fibroblast growth factor 21 (FGF21) agonist
- agents and compounds of the invention can be combined with pharmaceutically acceptable vehicles such as saline, Ringer’s solution, dextrose solution, and the like.
- pharmaceutically acceptable vehicles such as saline, Ringer’s solution, dextrose solution, and the like.
- the particular dosage regimen, i.e., dose, timing and repetition, will depend on the particular individual and that individual’s medical history.
- Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and may comprise buffers such as phosphate, citrate, and other organic acids; salts such as sodium chloride; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens, such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol) ; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or Igs; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine,
- Liposomes containing these agents and/or compounds of the invention are prepared by methods known in the art, such as described in U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556. Particularly useful liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE) . Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter.
- PEG-PE PEG-derivatized phosphatidylethanolamine
- agents and/or the compounds of the invention may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly- (methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
- colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
- sustained-release preparations may be used. Suitable examples of sustained-release preparations include semi-permeable matrices of solid hydrophobic polymers containing the compound of any one of the formulae described above, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly (2-hydroxyethyl-methacrylate) , or ‘poly (vinylalcohol) ) , polylactides (U.S. Pat. No.
- copolymers of L-glutamic acid and 7 ethyl-L-glutamate copolymers of L-glutamic acid and 7 ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as those used in LUPRON DEPOT TM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate) , sucrose acetate isobutyrate, and poly-D- (-) -3-hydroxybutyric acid.
- the formulations to be used for intravenous administration must be sterile. This is readily accomplished by, for example, filtration through sterile filtration membranes.
- Compounds of the invention are generally placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
- Suitable emulsions may be prepared using commercially available fat emulsions, such as Intralipid TM , Liposyn TM , Infonutrol TM , Lipofundin TM and Lipiphysan TM .
- the active ingredient may be either dissolved in a pre-mixed emulsion composition or alternatively it may be dissolved in an oil (e.g., soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil) and an emulsion formed upon mixing with a phospholipid (e.g., egg phospholipids, soybean phospholipids or soybean lecithin) and water.
- an oil e.g., soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil
- a phospholipid e.g., egg phospholipids, soybean phospholipids or soybean lecithin
- Suitable emulsions will typically contain up to 20%oil, for example, between 5 and 20%.
- the fat emulsion can comprise fat droplets between 0.1 and 1.0 ⁇ m, particularly 0.1 and 0.5 ⁇ m, and have a pH in the range of 5.5 to 8.0.
- the emulsion compositions can be those prepared by mixing a compound of the invention with Intralipid TM or the components thereof (soybean oil, egg phospholipids, glycerol and water) .
- compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above.
- the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
- Compositions in preferably sterile pharmaceutically acceptable solvents may be nebulised by use of gases. Nebulised solutions may be breathed directly from the nebulising device or the nebulising device may be attached to a face mask, tent or intermittent positive pressure breathing machine.
- Solution, suspension or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.
- kits comprising the compound of any one of the formulae described above or pharmaceutical compositions comprising the compound of any one of the formulae described above of the invention.
- a kit may include, in addition to the compound of any one of the formulae described above, of the invention or pharmaceutical composition thereof, diagnostic or therapeutic agents.
- a kit may also include instructions for use in a diagnostic or therapeutic method.
- the kit includes the compound of any one of the formulae described above, or a pharmaceutical composition thereof and a diagnostic agent.
- the kit includes the compound of any one of the formulae described above, or a pharmaceutical composition thereof.
- the invention comprises kits that are suitable for use in performing the methods of treatment described herein.
- the kit contains a first dosage form comprising one or more of the compounds of the invention in quantities sufficient to carry out the methods of the invention.
- the kit comprises one or more compounds of the invention in quantities sufficient to carry out the methods of the invention and a container for the dosage and a container for the dosage.
- the compounds of any one of the formulae described above may be prepared by the general and specific methods described below, using the common general knowledge of one skilled in the art of synthetic organic chemistry. Such common general knowledge can be found in standard reference books such as Comprehensive Organic Chemistry, Ed. Barton and Ollis, Elsevier; Comprehensive Organic Transformations: A Guide to Functional Group Preparations, Larock, John Wiley and Sons; and Compendium of Organic Synthetic Methods, Vol. I-XII (published by Wiley-Interscience) .
- the starting materials used herein are commercially available or may be prepared by routine methods known in the art.
- certain compounds contain primary amines or carboxylic acid functionalities which may interfere with reactions at other sites of the molecule if left unprotected. Accordingly, such functionalities may be protected by an appropriate protecting group which may be removed in a subsequent step.
- Suitable protecting groups for amine and carboxylic acid protection include those protecting groups commonly used in peptide synthesis (such as N-t-butoxycarbonyl (Boc) , benzyloxycarbonyl (Cbz) , and 9-fluorenylmethylenoxycarbonyl (Fmoc) for amines, and lower alkyl or benzyl esters for carboxylic acids) which are generally not chemically reactive under the reaction conditions described and can typically be removed without chemically altering other functionality in the any one of the formulae described above compounds.
- Amine compounds prepared via methods described herein can be alkylated with a protected 2-bromoacetate in the presence of a suitable base such as K 2 CO 3 , Et 3 N, NaH or LiHMDS in a polar aprotic solvent such as but not limited to DMF, DMAc, DMSO or NMP to deliver compounds.
- a suitable base such as K 2 CO 3 , Et 3 N, NaH or LiHMDS
- a polar aprotic solvent such as but not limited to DMF, DMAc, DMSO or NMP
- Standard ester hydrolysis can be performed to provide acids.
- Pg 2 is t-butyl
- standard acidic deprotection methods such as TFA/DCM, HCl/1, 4-dioxane, HCl/EtOAc or other suitable conditions may be used to deliver acids.
- GPCR G protein-coupled receptor
- GLP-1R agonists are so-called “biased agonists, ” in that they preferentially stimulate subsets among the natural signaling pathways, such as the G protein activation /cAMP production pathway, as compared to the recruitment of ⁇ -Arrestin, and/or the subsequent internalization of the GPCR (i.e., GLP-1R) - ⁇ -Arrestin complex.
- the assays below provide means to measure the various downstream signaling pathways upon activation by the subject compounds.
- GLP1 plays an important physiological role in maintaining blood glucose homeostasis.
- GLP-1R is known to be expressed in pancreatic beta cells. GLP-1 mediates its effects via a G ⁇ s–coupled pathway. Activated GLP-1R stimulates the adenylyl cyclase pathway thus increases the intracellular concentration of cAMP, which results in increased insulin synthesis and release of insulin. Consequently GLP-1R has been suggested as a potential target for the treatment of diabetes.
- GLP-1R activation following agonist /ligand binding also leads to ⁇ -arrestin recruitment to the GLP-1 receptor, which blocks GLP-1R signaling by, for example, occluding the binding site on GLP-1R for heterotrimeric G-protein to prevent its activation (desensitization) , and by linking the GLP-1R to elements of the internalization machinery, such as clathrin and clathrin adaptor AP2, which promotes receptor internalization via coated pits and subsequent transport to internal compartments endosomes. Subsequently, the receptor could be either directed to degradation compartments (lysosomes) or recycled back to the plasma membrane where it can again signal.
- GLP-1R agonist activity with respect to ⁇ -arrestin recruitment can be determined with a cell-based functional assay using PathHunter eXpress GLP1R CHO-K1 ⁇ -Arrestin GPCR Assay kit (DiscoverX Cat#93-0300E2CP0M) .
- the PathHunter ⁇ -Arrestin GPCR assay technology utilizes a ⁇ -galactosidase ( ⁇ -gal) enzyme that is split into two fragments, the smaller Enzyme Donor (ED) and the larger Enzyme Acceptor (EA) . These fragments can be fused to two proteins that may interact with each other, such as EA- ⁇ -Arrestin and ED-GLP-1R. The fusions can be stably expressed in a test cell line, such as the PathHunter CHO-K1 GLP1R ⁇ -Arrestin cells described below.
- these fragment fusions have no ⁇ -gal activity; however, in solution or in a living cell, they can be brought together and complement to form an active ⁇ -gal enzyme due to the interaction between the fused proteins, thus generating a chemiluminescent signal in the presence of a suitable ⁇ -gal substrate.
- PathHunter CHO-K1 GLP1R ⁇ -Arrestin cells from the assay kit were plated at a density of 1000 or 2000 cells/20 ⁇ l/well in a 384-well white/clear bottom plates (Greiner Cat#781098) . Frozen cells were quickly thawed and 10 mL of cell plating medium (provided by the kit) was added to thawed cells. Cells were stored in a 37 °C incubator under 5%CO 2 and kept for approximately 48 hours until ready to run the assay.
- Reference and test compounds were dissolved in 100%DMSO. 5 ⁇ concentration of an agonist was prepared in serum free DMEM (Thermo Cat#11965) . 5 ⁇ L of this solution was added to 20 ⁇ L cell medium in assay plate for a final top concentration of 10 ⁇ M. Plates were then incubated at 37 °C under 5%CO 2 for 90 min.
- detection reagents were made up by combining 1 part Galacton Star Substrate with 5 parts Emerald IITM Solution, and 19 parts of PathHunter Cell Assay Buffer, respectively. 12.5 ⁇ L detection reagent was added to each well. The plates were then incubated at room temperature in dark for 60 min. Plates were then read on Envision for 0.1sec/well.
- EC 50 determinations were made from agonist dose-response curves analyzed with a curve fitting program using a 4-parameter logistic dose response equation.
- the working solution is stable for at least 24 hours at room temperature with no impact on assay performance.
- Sufficient reagents are provided in each kit to perform the indicated number of assays.
- Cells were plated at a density of 1000 or 2000 cells/20 ⁇ L/well. Frozen cells were quickly thawed and added to 10 mL of cell plating medium. Cells were stored in a 37 °C incubator under 5%CO 2 and left for approximately 48 hours until ready to run the assay.
- Test compounds came solubilized in 100%DMSO. Prepare 10 ⁇ concentration of an agonist in serum free DMEM, and add all solutions into the compound plate. 2.5 ⁇ L of this solution was added to 20 ⁇ L cell medium in assay plate for a final top concentration of 10 ⁇ M. Plates were incubated at 37 °C under 5%CO 2 for 30 min. An additional 2.5 ⁇ L of Buffer was added to the entire plate for agonist mode and incubated at 37 °C for another 90 min.
- the tested compounds include Compounds 1, 10, 11, 19, and 35 in FIG. 1A, and Compounds 225 &236-239 in FIG. 1B.
- the partial maximum relative effect B max (at the highest concentration tested in the assays) for the tested compounds generally fall within about 10%to about 40%of the B max for the natural ligand GLP-1 (7-37) . See B max values in the table above.
- a similar assay can also be used to assess the extent of signal attenuation due to GLP-1R internalization (the ⁇ -Arrestin Internalization Assay) .
- activated GLP1R Internalization cells were engineered to co-express an untagged GLP1R, Enzyme Acceptor (EA) tagged ⁇ -Arrestin, and a ProLink TM (PK) tag localized to the endosomes.
- EA Enzyme Acceptor
- PK ProLink TM
- PathHunter engineered U2OS cells from the assay kit (Cat#93-0724E3CP0L) were plated at a density of 2000 cells/20 ⁇ L/well in a 384-well white/clear bottom plates (Greiner Cat#781098) . Frozen cells were quickly thawed and 10 mL of cell plating medium (provided by the kit) was added to thawed cells. Cells were stored in a 37°C incubator and kept for approximately 48 hours until ready for the assay.
- Reference and test compounds were dissolved in 100%DMSO. 5 ⁇ concentration of an agonist was prepared in serum free DMEM (Thermo Cat#11965) . 5 ⁇ L of this solution was added to 20 ⁇ L cell medium in assay plate for a final top concentration of 10 ⁇ M. Plates were incubated at 37°C for 180 min.
- detection reagents were made up by combining 1 part Galacton Star Substrate with 5 parts Emerald IITM Solution, and 19 parts of PathHunter Cell Assay Buffer, respectively. 12.5 ⁇ L detection reagent was added to each well. The plates were then incubated at room temperature for 60 min. Plates were then read on Envision for 0.1 sec/well.
- EC 50 determinations were made from agonist dose-response curves analyzed with a curve fitting program using a 4-parameter logistic dose response equation.
- the tested compounds include Compounds 19 &28 (left panel) , and Compounds 9, 33, &35 (right panel) in FIG. 2A, and Compounds 221, 222, &225 (left panel) , 224 &239 (middle panel) , and 236 (right panel) in FIG. 2B.
- the partial maximum relative effect B max (at the highest concentration tested in the assays) for the tested compounds generally fall within about 10%to about 35%of the B max for the natural ligand GLP-1 (7-37) .
- GLP-1R-mediated interaction with ⁇ -Arrestin by agonist activity is determined with a cell-based functional assay, utilizing a Binary Technology (NanoBiT) (Promega N2015) designed to detect GLP-1R and ⁇ -Arrestin interaction in a living cell.
- the method is a two-subunit system based on luciferase that can be used for intracellular detection of protein: protein interactions (PPIs) .
- the two subunits are known as the Large BiT (LgBiT; 17.6kDa) and the Small BiT (SmBiT; 11 amino acids) . These two subunits are fused to two proteins of interest, respectively. When both are expressed, the PPI brings the subunits into close proximity to form a functional enzyme that generates a bright, luminescent signal.
- the human GLP-1R coding sequence (NCBI Reference Sequence NM_002062) and ⁇ -Arrestin2 coding sequence (NCBI Reference Sequence NM_004313.3) were subcloned into transient expression vectors provided in the NanoBiT kit, such that GLP-1R-LgBiT and SmBiT- ⁇ -Arrestin2 fusions were generated.
- a total of 8 combinations were selected using HEK293T-based transfection with activation by the natural ligand GLP-1 7-37 .
- the combination showed the highest assay window (GLP-1R-LgBiT and SmBiT- ⁇ -Arrestin2) was selected for testing the compounds of the invention.
- HEK293T cells (7.5 k cells/well) were seeded in 96-well culture plate (Corning Cat#3917) in DMEM (Thermo Cat#11965) with 10%FBS (Biosera Cat#FB-10581) that was heat inactivated, and 25 mM glucose. After 48 hours, cells were transfected with the GLP-1R-LgBiT and SmBiT- ⁇ -Arrestin2 constructs using Lipofectamine2000 (Thermo Cat#11668019) following the manufacturer's assay protocol.
- plasmids encoding the GLP-1R-LgBiT and SmBiT- ⁇ -Arrestin2 fusions, and transfection reagent were diluted with Opti-MEM (Thermo Cat#31985-070) . Then about 50 ng of GLP-1R-LgBiT and 50 ng of SmBiT- ⁇ -Arrestin2 plasmid constructs were mixed, and the resulting plasmids mixture was added into diluted transfection reagent. The ratio of plasmid ( ⁇ g) : Lipofectamine2000 ( ⁇ l) was 1: 10. The mixtures were then added into cells after 5 minutes’ incubation at room temperature. About 48 hours after transfection, medium was replaced by 65 ⁇ L/well fresh Opti-MEM.
- Live Cell Substrate was then diluted with LCS Dilution Buffer at 1: 24 ratio. About 25 ⁇ L of Live Cell Reagent was added into each well. Varying concentrations of each subject compound to be tested (in DMSO) were diluted in Opti-MEM with 0.1%BSA (Sigma Cat#A7409) to make 10x stocks. About 10 ⁇ L compound stocks were added into each well using pipette. Luminescence was measured immediately by EnVision for 40, 60, or 120 repeats, with 0.25 seconds per well.
- EC 50 determinations were made from agonist dose-response curves analyzed with a curve fitting program using a 4-parameter logistic dose response equation.
- GLP-1 (7-36) is dissolved in 100%DMSO and the stock concentration is 1mM.
- a typical plate layout for GLP-1 is shown below.
- test compounds dilute 1 mM stock to 100 ⁇ M using Opti-MEM containing 1%BSA, final top concentration is 10 ⁇ M, 1/4 log (4-fold) dilution, 8-dilution points, duplicate samples for each dilution.
- the layout is similar to GLP-1 above (not shown) .
- tested Compounds 19 and 35 clearly behaved differently from the natural agonist GLP-1 (7-37) .
- FIGs. 5A-5C show NanoBit assay time-course responses for both GLP-1 (7-37) and Compound 19, 10, or 35, respectively, at different compound concentrations.
- FIGs. 7A-7B showing dose-response curves at 3-minute (180-second) and 5-minute (300-second) readouts for the GLP-1R/ ⁇ -Arrestin NanoBit assay, using Compounds 19 and 35 (FIG. 7A) and Compound 10 (FIG. 7B) , with GLP-1 (7-37) as control.
- the maximum relative effects for the tested compounds B max for the highest concentrations tested, are generally no more than 40% (usually about 20-40%) of that of GLP-1 (7-37) .
- data analysis/report to obtain EC 50 values can also be done when compounds reach maximal signals –such as at 450-500 sec ( ⁇ 8 min) .
- GLP-1R-mediated agonist activity was determined with a cell-based functional assay utilizing an HTRF (Homogeneous Time-Resolved Fluorescence) cAMP detection kit (cAMP Dynamic 2 Assay Kit; CisBio cat #62AM4PEC) that measures cAMP levels in the cell.
- the method is a competitive immunoassay between native cAMP produced by the cells and exogenous cAMP labeled with the dye d2.
- the tracer binding is visualized by a mAb anti-cAMP labeled with Cryptate.
- the specific signal i.e., energy transfer
- the human GLP-1R coding sequence (NCBI Reference Sequence NM_002062) was subcloned into pcDNA3.1+/Hygro vector (Invitrogen) and transfected into HEK293/CRE/Luc parental cell line. A cell line stably expressing the receptor was isolated. Saturation binding analyses (filtration assay procedure) using 125 I-GLP-1 7-36 (Perkin Elmer) shows that plasma membranes derived from this cell line express a high GLP-1R density (K d : ⁇ 1 nM, B max : >800 fmol/mg protein) .
- Varying concentrations of each compound to be tested were diluted in DMSO to obtain 200 ⁇ compound working solution first and then 50 nl compounds were added to a white 384-well assay plate (Greiner 784075) with ECHO. The final DMSO concentration was 0.5%. The compound concentration range may be adjusted at any time.
- Cells were removed from cryopreservation, re-suspended in 5 mL of Dulbecco's Phosphate Buffered Saline (DPBS-Sigma Cat #D8537) and centrifuged at 900 g for 5 min at 22 °C. The cell pellet was then re-suspended in 1 mL of assay buffer [DPBS with 500 ⁇ M IBMX (Sigma #I5879) and 0.1%BSA (Sigma #A1933) . IBMX and BSA were freshly added on the day of assay] . A 10 ⁇ L sample of the cell suspension was counted on an Invitrogen Countess II to determine cell viability and cell count per mL.
- the remaining cell suspension was then adjusted with assay buffer to deliver 1000 viable cells per well using a Matrix Combi Multidrop reagent dispenser. 10 ⁇ L cell suspensions were added to each well of the assay plate which already contains compound. The plate was sealed and incubated at 37 °C with 5%CO 2 for 30 minutes.
- Raw data were converted to nM cAMP by interpolation from a cAMP standard curve (as described in the manufacturer's assay protocol) and the percent effect was determined relative to a saturating concentration of the full agonist GLP-1 7-37 (10 nM) included on each plate.
- EC 50 determinations were made from agonist dose-response curves analyzed with a curve fitting program using a 4-parameter logistic dose response equation.
- This assay demonstrates that the compounds of the invention activates GLP-1R signaling through the cAMP pathway, thus behave as GLP-1R agonists.
- the representive commercial reagents /kits that can be (were) used in such assays are described below.
- the lyophilisate was reconstituted with an appropriate amount of distilled water according to manufacturer’s instructions to make working stock which can be aliquoted and frozen (-20 °C) .
- DMSO was removed from the media by carefully transferring thawed cells to a sterile 15/50 mL tube, filling a tube with 10-50 mL of complete media pre-warmed to 37 °C, and allowing the cells to sit 5 min before centrifuging at 900 rpm for 5 minutes for cell collection.
- the optimized cell density is 1000 cells/well. Caution was taken because cell density optimization was crucial and needed to be optimized in different labotatories. The level of cAMP produced by the cells must fall within the linear range of the standard curve.
- Test compounds were dissolved with DMSO to make stock solutions, aliquoted and stored at -80°C. Serial dilutions of compound solutions were made using DMSO to obtain a 200 ⁇ compound working solution first and then 50 nL of the working solution to 384-well plate with ECHO. The final DMSO concentration is 0.5%. The compound concentration range may be adjusted at any time.
- IBMX 500 mM stock solution dissolved in DMSO, aliquot and stored at -20°C.
- Cell preparation cell suspensions were prepared according to procedures described above before running the assay.
- Compound preparation prepare compound addition plates in advance of assay. Prepare 200 ⁇ concentration of compound working solutions according to procedures described above.
- Cell preparation cell suspensions are prepared according to procedures described above before running the assay.
- Exendin (9-39) Antagonist addition Add 5 ⁇ L of 2x Exendin (9-39) to each well of the assay plate which already contains compound and cells. The final concentration of Exendin (9-39) is IC80. Seal the plate and incubate at 37°C with 5%CO2 for 30 minutes.
- ⁇ Z height Must be optimized (use optimization Wizard, optimize on a well with maximum FRET)
- EC 50 value for each compound is defined as the compound concentration that yielded 50%of the maximum cAMP level achieved with the same compound.
- each compound was tested in HEK293T cells. The results are shown below in Table 1.
- selected compounds were also tested in CHO cells that have been stably transfected to express human GLP-1R. The results are shown below in Table 2.
- the compounds of the invention generally have B max approaching about 20-40%of that of GLP-1 (7-37) in the ⁇ -Arrestin recruitment assay and GLP-1R internalization assay, and the NanoBit time course profiles are different between the compounds of the invention and those of GLP-1 (7-37) .
- test compounds i.e., Compound 19, Compound 28, Compounds 29, Compound 225, or Compound 418 (Control Compound) were weighed into a mortar, and grinded until no obvious granules were left.
- Appropriate volumes of vehicles e.g., 2%Tween 80 (v: v) and 0.5%MC (w: v) in saline or 0.5%MC (w: v) in water were then added into the mortar containing the ground compounds, and the mixture was then grinded with a pestle until a homogeneous paste was formed. Additional appropriate volumes of vehicles were added into the mortar containing each compound, and the mixture was grinded further with the pestle until a homogeneous suspension was obtained.
- vehicles e.g., 2%Tween 80 (v: v) and 0.5%MC (w: v) in saline or 0.5%MC (w: v) in water were then added into the mortar containing the ground compounds, and the mixture was then grinded with
- the suspension was then transferred into a glass bottle.
- the mortar and the pestle were rinsed with the vehicle until no compound was left in the mortar or on the pestle.
- the rest of the vehicle was added to make up the final dosing volume of about 1 mg/mL or 2 mg/mL (i.e., final dosing volume of about 5 mL/kg) , and the homogenous suspension was continuously stirred prior to and during the dosing.
- Dose 1 or Dose 2 blood samples were collected at pre-dose, and at 15 min, 30 min, 1 hr, 2 hr, 4 hr, (6 hr for compounds 19 and 28 with cynomolgus monkeys only) , 8 hr, 12 hr, and 24 hr post dose (i.e., 9 or 10 total time points for each compound at each dose) .
- the blood samples were centrifuged at approximately 2,000-4,000 rpm for about 10-15 minutes at 2-8°C, and each resulting plasma portion was then transferred into an individual tube.
- LC-MS/MS methods were developed, and bioanalysis for the test articles in monkey plasma was performed according to the developed LC-MS/MS methods.
- Undiluted plasma samples An aliquot of 20-50 ⁇ L plasma sample was mixed with 200 ⁇ L of ACN or MeOH containing one of the internal standards (IS, e.g., Diclofenac or Terfenadine) . The mixture was then vortexed for about 1-5 min, and centrifuged at about 4,000-5,800 rpm for about 10-15 min. An aliquot of 1 ⁇ L supernatant was used for LC-MS/MS analysis.
- IS Diclofenac or Terfenadine
- Plasma samples with 10-fold dilution An aliquot of 2 ⁇ L plasma sample was first mixed with 18 ⁇ L of blank plasma, then 200 ⁇ L of ACN containing 100 ng/mL IS (e.g. Diclofenac) was added to the mixture. The mixture was then vortexed for about 10 min, and was centrifuged at about 5, 800 rpm for about 10 min. An aliquot of 1 ⁇ L supernatant was used for LC-MS/MS analysis.
- ACN containing 100 ng/mL IS e.g. Diclofenac
- MS conditions Positive ion, ESI, MRM detection with parent and daughter ions, internal standard Diclofenac.
- Retention time approximately between 1.0 to 1.4 min for the analyte (s)
- Pharmacokinetics parameters including area under the curve (AUC 0-t ) , maximum plasma concentration (C max ) , time to reach maximum plasma concentration (T max ) , oral bioavailability (F%) , etc., were calculated using Phoenix software (Version 6.4) and non-compartment model.
- the comparator /control compound (Compound 418)
- Dose 2 the comparator /control compound
- the comparator /control compound has a relatively precipitous drop of about 10-fold in plasma concentration over a period of about 24 hours post oral dosing.
- the plasma concentrations of PO-administered Compounds 19, 28, 29, and 225 at the same dose level were surprisingly sustained at a more constant level over the entire course of about 24 hours after oral dosing, with relatively minimal reduction in plasma concentration. Similar data has also been obtained (data not shown) or is expected for other compounds of the invention. Collectively, these data suggest that the compounds of the invention have a prolonged or sustained bioavailability, at least over the course of about 1 day (24 hours) following the administration of a single oral dose.
- Compound 418 is the control compound.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Compound No. | B max (POC) * | Compound No. | B max (POC) * |
1 | 2.80 (n=1) | 35 | 19.9 ± 4.44 (n=4) |
10 | 4.48 (n=1) | 221 | 35.6 ± 5.38 (n=2) |
11 | 7.16 (n=1) | 222 | 31.1 ± 4.67 (n=2) |
12 | 9.66 (n=1) | 224 | 33.4 ± 3.78 (n=2) |
18 | 26.2 ± 1.55 (n=2) | 225 | 32.5 ± 3.55 (n=3) |
19 | 26.0 ± 2.78 (n=2) | 236 | 40.3 ± 4.10 (n=3) |
21 | 19.0 ± 0.982 (n=2) | 237 | 37.9 ± 4.66 (n=3) |
22 | 10.9 ± 0.0317 (n=2) | 238 | 55.8 ± 14.1 (n=3) |
23 | 18.2 ± 1.51 (n=2) | 239 | 25.6 ± 5.31 (n=2) |
28 | 28.5 ± 6.36 (n=3) | 242 | 22.5 ± 4.32 (n=2) |
29 | 36.6 ± 7.77 (n=3) | 245 | 38.0 ± 6.42 (n=2) |
34 | 20.2 ± 1.89 (n=2) |
Compound No. | B max (POC) * | Compound No. | B max (POC) * |
9 | 27.03 (n=1) | 47 | 22.8 (n=1) |
18 | 21.3 ± 3.47 (n=3) | 105 | 24.2 (n=1) |
19 | 20.1 (n=1) | 221 | 30.0 ± 6.40 (n=2) |
21 | 6.64 ± 1.55 (n=2) | 222 | 31.4 ± 2.62 (n=2) |
22 | 7.40 ± 6.97 (n=2) | 224 | 22.5 ± 1.41 (n=2) |
23 | 8.92 ± 3.70 (n=2) | 225 | 24.0 ± 6.70 (n=2) |
28 | 17.6 ± 6.62 (n=3) | 236 | 30.0 (n=1) |
29 | 25.9 ± 1.24 (n=3) | 237 | 17.7 ± 1.20 (n=2) |
34 | 8.88 ± 3.19 (n=2) | 238 | 52.8 ± 1.14 (n=2) |
35 | 14.3 ± 9.21 (n=3) | 239 | 14.1 ± 1.57 (n=2) |
45 | 19.1 (n=1) | 242 | 15.4 (n=1) |
46 | 27.4 (n=1) | 245 | 27.7 (n=1) |
Claims (40)
- A compound represented by structural formula (I) :or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein:X 1, X 2, X 3, X 4, and X 5 are each independently selected from N and CH; wherein no more than three of X 1, X 2, X 3, X 4, and X 5 are N and wherein ring A does not contain 3 nitrogen ring atoms at 3 contiguous positions;W is selected from O, S, CR 5R 6, and NR 5’;Y 1, Y 3, Y 4, and Y 5 are each independently selected from N, NH, CH, and CH 2;Y 2 and Y 6 are each independently selected from N, C, or CH;wherein there is no more than 3 nitrogen ring atoms in ring B and wherein ring B does not contain 3 nitrogen ring atoms at 3 contiguous positions;Z 1 and Z 2 are each independently selected from N, C, and CH; wherein at least one of Z 1 and Z 2 is N; Z 3 and Z 4 are each independently selected from a bond, CH, CH 2, CH=CH, CH 2CH 2, CH 2CH, and CHCH 2; wherein ring C contains no more than two double bonds;provided that when ring B is then (1) W is not O, and/or (2) ring C is not and/or (3) ring C is not wherein Z 1 is N, and/or (4) ring A is not phenyl;wherein:T 2, T 3, and T 4 are each independently selected from N, NR 4, O, S, C, and CR 4;T 6, T 7, and T 8 are each independently selected from N and CR 4;wherein no more than 4 of T 2, T 3, T 4, T 6, T 7, and T 8 are selected from N, O, and S;EE is –COOH or a carboxylic group surrogate, optionally, the carboxylic group surrogate is:R a is selected from hydrogen, deuterium, halogen, -CN, C 1-C 6 alkyl, C 1-C6 alkoxy, NR 5’R 6’, 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C 1-C 6 alkyl or C 1-C 6 alkoxy represented by R a is optionally substituted with one or more groups selected from halogen, oxo, CN, OH, and C 3-C 6 saturated or partially saturated cycloalkyl; and wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclyl represented by R a or in the group represented by R a is optionally substituted with one or more groups selected from halogen, oxo, CN, OH, C 1-C 3 alkyl (optionally substituted with 1 to 3 groups selected from F, OH, and OCH 3) , and C 1-C 3 alkoxy (optionally substituted with 1 to 3 groups selected from F, OH, and OCH 3) , and NR 5’R 6’;R b is selected from hydrogen, deuterium, halogen, -CN, C 1-C 6 alkyl, C 1-C 6 alkoxy, NR 5’R 6’, 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C 1-C 6 alkyl or C 1-C 6 alkoxy represented by R b is optionally substituted with one or more groups selected from halogen, oxo, CN, OH, and C 3-C 6 saturated or partially saturated cycloalkyl; and wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclyl represented by R b or in the group represented by R b is optionally substituted with one or more groups selected from halogen, oxo, CN, OH, C 1-C 3 alkyl (optionally substituted with 1 to 3 groups selected from F, OH, and OCH 3) , and C 1-C 3 alkoxy (optionally substituted with 1 to 3 groups selected from F, OH, and OCH 3) , and NR 5’R 6’;R c is selected from hydrogen, deuterium, halogen, -CN, C 1-C 6 alkyl, C 1-C 6 alkoxy, NR 5’R 6’, 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C 1-C 6 alkyl or C 1-C 6 alkoxy represented by R c is optionally substituted with one or more groups selected from halogen, oxo, CN, OH, and C 3-C 6 saturated or partially saturated cycloalkyl; and wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclyl represented by R c or in the group represented by R c is optionally substituted with one or more groups selected from halogen, oxo, CN, and NR 5’R 6’;R d is selected from hydrogen, deuterium, halogen, -CN, C 1-C 6 alkyl, C 1-C 6 alkoxy, NR 5’R 6’, 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C 1-C 6 alkyl or C 1-C 6 alkoxy represented by R d is optionally substituted with one or more groups selected from halogen, oxo, CN, and saturated or partially saturated C 3-C 6 cycloalkyl; and wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclyl represented by R d or in the group represented by R d is optionally substituted with one or more groups selected from halogen, oxo, CN, and NR 5’R 6’;each R 1 is independently selected from halogen, -CN, OH, C 1-C 6 alkyl, C 1-C 6 alkoxy, C 1-C 6 alkenyl, C 1-C 6 alkynyl, NR 5’R 6’, 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C 1-C 6 alkyl, C 1-C 6 alkoxy, C 1-C 6 alkenyl, or C 1-C 6 alkynyl represented by R 1 is optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3, OH, OCH 3, OCH 2CH 3, and saturated or partially saturated C 3-C 6 cycloalkyl (optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3, OH, OCH 3, OCH 2CH 3) ; and wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclyl represented by R 1 or in the group represented by R 1 is optionally substituted with one or more groups selected from halogen, oxo, CN, OH, C 1-C 3 alkyl (optionally substituted with 1 to 3 groups selected from F, OH, and OCH 3) , and C 1-C 3 alkoxy (optionally substituted with 1 to 3 groups selected from F, OH, and OCH 3) , and NR 5’R 6’;each R 2 is independently selected from halogen, -CN, OH, oxo, C 1-C 6 alkyl, C 1-C 6 alkoxy, NR 5’R 6’, 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C 1-C 6 alkyl or C 1-C 6 alkoxyrepresented by R 2 is optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3, OH, OCH 3, OCH 2CH 3, and saturated or partially saturated C 3-C 6 cycloalkyl (optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3, OH, OCH 3, OCH 2CH 3) ; and wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclyl represented by R 2 or in the group represented by R 2 is optionally substituted with one or more groups selected from halogen, oxo, CN, OH, C 1-C 3 alkyl (optionally substituted with 1 to 3 groups selected from F, OH, and OCH 3) , and C 1-C 3 alkoxy (optionally substituted with 1 to 3 groups selected from F, OH, and OCH 3) , and NR 5’R 6’;each R 3 is independently selected from halogen, -CN, OH, oxo, C 1-C 6 alkyl, C 1-C 6 alkoxy, NR 5’R 6’, 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C 1-C 6 alkyl or C 1-C 6 alkoxy represented by R 3 is optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3, OH, OCH 3, OCH 2CH 3, and saturated or partially saturated C 3-C 6 cycloalkyl (optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3, OH, OCH 3, OCH 2CH 3) ; and wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclyl represented by R 3 or in the group represented by R 3 is optionally substituted with one or more groups selected from halogen, oxo, CN, OH, C 1-C 3 alkyl (optionally substituted with 1 to 3 groups selected from F, OH, and OCH 3) , and C 1-C 3 alkoxy (optionally substituted with 1 to 3 groups selected from F, OH, and OCH 3) , and NR 5’R 6’;each R 4 is H, deuterium, halogen, OH, -CN, C 1-C 6 alkyl, C 1-C 6 alkoxy, or NR 5’R 6’, wherein the C 1-C 6 alkyl and C 1-C 6 alkoxy represented by R 4 is optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3, and saturated or partially saturated C 3-C 6 cycloalkyl (optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3, OH, OCH 3, OCH 2CH 3) ;R 5 and R 6 are each independently selected from hydrogen, deuterium, halogen, CN, OH, oxo, C 1-C 6 alkyl, C 1-C 6 alkoxy, NR 5’R 6’, 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclyl, wherein the C 1-C 6 alkyl, C 1-C 6 alkoxy, C 1-C 6 alkenyl, or C 1-C 6 alkynyl represented by R 5 or R 6 is optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3, OH, OCH 3, OCH 2CH 3, and saturated or partially saturated C 3-C 6 cycloalkyl (optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3, OH, OCH 3, OCH 2CH 3) ; and wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclyl represented by R 5 or R 6 or in the group represented by R 5 or R 6 is optionally substituted with one or more groups selected from halogen, oxo, CN, OH, C 1-C 3 alkyl (optionally substituted with 1 to 3 groups selected from F, OH, and OCH 3) , and C 1-C 3 alkoxy (optionally substituted with 1 to 3 groups selected from F, OH, and OCH 3) , and NR 5’R 6’;R 5’ and R 6’ are each independently selected from hydrogen, deuterium, and C 1-C 6 alkyl;wherein optionally two R 1; two R 2; two R 3; two R 4; R 1 and R 2; R 2 and R 3; R a and R 1; R a and R 2; R 1 and any of R 5, R 5’ (in the group represented by W) , or R 6; R a and any of R 5, R 5’ (in the group represented by W) , or R 6; R 2 and any of R 5, R 5’ (in the group represented by W) , or R 6; R 5 and R 6; any of two groups selected from R c, R d, R e, and R f; or R 4 and any one of R c, R d, R e, and R f;taken together with their respective intervening carbon or hetero atom (s) , form phenyl, 5-6 membered heteroaryl, 4-8 membered saturated or partially saturated cycloalkyl or 4-8 membered saturated or partially saturated heterocyclyl, each of which is optionally substituted with one or more groups selected from halogen, -CN, -OH, CF 3, C 1-C 6 alkyl, C 1-C 6 alkoxy, -NH 2, -NHC 1-C 6 alkyl, –N (C 1-C 6 alkyl) 2, oxo, and saturated or partially saturated C 3-C 6 cycloalkyl, wherein the C 1-C 6 alkyl and C 1-C 6 alkoxy is optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3, OH, OCH 3, OCH 2CH 3, and saturated or partially saturated C 3-C 6 cycloalkyl, wherein the cycloalkyl is optionally substituted with one or more groups selected from halogen, oxo, CN, CF 3, OH, OCH 3, OCH 2CH 3;m is an integer selected from 0, 1, 2, 3, and 4,n is an integer selected from 0, 1, 2, 3, 4, and 5, ando is an integer selected from 0, 1, 2, 3, 4, and 5.
- The compound according to claim 1 or 2, wherein the compound is represented by structural formula (III-A) :
- The compound according to any one of claims 1-3, wherein the compound is represented by structural formula (IV-A) :or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, whereinT 4 is N or CH; andR a is H, CH 3, or CF 3; or R a, R 1 and X 5, taken together with their respective intervening carbons, form 5-7 membered cycloalkenyl or 5-7 membered partially saturated monoheterocyclyl.
- The compound according to any one of claims 1-4, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein R b iswherein R b is optionally substituted with 1 or 2 groups selected from oxo, CN, F, Cl, C 1-C 3 alkyl, and C 1-C 3 alkoxy, wherein the C 1-C 3 alkyl or C 1-C 3 alkoxy in the group represented by R b is optionally substituted with 1 or 2 groups selected from F, OH, and OCH 3.
- The compound according to any one of claims 1-4, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein R b iswherein R b is optionally substituted with 1 or 2 groups selected from halogen, OH, NR 5’R 6’, C 1-C 3 alkyl, and C 1-C 3 alkoxy, wherein the C 1-C 3 alkyl or C 1-C 3 alkoxy in the group represented by R b is optionally substituted with 1 or 2 groups selected from F, OH, and OCH 3.
- The compound according to any one of claims 1-9, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein is each of which is optionally substituted with 1 or 2 groups selected from halogen, CN, and oxo; or two R 3 groups taken together with ring C, form bridged (C 5-C 8) heterocyclene or bridged (C 5-C 8) cycloalkylene.
- The compound according to any one of claims 1-11, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein iswherein each R 2 is independently selected from halogen, -CN, OH, oxo, C 1-C 2 alkyl, C 1-C 2 haloalkyl, and C 1-C 2 alkoxy; and n is an integer selected from 0, 1, 2, and 3.
- The compound according to claim 12, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein two R 2 groups together with ring B form a bicyclic structure:each of which is optionally substituted with 1 or 2 groups selected from halogen, oxo, CN, CF 3, C 1-C 2 alkyl, C 1-C 2 haloalkyl, C 1-C 2 alkoxy, -NH 2, -NHC 1-C 2 alkyl, and –N (C 1-C 2 alkyl) 2.
- The compound according to claim 12, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein W and ring B form a bicyclic structure:each of which is optionally substituted with 1 or 2 groups selected from halogen, oxo, CN, CF 3, -NH 2, -NHC 1-C 2 alkyl, and –N (C 1-C 2 alkyl) 2.
- The compound according to any one of claims 1-16, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein ring A is each R 1 is independently selected from halogen, OH, CN, CF 3, C 1-C 2 alkyl, C 1-C 2 haloalkyl, C 1-C 2 alkoxy, -NH 2, -NHC 1-C 2 alkyl, –N (C 1-C 2 alkyl) 2, and C 2-C 4alkynyl optionally substituted with cyclopropane; and m is an integer selected from 0, 1, 2, and 3.
- The compound according to any one of claims 1-16, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein ring A iseach R 1 is independently selected from halogen, OH, CN, CF 3, C 1-C 2 alkyl, C 1-C 2 haloalkyl, C 1-C 2 alkoxy, -NH 2, -NHC 1-C 2 alkyl, –N (C 1-C 2 alkyl) 2, and C 2-C 4alkynyl optionally substituted with cyclopropane; and m is an integer selected from 0, 1, and 2.
- The compound according to any one of claims 1-15 and 17-20, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein W is O, NH or CH 2.
- The compound according to any one of claims 1-21, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein R 1 is selected from halogen, CN, CH 3, CF 3, and C≡CH.
- The compound according to claim 1, wherein the compound is represented by the structural formula (I’) :or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, whereinX 1, X 2, X 3, X 4, and X 5 are each independently selected from N and CH; wherein no more than three of X 1, X 2, X 3, X 4, and X 5 are N and ring A does not contain 3 nitrogen ring atoms at 3 contiguous positions;W is selected from O, CR 5’R 6’, and NR 5’;Y 1, Y 3, Y 4, and Y 5 are each independently selected from N, NH, CH, and CH 2;Y 2 and Y 6 are each independently selected from N, C, or CH;wherein there is no more than 3 nitrogen ring atoms in ring B and wherein ring B does not contain 3 nitrogen ring atoms at 3 contiguous positions;provided that when ring B is then (1) W is not O, and/or (2) ring C is not and/or (3) ring C is not wherein Z 1 is N, and/or (4) ring A is not phenyl;T 6, T 7, and T 8 are each independently selected from N and CR 4; and no more than 2 of T 6, T 7, and T 8 are selected from N;EE is –COOH,R a is selected from hydrogen, halogen, C 1-C 6 alkyl, C 1-C 6 alkoxy, NR 5’R 6’, wherein the C 1-C 6 alkyl or C 1-C 6 alkoxy represented by R a is optionally substituted with one or more groups selected from halogen, oxo, CN, and OH;R b is 5-6 membered heteroaryl or 4-7 membered saturated or partially saturated heterocyclyl, wherein the heteroaryl or saturated or partially saturated heterocyclyl represented by R b is optionally substituted with one or more groups selected from halogen, C 1-C 3 alkyl, C 1-C 3 haloalkyl, C 1-C 3 hydroxyalkyl, C 1-C 3 alkoxy, and C 1-C 3 haloalkoxy;R c is hydrogen, C 1-C 6 alkyl, or C 1-C 6 haloalkyl;each R 1 is independently halogen, -CN, OH, C 1-C 6 alkyl, C 1-C 6 alkoxy, C 2-C 6 alkenyl, C 2-C 6 alkynyl, NR 5’R 6’, phenyl, 5-6 membered heteroaryl, 4-6 membered saturated or partially saturated cycloalkyl and 3-7 membered saturated or partially saturated heterocyclyl, wherein the C 1-C 6 alkyl, C 1-C 6 alkoxy, C 2-C 6 alkenyl, or C 2-C 6 alkynyl represented by R 1 is optionally substituted with one or more groups selected from halogen, CN, OH, and C 3-C 6 cycloalkyl; and wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclyl represented by R 1 or in the group represented by R 1 is optionally substituted with one or more groups selected from halogen, oxo, CN, OH, C 1-C 3 alkyl, C 1-C 3 haloalkyl, C 1-C 3 hydroxyalkyl, C 1-C 3 alkoxy, C 1-C 3 haloalkoxy, C 1-C 3 hydroxyalkoxy, and NR 5’R 6’;each R 2 is independently selected from halogen, oxo, C 1-C 6 alkyl, C 1-C 6 haloalkyl, C 1-C 6 alkoxy, C 1-C 6 haloalkoxy, and NR 5’R 6’;each R 3 is independently halogen, -CN, oxo, C 1-C 6 alkyl, C 1-C 6 haloalkyl, C 1-C 6 alkoxy, or C 1-C 6 haloalkoxy; and/ortwo R 3 taken together with Ring C, form 6-10 membered bridged heterocyclyl optionally substituted with one or more groups selected from halogen, C 1-C 6 alkyl, C 1-C 6 haloalkyl, C 1-C 6 alkoxy, or C 1-C 6 haloalkoxy;each R 4 is independently H, halogen, or C 1-C 6 alkyl optionally substituted with one or more groups selected from halogen;R 5’ and R 6’ are each independently hydrogen or C 1-C 6 alkyl;wherein optionally two R 1; two R 2; two R 3; R a and R 1; R a and R 2; R 1 and R 5’; R 2 and R 5’; taken together with their respective intervening carbon or hetero atom (s) , form phenyl, 5-6 membered heteroaryl, 4-6 membered saturated or partially saturated cycloalkyl or 4-7 membered saturated or partially saturated heterocyclyl, each of which is optionally substituted with one or more groups selected from halogen, -CN, -OH, C 1-C 6 alkyl, C 1-C 6 haloalkyl, C 1-C 6 alkoxy, C 1-C 6 haloalkoxy, and NR 5’R 6’;m is 0, 1, 2, 3, or 4;n is 0, 1, 2, 3, or 4; ando is 0, 1, 2, 3, or 4.
- The compound according to any one of claims 23-29, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein W is O, NH or CH 2, and R a is H.
- The compound according to any one of claims 23-32, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, whereineach R 1 is independently selected from halogen, CN, C 1-C 4 alkyl, C 1-C 4 haloalkyl, C 1-C 4 alkoxy, C 1-C 4 haloalkoxy, C 2-C 4alkynyl optionally substituted with cyclopropyl, 5-6 membered heteroaryl (wherein the hetero ring atom is nitrogen) optionally substituted with C 1-C 4 alkyl; and/ortwo R 1, taken together with and their respective intervening carbon atoms, form 4-7 membered heterocyclyl (wherein the hetero ring atom is nitrogen and/or oxygen) optionally substituted with C 1-C 4 alkyl; andm is 0, 1, 2, or 3.
- The compound according to any one of claims 23-33, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein W is O.
- The compound according to any one of claims 23-34, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein ring A is each R 1 is independently selected from halogen, CN, C 1-C 4 alkyl, C 1-C 4 haloalkyl, C 1-C 4 alkoxy, imidazolyl, triazolyl, pyridyl, and C 2-C 4alkynyl optionally substituted with cyclopropyl; and m is 0, 1, or 2.
- The compound according to any one of claims 23-35, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein R 1 is selected from halogen and CN.
- The compound according to claim 1, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, wherein the compound is a compound listed in Table 1.
- A pharmaceutical composition comprising the compound of any of claims 1-37, or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, and a pharmaceutically acceptable excipient.
- A method of treating cardiometabolic and associated diseases comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of any of claims 1-37 or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, or the pharmaceutical composition of claim 38, wherein the disease is T1D, T2DM, pre-diabetes, idiopathic T1D, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea, obesity, eating disorders, weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, cirrhosis, hepatocellular carcinoma, cardiovascular disease, atherosclerosis, coronary artery disease, peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson's Disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer's Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome Crohn's disease, colitis, irritable bowel syndrome, prevention or treatment of Polycystic Ovary Syndrome and treatment of addiction.
- Use of a therapeutically effective amount of a compound of any of claims 1-37 or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof, or the pharmaceutical composition of claim 38, in the manufacture of a medicament for of treating a subject in need of with cardiometabolic and associated diseases, wherein the disease is T1D, T2DM, pre-diabetes, idiopathic T1D, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea, obesity, eating disorders, weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, cirrhosis, hepatocellular carcinoma, cardiovascular disease, atherosclerosis, coronary artery disease, peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson's Disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer's Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome Crohn's disease, colitis, irritable bowel syndrome, prevention or treatment of Polycystic Ovary Syndrome and treatment of addiction.
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/296,078 US20220024901A1 (en) | 2018-11-22 | 2019-11-19 | Glp-1r agonists and uses thereof |
MX2021006034A MX2021006034A (en) | 2018-11-22 | 2019-11-19 | Glp-1r agonists and uses thereof. |
PE2021000746A PE20211871A1 (en) | 2018-11-22 | 2019-11-19 | GLP-1R AGONISTS AND USES OF THEM |
KR1020217019126A KR20210106447A (en) | 2018-11-22 | 2019-11-19 | GLP-1R agonists and uses thereof |
BR112021009877-1A BR112021009877A2 (en) | 2018-11-22 | 2019-11-19 | glp-1r agonists and uses thereof |
AU2019382642A AU2019382642A1 (en) | 2018-11-22 | 2019-11-19 | GLP-1R agonists and uses thereof |
CA3120499A CA3120499A1 (en) | 2018-11-22 | 2019-11-19 | Glp-1r agonists and uses thereof |
CU2021000042A CU20210042A7 (en) | 2018-11-22 | 2019-11-19 | Glp-1r agonists |
EA202191432A EA202191432A1 (en) | 2018-11-22 | 2019-11-19 | GLP-1R AGONISTS AND THEIR APPLICATIONS |
EP19887901.7A EP3883928A4 (en) | 2018-11-22 | 2019-11-19 | Glp-1r agonists and uses thereof |
JP2021529110A JP2022508203A (en) | 2018-11-22 | 2019-11-19 | GLP-1R agonist and its use |
SG11202105241YA SG11202105241YA (en) | 2018-11-22 | 2019-11-19 | Glp-1r agonists and uses thereof |
CN201980087385.0A CN113227068B (en) | 2018-11-22 | 2019-11-19 | GLP-1R agonists and uses thereof |
CR20210341A CR20210341A (en) | 2018-11-22 | 2019-11-19 | Glp-1r agonists and uses thereof |
US16/874,908 US10844049B2 (en) | 2018-11-22 | 2020-05-15 | GLP-1R agonists and uses thereof |
IL283322A IL283322A (en) | 2018-11-22 | 2021-05-20 | Glp-1r agonists and uses thereof |
PH12021551165A PH12021551165A1 (en) | 2018-11-22 | 2021-05-21 | Glp-1r agonists and uses thereof |
CONC2021/0008089A CO2021008089A2 (en) | 2018-11-22 | 2021-06-21 | Glp-1r agonists and their uses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2018/117047 | 2018-11-22 | ||
CN2018117047 | 2018-11-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/874,908 Continuation US10844049B2 (en) | 2018-11-22 | 2020-05-15 | GLP-1R agonists and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020103815A1 true WO2020103815A1 (en) | 2020-05-28 |
Family
ID=70774321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/119373 WO2020103815A1 (en) | 2018-11-22 | 2019-11-19 | Glp-1r agonists and uses thereof |
Country Status (20)
Country | Link |
---|---|
US (2) | US20220024901A1 (en) |
EP (1) | EP3883928A4 (en) |
JP (1) | JP2022508203A (en) |
KR (1) | KR20210106447A (en) |
CN (1) | CN113227068B (en) |
AU (1) | AU2019382642A1 (en) |
BR (1) | BR112021009877A2 (en) |
CA (1) | CA3120499A1 (en) |
CL (1) | CL2021001332A1 (en) |
CO (1) | CO2021008089A2 (en) |
CR (1) | CR20210341A (en) |
CU (1) | CU20210042A7 (en) |
EA (1) | EA202191432A1 (en) |
IL (1) | IL283322A (en) |
MA (1) | MA54555A (en) |
MX (1) | MX2021006034A (en) |
PE (1) | PE20211871A1 (en) |
PH (1) | PH12021551165A1 (en) |
SG (1) | SG11202105241YA (en) |
WO (1) | WO2020103815A1 (en) |
Cited By (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021018023A1 (en) * | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | Small molecule glp-1 receptor modulator |
WO2021081207A1 (en) * | 2019-10-25 | 2021-04-29 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
WO2021160127A1 (en) * | 2020-02-13 | 2021-08-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2021197464A1 (en) * | 2020-04-03 | 2021-10-07 | 江苏恒瑞医药股份有限公司 | Fused imidazole derivatives, preparation method and medical use thereof |
US20210332034A1 (en) * | 2018-06-15 | 2021-10-28 | Pfizer Inc. | GLP-1 Receptor Agonists and Uses Thereof |
WO2021242817A1 (en) * | 2020-05-27 | 2021-12-02 | Qilu Regor Therapeutics Inc. | Salt and crystal forms of glp-1r agonists and uses thereof |
WO2021244645A1 (en) * | 2020-06-04 | 2021-12-09 | 杭州先为达生物科技有限公司 | Five-membered heteroaromatic imidazole compound and use thereof |
CN113773310A (en) * | 2020-06-10 | 2021-12-10 | 济南泰达领创医药技术有限公司 | GLP-1 small molecules with cardiovascular benefits |
CN113816948A (en) * | 2020-06-19 | 2021-12-21 | 江苏恒瑞医药股份有限公司 | Condensed imidazole derivative, preparation method and application thereof in medicine |
CN113831337A (en) * | 2020-06-24 | 2021-12-24 | 广州市恒诺康医药科技有限公司 | GLP-1 receptor agonist, and pharmaceutical composition and use thereof |
WO2022007979A1 (en) * | 2020-09-01 | 2022-01-13 | 江苏恒瑞医药股份有限公司 | Fused imidazole derivative, preparation method therefor, and medical use thereof |
WO2022031994A1 (en) * | 2020-08-06 | 2022-02-10 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
WO2022068772A1 (en) * | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | Benzimidazole derivative, and preparation method therefor, and medical use thereof |
WO2022078152A1 (en) | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | Benzimidazolone glp-1 receptor agonist and use thereof |
WO2022078407A1 (en) * | 2020-10-13 | 2022-04-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2022078380A1 (en) * | 2020-10-13 | 2022-04-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
CN114478497A (en) * | 2020-11-12 | 2022-05-13 | 杭州中美华东制药有限公司 | Aryl alkyl acids GLP-1 receptor agonists and uses thereof |
WO2022109182A1 (en) * | 2020-11-20 | 2022-05-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
WO2022111624A1 (en) | 2020-11-27 | 2022-06-02 | 深圳信立泰药业股份有限公司 | Benzimidazole derivative and preparation method therefor and medical use thereof |
WO2022135572A1 (en) * | 2020-12-25 | 2022-06-30 | 四川海思科制药有限公司 | Five-membered ring derivative and medical use thereof |
WO2022165076A1 (en) * | 2021-01-28 | 2022-08-04 | Carmot Therapeutics, Inc. | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
WO2022184849A1 (en) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
WO2022192430A1 (en) * | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
WO2022192428A1 (en) * | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
WO2022199458A1 (en) | 2021-03-22 | 2022-09-29 | 杭州中美华东制药有限公司 | Thiophene glp-1 receptor agonist and use thereof |
WO2022202864A1 (en) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
WO2022228490A1 (en) * | 2021-04-30 | 2022-11-03 | 上海翰森生物医药科技有限公司 | Polycyclic derivative modulator, and preparation method therefor and use thereof |
US11492365B2 (en) | 2020-02-07 | 2022-11-08 | Gasherbrum Bio, Inc. | Heterocyclic GLP-1 agonists |
WO2022235717A1 (en) * | 2021-05-03 | 2022-11-10 | Carmot Therapeutics, Inc. | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
WO2022246019A1 (en) | 2021-05-20 | 2022-11-24 | Eli Lilly And Company | Macrocyclic glucagon-like peptide 1 receptor agonists |
WO2022268152A1 (en) * | 2021-06-24 | 2022-12-29 | 杭州中美华东制药有限公司 | Glp-1 receptor agonist and composition and use thereof |
JP2023502619A (en) * | 2019-11-15 | 2023-01-25 | イルドン ファーマシューティカル カンパニー リミテッド | GLP-1 RECEPTOR AGONISTS AND USES THEREOF |
WO2023000834A1 (en) * | 2021-07-23 | 2023-01-26 | 广州必贝特医药股份有限公司 | Benzimidazole or azabenzimidazole-6-carboxylic acid compound and use thereof |
WO2023001237A1 (en) * | 2021-07-21 | 2023-01-26 | Hepagene Therapeutics (HK) Limited | Glucagon-like peptide-1 receptor modulators and uses thereof |
WO2023011539A1 (en) * | 2021-08-04 | 2023-02-09 | 上海翰森生物医药科技有限公司 | Cycloalkene derivative regulator, preparation method therefor, and application thereof |
US11591321B2 (en) | 2019-04-12 | 2023-02-28 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
WO2023038039A1 (en) | 2021-09-08 | 2023-03-16 | 塩野義製薬株式会社 | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
CN115850296A (en) * | 2021-12-03 | 2023-03-28 | 杭州先为达生物科技有限公司 | Crystal form of thienoimidazole compound and preparation method thereof |
WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
WO2023057427A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
WO2023076237A1 (en) * | 2021-10-25 | 2023-05-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
US11655242B2 (en) | 2019-06-28 | 2023-05-23 | Eli Lilly And Company | Glucagon-like peptide1 receptor agonists |
WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
EP3953344A4 (en) * | 2019-04-12 | 2023-08-09 | Qilu Regor Therapeutics Inc. | Glp-ir agonists and uses thereof |
WO2023151575A1 (en) * | 2022-02-09 | 2023-08-17 | Gasherbrum Bio Inc. | Heterocyclic glp-1 agonists |
WO2023169456A1 (en) * | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023198140A1 (en) * | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
US11802133B2 (en) | 2018-08-13 | 2023-10-31 | Hoffmann-La Roche Inc. | Heterocyclic compounds as monoacylglycerol lipase inhibitors |
US11814375B2 (en) | 2019-09-12 | 2023-11-14 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
US11858918B2 (en) | 2021-04-21 | 2024-01-02 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
WO2024026338A1 (en) * | 2022-07-27 | 2024-02-01 | Carmot Therapeutics, Inc. | N-heterocylic gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
US11897851B2 (en) | 2020-08-06 | 2024-02-13 | Gasherbrum Bio, Inc. | Heterocyclic GLP-1 agonists |
US11926626B2 (en) | 2020-08-28 | 2024-03-12 | Gasherbrum Bio, Inc. | Heterocyclic GLP-1 agonists |
WO2024051749A1 (en) * | 2022-09-06 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | Polymorph of glp-1r agonist compound, preparation method therefor, and use thereof |
JP7456699B2 (en) | 2020-12-03 | 2024-03-27 | スーチョウ ヴィンセンテージ ファーマ カンパニー リミテッド | GLP-1R receptor agonist compounds and uses thereof |
US11981666B2 (en) | 2021-06-24 | 2024-05-14 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | GLP-1 receptor agonist and composition and use thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202317554A (en) * | 2021-10-22 | 2023-05-01 | 大陸商盛世泰科生物醫藥技術(蘇州)有限公司 | Compounds as glp-1 receptor agonist, pharmaceutical composition including the same and use thereof |
CN114163438A (en) * | 2021-12-13 | 2022-03-11 | 无锡捷化医药科技有限公司 | Preparation method of 2-methyl-3-carbonyl pyrazolo [4,3-c ] pyridine-7-carboxylic acid hydrochloride |
TW202328114A (en) * | 2021-12-23 | 2023-07-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | Pharmaceutically acceptable salt, crystalline form of glp-1 receptor agonist and preparation method thereof |
CN116354945A (en) * | 2021-12-27 | 2023-06-30 | 长春金赛药业有限责任公司 | Fused imidazole carboxylic acid compound and preparation method and application thereof |
WO2023130878A1 (en) * | 2022-01-10 | 2023-07-13 | 海思科医药集团股份有限公司 | Glp-1 agonist salt, and crystal form and medical use thereof |
CN117362282A (en) * | 2022-07-07 | 2024-01-09 | 杭州德睿智药科技有限公司 | Salt of GLP-1R agonist, preparation method and application thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
WO2011143365A1 (en) * | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
WO2013090454A2 (en) * | 2011-12-12 | 2013-06-20 | Receptos, Inc. | Novel glp-1 receptor modulators |
WO2018109607A1 (en) | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040127504A1 (en) | 2002-09-06 | 2004-07-01 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
MXPA05011539A (en) | 2003-04-30 | 2006-01-23 | Inst For Pharm Discovery Inc | Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b. |
CN101775013A (en) | 2004-09-13 | 2010-07-14 | 小野药品工业株式会社 | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
JP2008520692A (en) | 2004-11-18 | 2008-06-19 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | Heterocyclic substituted carboxylic acids |
EP1976873A2 (en) | 2006-01-11 | 2008-10-08 | Brystol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
EP2515914A4 (en) | 2009-12-23 | 2013-09-11 | Scripps Research Inst | Tyrosine bioconjugation through aqueous ene-like reactions |
US8501982B2 (en) | 2010-06-09 | 2013-08-06 | Receptos, Inc. | GLP-1 receptor stabilizers and modulators |
EP2677869B1 (en) * | 2011-02-25 | 2017-11-08 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
AU2015374118B2 (en) | 2014-12-29 | 2020-07-23 | The Trustees Of The University Of Pennsylvania | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof |
JP6919977B2 (en) | 2016-03-16 | 2021-08-18 | クラ オンコロジー,インク. | Substituted inhibitors of menin-MLL and how to use them |
TWI707683B (en) * | 2018-06-13 | 2020-10-21 | 美商輝瑞股份有限公司 | Glp-1 receptor agonists and uses thereof |
BR112020024956A2 (en) * | 2018-06-15 | 2021-03-09 | Pfizer Inc. | GLP-1 RECEPTOR AGONISTS AND USES OF THE SAME |
US11945803B2 (en) | 2018-08-07 | 2024-04-02 | Tosk, Inc. | Modulators of RAS GTPase |
US11254660B2 (en) * | 2018-08-31 | 2022-02-22 | Pfizer Inc. | Combinations for treatment of NASH/NAFLD and related diseases |
-
2019
- 2019-11-19 EP EP19887901.7A patent/EP3883928A4/en active Pending
- 2019-11-19 WO PCT/CN2019/119373 patent/WO2020103815A1/en active Application Filing
- 2019-11-19 CN CN201980087385.0A patent/CN113227068B/en active Active
- 2019-11-19 CR CR20210341A patent/CR20210341A/en unknown
- 2019-11-19 KR KR1020217019126A patent/KR20210106447A/en unknown
- 2019-11-19 EA EA202191432A patent/EA202191432A1/en unknown
- 2019-11-19 JP JP2021529110A patent/JP2022508203A/en active Pending
- 2019-11-19 CU CU2021000042A patent/CU20210042A7/en unknown
- 2019-11-19 AU AU2019382642A patent/AU2019382642A1/en active Pending
- 2019-11-19 US US17/296,078 patent/US20220024901A1/en active Pending
- 2019-11-19 MX MX2021006034A patent/MX2021006034A/en unknown
- 2019-11-19 PE PE2021000746A patent/PE20211871A1/en unknown
- 2019-11-19 BR BR112021009877-1A patent/BR112021009877A2/en unknown
- 2019-11-19 CA CA3120499A patent/CA3120499A1/en active Pending
- 2019-11-19 SG SG11202105241YA patent/SG11202105241YA/en unknown
- 2019-11-19 MA MA054555A patent/MA54555A/en unknown
-
2020
- 2020-05-15 US US16/874,908 patent/US10844049B2/en active Active
-
2021
- 2021-05-20 CL CL2021001332A patent/CL2021001332A1/en unknown
- 2021-05-20 IL IL283322A patent/IL283322A/en unknown
- 2021-05-21 PH PH12021551165A patent/PH12021551165A1/en unknown
- 2021-06-21 CO CONC2021/0008089A patent/CO2021008089A2/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
WO2011143365A1 (en) * | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
WO2013090454A2 (en) * | 2011-12-12 | 2013-06-20 | Receptos, Inc. | Novel glp-1 receptor modulators |
WO2018109607A1 (en) | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
Non-Patent Citations (16)
Title |
---|
"Handbook of Pharmaceutical Excipients", 1999, AMERICAN PHARMACEUTICAL ASSOCIATION |
"Pharmaceutical Dosage Forms", 1980, MARCEL DECKER |
"Remington, The Science and Practice of Pharmacy", 2000, MACK PUBLISHING |
DIABETES CARE, vol. 37, 2014, pages 1367 - 1374 |
FINNINMORGAN, J. PHARM. SCI., vol. 88, 1999, pages 955 - 958 |
GREENE: "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", vol. I-XII, 1991, JOHN WILEY AND SONS |
HAMPP ET AL., USE OF ANTIDIABETIC DRUGS IN THE U.S., 2003 |
HOIST, PHYSIOL. REV., vol. 87, 2007, pages 1409 |
HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO. |
K. R. MORRIS: "Polymorphism in Pharmaceutical Solids", 1995, MARCEL DEKKER |
MEIER ET AL., BIODRUGS, vol. 17, no. 2, 2013, pages 93 - 102 |
MEIER, NAT. REV. ENDOCRINOL., vol. 8, 2012, pages 728 |
See also references of EP3883928A4 |
SMITH, ROGER M.: "Chromatographic Science Series", vol. 75, 1998, LOUGHBOROUGH UNIVERSITY, pages: 223 - 249 |
STAHLWERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH |
VILSBOLL ET AL., DIABETES, vol. 50, 2001, pages 609 - 613 |
Cited By (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11858916B2 (en) * | 2018-06-15 | 2024-01-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
US20210332034A1 (en) * | 2018-06-15 | 2021-10-28 | Pfizer Inc. | GLP-1 Receptor Agonists and Uses Thereof |
US11802133B2 (en) | 2018-08-13 | 2023-10-31 | Hoffmann-La Roche Inc. | Heterocyclic compounds as monoacylglycerol lipase inhibitors |
US11591321B2 (en) | 2019-04-12 | 2023-02-28 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
EP3953344A4 (en) * | 2019-04-12 | 2023-08-09 | Qilu Regor Therapeutics Inc. | Glp-ir agonists and uses thereof |
US11655242B2 (en) | 2019-06-28 | 2023-05-23 | Eli Lilly And Company | Glucagon-like peptide1 receptor agonists |
WO2021018023A1 (en) * | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | Small molecule glp-1 receptor modulator |
US11814375B2 (en) | 2019-09-12 | 2023-11-14 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
US11702404B2 (en) | 2019-10-25 | 2023-07-18 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
WO2021081207A1 (en) * | 2019-10-25 | 2021-04-29 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
CN114630823A (en) * | 2019-10-25 | 2022-06-14 | 吉利德科学公司 | GLP-1R modulating compounds |
JP7386997B2 (en) | 2019-11-15 | 2023-11-27 | イルドン ファーマシューティカル カンパニー リミテッド | GLP-1 receptor agonists and their uses |
US11932618B2 (en) | 2019-11-15 | 2024-03-19 | Ildong Pharmaceutical Co., Ltd. | GLP-1 receptor agonist and use thereof |
JP2023502619A (en) * | 2019-11-15 | 2023-01-25 | イルドン ファーマシューティカル カンパニー リミテッド | GLP-1 RECEPTOR AGONISTS AND USES THEREOF |
US11926643B2 (en) | 2020-02-07 | 2024-03-12 | Gasherbrum Bio, Inc. | Heterocyclic GLP-1 agonists |
US11492365B2 (en) | 2020-02-07 | 2022-11-08 | Gasherbrum Bio, Inc. | Heterocyclic GLP-1 agonists |
WO2021160127A1 (en) * | 2020-02-13 | 2021-08-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
EP4130003A4 (en) * | 2020-04-03 | 2023-09-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused imidazole derivatives, preparation method and medical use thereof |
WO2021197464A1 (en) * | 2020-04-03 | 2021-10-07 | 江苏恒瑞医药股份有限公司 | Fused imidazole derivatives, preparation method and medical use thereof |
CN115244056A (en) * | 2020-04-03 | 2022-10-25 | 江苏恒瑞医药股份有限公司 | Condensed imidazole derivative, preparation method and application thereof in medicine |
WO2021242817A1 (en) * | 2020-05-27 | 2021-12-02 | Qilu Regor Therapeutics Inc. | Salt and crystal forms of glp-1r agonists and uses thereof |
JP7359974B2 (en) | 2020-06-04 | 2023-10-11 | ハンチョウ サイウィンド バイオサイエンスィズ カンパニー リミテッド | Five-membered heteroaromatic imidazole compound and its use |
US11542272B2 (en) | 2020-06-04 | 2023-01-03 | Hangzhou Sciwind Biosciences Co., Ltd | Five-membered heteroaryl-fused imidazole compound and application thereof |
WO2021244645A1 (en) * | 2020-06-04 | 2021-12-09 | 杭州先为达生物科技有限公司 | Five-membered heteroaromatic imidazole compound and use thereof |
CN115698022B (en) * | 2020-06-04 | 2024-03-15 | 杭州先为达生物科技股份有限公司 | Five-membered heteroaromatic imidazole compound and application thereof |
CN115698022A (en) * | 2020-06-04 | 2023-02-03 | 杭州先为达生物科技有限公司 | Five-membered heteroaromatic imidazole compound and application thereof |
KR20230016701A (en) * | 2020-06-04 | 2023-02-02 | 항저우 사이윈드 바이오사이언시즈 컴퍼니 리미티드 | 5-membered heteroaromatic imidazole compounds and uses thereof |
JP2023520260A (en) * | 2020-06-04 | 2023-05-16 | ハンチョウ サイウィンド バイオサイエンスィズ カンパニー リミテッド | Five-membered ring heteroaromatic imidazole compound and its use |
AU2021286086B2 (en) * | 2020-06-04 | 2023-09-07 | Hangzhou Sciwind Biosciences Co., Ltd | Five-membered heteroaromatic imidazole compound and use thereof |
KR102588241B1 (en) | 2020-06-04 | 2023-10-11 | 항저우 사이윈드 바이오사이언시즈 컴퍼니 리미티드 | Five-membered heteroaromatic imidazole compounds and uses thereof |
CN113773310A (en) * | 2020-06-10 | 2021-12-10 | 济南泰达领创医药技术有限公司 | GLP-1 small molecules with cardiovascular benefits |
CN113773310B (en) * | 2020-06-10 | 2023-12-22 | 重庆康丁医药技术有限公司 | GLP-1 small molecule with cardiovascular benefit |
CN113816948A (en) * | 2020-06-19 | 2021-12-21 | 江苏恒瑞医药股份有限公司 | Condensed imidazole derivative, preparation method and application thereof in medicine |
CN113816948B (en) * | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | Condensed imidazole derivative, preparation method and medical application thereof |
CN113831337A (en) * | 2020-06-24 | 2021-12-24 | 广州市恒诺康医药科技有限公司 | GLP-1 receptor agonist, and pharmaceutical composition and use thereof |
WO2021259309A1 (en) * | 2020-06-24 | 2021-12-30 | 广州市恒诺康医药科技有限公司 | Glp-1 receptor agonist, and pharmaceutical composition and use thereof |
WO2022031994A1 (en) * | 2020-08-06 | 2022-02-10 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
US11897851B2 (en) | 2020-08-06 | 2024-02-13 | Gasherbrum Bio, Inc. | Heterocyclic GLP-1 agonists |
US11926626B2 (en) | 2020-08-28 | 2024-03-12 | Gasherbrum Bio, Inc. | Heterocyclic GLP-1 agonists |
WO2022007979A1 (en) * | 2020-09-01 | 2022-01-13 | 江苏恒瑞医药股份有限公司 | Fused imidazole derivative, preparation method therefor, and medical use thereof |
WO2022068772A1 (en) * | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | Benzimidazole derivative, and preparation method therefor, and medical use thereof |
CN115515956A (en) * | 2020-09-29 | 2022-12-23 | 深圳信立泰药业股份有限公司 | Benzimidazole derivative and preparation method and medical application thereof |
WO2022078152A1 (en) | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | Benzimidazolone glp-1 receptor agonist and use thereof |
WO2022078407A1 (en) * | 2020-10-13 | 2022-04-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2022078380A1 (en) * | 2020-10-13 | 2022-04-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
CN114478497B (en) * | 2020-11-12 | 2023-10-20 | 杭州中美华东制药有限公司 | Arylalkyl acid GLP-1 receptor agonists and uses thereof |
CN114478497A (en) * | 2020-11-12 | 2022-05-13 | 杭州中美华东制药有限公司 | Aryl alkyl acids GLP-1 receptor agonists and uses thereof |
WO2022109182A1 (en) * | 2020-11-20 | 2022-05-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
US11851419B2 (en) | 2020-11-20 | 2023-12-26 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
TWI828008B (en) * | 2020-11-20 | 2024-01-01 | 美商基利科學股份有限公司 | Glp-1r modulating compounds |
CN115461334A (en) * | 2020-11-27 | 2022-12-09 | 深圳信立泰药业股份有限公司 | Benzimidazole derivative and preparation method and medical application thereof |
WO2022111624A1 (en) | 2020-11-27 | 2022-06-02 | 深圳信立泰药业股份有限公司 | Benzimidazole derivative and preparation method therefor and medical use thereof |
JP7456699B2 (en) | 2020-12-03 | 2024-03-27 | スーチョウ ヴィンセンテージ ファーマ カンパニー リミテッド | GLP-1R receptor agonist compounds and uses thereof |
WO2022135572A1 (en) * | 2020-12-25 | 2022-06-30 | 四川海思科制药有限公司 | Five-membered ring derivative and medical use thereof |
WO2022165076A1 (en) * | 2021-01-28 | 2022-08-04 | Carmot Therapeutics, Inc. | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
WO2022184849A1 (en) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
WO2022192428A1 (en) * | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
WO2022192430A1 (en) * | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
WO2022199458A1 (en) | 2021-03-22 | 2022-09-29 | 杭州中美华东制药有限公司 | Thiophene glp-1 receptor agonist and use thereof |
WO2022202864A1 (en) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
US11858918B2 (en) | 2021-04-21 | 2024-01-02 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
WO2022228490A1 (en) * | 2021-04-30 | 2022-11-03 | 上海翰森生物医药科技有限公司 | Polycyclic derivative modulator, and preparation method therefor and use thereof |
WO2022235717A1 (en) * | 2021-05-03 | 2022-11-10 | Carmot Therapeutics, Inc. | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
WO2022246019A1 (en) | 2021-05-20 | 2022-11-24 | Eli Lilly And Company | Macrocyclic glucagon-like peptide 1 receptor agonists |
WO2022268152A1 (en) * | 2021-06-24 | 2022-12-29 | 杭州中美华东制药有限公司 | Glp-1 receptor agonist and composition and use thereof |
US11981666B2 (en) | 2021-06-24 | 2024-05-14 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | GLP-1 receptor agonist and composition and use thereof |
WO2023001237A1 (en) * | 2021-07-21 | 2023-01-26 | Hepagene Therapeutics (HK) Limited | Glucagon-like peptide-1 receptor modulators and uses thereof |
TWI816437B (en) * | 2021-07-23 | 2023-09-21 | 大陸商廣州必貝特醫藥股份有限公司 | Benzimidazole or azabenzimidazole-6-carboxylic acid compounds and applications thereof |
WO2023000834A1 (en) * | 2021-07-23 | 2023-01-26 | 广州必贝特医药股份有限公司 | Benzimidazole or azabenzimidazole-6-carboxylic acid compound and use thereof |
WO2023011539A1 (en) * | 2021-08-04 | 2023-02-09 | 上海翰森生物医药科技有限公司 | Cycloalkene derivative regulator, preparation method therefor, and application thereof |
WO2023038039A1 (en) | 2021-09-08 | 2023-03-16 | 塩野義製薬株式会社 | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
WO2023057427A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
WO2023076237A1 (en) * | 2021-10-25 | 2023-05-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
CN115850296A (en) * | 2021-12-03 | 2023-03-28 | 杭州先为达生物科技有限公司 | Crystal form of thienoimidazole compound and preparation method thereof |
WO2023098852A1 (en) * | 2021-12-03 | 2023-06-08 | Hangzhou Sciwind Biosciences Co., Ltd. | Crystal forms of thienoimidazole compound and preparation method thereof |
WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2023151575A1 (en) * | 2022-02-09 | 2023-08-17 | Gasherbrum Bio Inc. | Heterocyclic glp-1 agonists |
WO2023169456A1 (en) * | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023198140A1 (en) * | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024026338A1 (en) * | 2022-07-27 | 2024-02-01 | Carmot Therapeutics, Inc. | N-heterocylic gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
WO2024051749A1 (en) * | 2022-09-06 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | Polymorph of glp-1r agonist compound, preparation method therefor, and use thereof |
Also Published As
Publication number | Publication date |
---|---|
CL2021001332A1 (en) | 2021-11-05 |
SG11202105241YA (en) | 2021-06-29 |
MA54555A (en) | 2021-09-29 |
EP3883928A1 (en) | 2021-09-29 |
US20220024901A1 (en) | 2022-01-27 |
PE20211871A1 (en) | 2021-09-21 |
KR20210106447A (en) | 2021-08-30 |
EA202191432A1 (en) | 2021-10-14 |
TW202039458A (en) | 2020-11-01 |
CO2021008089A2 (en) | 2021-09-09 |
US10844049B2 (en) | 2020-11-24 |
IL283322A (en) | 2021-07-29 |
CU20210042A7 (en) | 2022-01-13 |
AU2019382642A1 (en) | 2021-06-10 |
EP3883928A4 (en) | 2022-06-29 |
US20200283424A1 (en) | 2020-09-10 |
CN113227068B (en) | 2023-06-13 |
PH12021551165A1 (en) | 2021-10-25 |
CA3120499A1 (en) | 2020-05-28 |
CR20210341A (en) | 2021-11-25 |
JP2022508203A (en) | 2022-01-19 |
CN113227068A (en) | 2021-08-06 |
MX2021006034A (en) | 2021-09-21 |
BR112021009877A2 (en) | 2021-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020103815A1 (en) | Glp-1r agonists and uses thereof | |
WO2020207474A1 (en) | Glp-1r agonists and uses thereof | |
US11802121B2 (en) | GLP-1 receptor agonists and uses thereof | |
US10934279B2 (en) | GLP-1 receptor agonists and uses thereof | |
US10954221B2 (en) | GLP-1R agonists and uses thereof | |
WO2022031994A1 (en) | Glp-1r agonists and uses thereof | |
TWI839416B (en) | Glp-1r agonists and uses thereof | |
EA046435B1 (en) | GLP-1R AGONISTS AND THEIR APPLICATIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19887901 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3120499 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021529110 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021009877 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2019382642 Country of ref document: AU Date of ref document: 20191119 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019887901 Country of ref document: EP Effective date: 20210622 |
|
ENP | Entry into the national phase |
Ref document number: 112021009877 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210521 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 521422068 Country of ref document: SA |